var title_f29_56_30592="M mode aorta cardiomyopathy";
var content_f29_56_30592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of aortic root in cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In cardiomyopathy with reduced stroke volume the systolic anterior excursion of the aortic (Ao) root is greatly reduced in comparison to the normal pattern. Additionally, the aortic valve (AoV) opening is greatly reduced and its duration abbreviated. Just after achieving their maximum separation, the AoV leaflets immediately begin drifting closed, with a loss of the normal box-like configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30592=[""].join("\n");
var outline_f29_56_30592=null;
var title_f29_56_30593="Vulvoperineoplasty";
var content_f29_56_30593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvoperineoplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Mucocutaneous incision, (B) Dissection of the posterior vaginal wall, (C) Excision of a triangular patch of perineal skin, (D and E) radial incision of the fibrous perineal body to reduce its height, (F) Individualization of a vaginal flap, (G) The vaginal flap is drawn down, making a cover for the perineal defect, and sutured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30593=[""].join("\n");
var outline_f29_56_30593=null;
var title_f29_56_30594="Ankle cutaneous larva migrans";
var content_f29_56_30594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous larva migrans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serpiginous track left by the migrating&nbsp;parasite is seen on the ankle of this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30594=[""].join("\n");
var outline_f29_56_30594=null;
var title_f29_56_30595="Thoracoabdominal aortic aneurysm on aortogram";
var content_f29_56_30595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Thoracoabdominal aortic aneurysm on aortogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aortogram shows a thoracoabdominal aneurysm. Contrast injection into the distal thoracic aorta (A) shows a large aneurysm involving the aorta above and below (to lesser extent)&nbsp;the diaphragm.&nbsp;The aorta is normal in caliber at the level of the renal arteries (arrows). Contrast injection into the abdominal aorta (B) confirms the suprarenal nature of the aneurysm.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30595=[""].join("\n");
var outline_f29_56_30595=null;
var title_f29_56_30596="Fluocinonide: Drug information";
var content_f29_56_30596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinonide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/16/8452?source=see_link\">",
"    see \"Fluocinonide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/1/9235?source=see_link\">",
"    see \"Fluocinonide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vanos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lidemol&reg;;",
"     </li>",
"     <li>",
"      Lidex&reg;;",
"     </li>",
"     <li>",
"      Lyderm&reg;;",
"     </li>",
"     <li>",
"      Tiamol&reg;;",
"     </li>",
"     <li>",
"      Topactin;",
"     </li>",
"     <li>",
"      Topsyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus and inflammation:",
"     </b>",
"     Topical (0.05% cream): Apply thin layer to affected area 2-4 times/day depending on the severity of the condition. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plaque-type psoriasis (Vanos&trade;):",
"     </b>",
"     Topical (0.1% cream): Apply a thin layer once or twice daily to affected areas (limited to &lt;10% of body surface area).",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Discontinue when control is achieved.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/1/9235?source=see_link\">",
"      see \"Fluocinonide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus and inflammation:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plaque-type psoriasis:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vanos&reg;: 0.1% (30 g, 60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, anhydrous, emollient, topical: 0.05% (15 g, 30 g, 60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, aqueous, emollient, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.05% (20 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory, antipruritic; treatment of plaque-type psoriasis (up to 10% of body surface area) [high-potency topical corticosteroid]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluocinonide may be confused with flunisolide, fluocinolone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lidex&reg; may be confused with Lasix&reg;, Videx&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, contact dermatitis, dry skin, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, pruritus, skin atrophy, striae, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing's syndrome, growth retardation, HPA axis suppression, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinonide or any component of the formulation; viral, fungal, or tubercular skin lesions, herpes simplex",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use of the 0.1% cream in children &lt;12 years of age is not recommended. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Application site: Lower-strength cream (0.05%) may be used cautiously on face or opposing skin surfaces that may rub or touch (eg, skin folds of the groin, axilla, and breasts); higher-strength (0.1%) should not be used on the face, groin, or axillae.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Use of the 0.1% cream for &gt;2 weeks is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13277395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13277394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F172326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fluocinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $22.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Vanos External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 g): $522.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Fluocinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $58.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Fluocinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (30 g): $34.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluocinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 mL): $97.19",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acderma (JP);",
"     </li>",
"     <li>",
"      Amfulan (TW);",
"     </li>",
"     <li>",
"      Biscosal (JP);",
"     </li>",
"     <li>",
"      Delipo (JP);",
"     </li>",
"     <li>",
"      Dermadex (PH);",
"     </li>",
"     <li>",
"      Etonalin F (JP);",
"     </li>",
"     <li>",
"      Flu-21 (IT);",
"     </li>",
"     <li>",
"      Flubiol (JP);",
"     </li>",
"     <li>",
"      Flunide (TW);",
"     </li>",
"     <li>",
"      Glycobase (JP);",
"     </li>",
"     <li>",
"      Hakelon (JP);",
"     </li>",
"     <li>",
"      KC-F (JP);",
"     </li>",
"     <li>",
"      Klariderm (ES);",
"     </li>",
"     <li>",
"      Lidex (BE, GR, KP, LU);",
"     </li>",
"     <li>",
"      Medrexim (JP);",
"     </li>",
"     <li>",
"      Metosyn (BB, BF, BJ, BM, BS, BZ, CI, CZ, DK, ET, GB, GH, GM, GN, GY, IE, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NO, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Murukos F (JP);",
"     </li>",
"     <li>",
"      Novoter (MY);",
"     </li>",
"     <li>",
"      Rauracid (JP);",
"     </li>",
"     <li>",
"      Rufull (JP);",
"     </li>",
"     <li>",
"      Simaron (JP);",
"     </li>",
"     <li>",
"      Solunim (JP);",
"     </li>",
"     <li>",
"      Tohsino (JP);",
"     </li>",
"     <li>",
"      Topsym (AE, AT, BH, CH, CY, DE, EC, EG, IL, IQ, IR, JO, JP, KW, LB, LY, OM, PE, PT, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Topsym F (AT);",
"     </li>",
"     <li>",
"      Topsym Polyol (PY);",
"     </li>",
"     <li>",
"      Topsyn (IT, MX);",
"     </li>",
"     <li>",
"      Topsyne (FR, NL);",
"     </li>",
"     <li>",
"      Trappen (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluorinated topical corticosteroid considered to be of high potency. The mechanism of action for all topical corticosteroids is not well defined, however, is felt to be a combination of three important properties: anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Dependent on strength of product, amount applied, and nature of skin at application site; ranges from ~1% in areas of thick stratum corneum (palms, soles, elbows, etc) to 36% in areas of thin stratum corneum (face, eyelids, etc); increased in areas of skin damage, inflammation, or occlusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Throughout local skin; absorbed drug into muscle, liver, skin, intestines, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily in skin; small amount absorbed into systemic circulation is primarily hepatic to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as glucuronide and sulfate, also as unconjugated products); feces (small amounts as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/56/30596/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8460 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30596=[""].join("\n");
var outline_f29_56_30596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172363\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172336\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172351\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172337\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172320\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172307\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172321\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172368\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172361\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172325\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172311\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299350\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172315\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172316\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277393\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277395\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277394\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172326\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172327\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172310\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172324\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8460|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/16/8452?source=related_link\">",
"      Fluocinonide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/1/9235?source=related_link\">",
"      Fluocinonide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_56_30597="Mandibular advance splint I";
var content_f29_56_30597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52099%7EPULM%2F64842%7EPULM%2F75613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52099%7EPULM%2F64842%7EPULM%2F75613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This mandibular advancement splint is manufactured in a laboratory from dental impressions (Klearway appliance, Great Lakes Orthodontics, Inc, Tonawanda, NY). Special features stressed by the manufacturer are the full dental coverage, the low profile of the appliance, and adjustability of mandibular position by means of a screw.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This mandibular advancement splint is manufactured in a laboratory from dental impressions (Klearway appliance, Great Lakes Orthodontics, Inc, Tonawanda, NY). Special features stressed by the manufacturer are the full dental coverage, the low profile of the appliance, and adjustability of mandibular position by means of a screw.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Another example of a two-piece device, with full occlusal coverage, and a titratable slot and flange coupling mechanism in the vicinity of the posterior teeth, permitting mouth opening and closing whilst in advancement (SomnoMed MAS&reg;, SomnoMed Ltd, Australia).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: SomnoMed, Inc. file://www.somnomed.com.au/index.php?id=281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30597=[""].join("\n");
var outline_f29_56_30597=null;
var title_f29_56_30598="Magnetic endoscopic imaging";
var content_f29_56_30598=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Magnetic endoscopic imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Adam V Haycock, MD, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Brian P Saunders, MD, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Christopher B Williams, BM, FRCP, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30598/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/56/30598/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1066177960\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variations in colonic anatomy can make colonoscopy technically difficult to perform and to teach. In addition, it is not always possible to precisely localize lesions within the colon, information that is important if patients require subsequent endoscopic or surgical therapy.",
"   </p>",
"   <p>",
"    One method for overcoming these limitations is to provide a view of the colonoscope during the procedure. This was initially done with fluoroscopic guidance, but this approach has been largely abandoned because of its inconvenience, added expense, and necessity for radiation exposure. An alternative to fluoroscopy is magnetic endoscopic imaging (MEI), which provides real-time three-dimensional views of the colonoscope shaft configuration and its location within the abdomen. This may aid trainees and less experienced endoscopists as they perform routine colonoscopies and may aid experienced endoscopists during difficult cases.",
"   </p>",
"   <p>",
"    Issues related to MEI will be reviewed here. Other options for localizing lesions within the colon are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30519?source=see_link\">",
"     \"Tattooing and other methods for localizing colonic lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066177967\">",
"    <span class=\"h1\">",
"     PROBLEMS ENCOUNTERED DURING COLONOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to visualize the colonoscope during colonoscopy may be helpful in multiple settings. It may aid the endoscopist during a difficult colonoscopy, it may help with lesion localization, and it may improve the teaching of colonoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066177974\">",
"    <span class=\"h2\">",
"     Difficult colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that can increase the difficulty of colonoscopy include variations in colonic anatomy, loop formation during instrument insertion, and the presence of abdominal or pelvic adhesions. Increased colonic mobility can predispose to loop formation, whereas adhesions can interfere with normal scope insertion and loop reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066177981\">",
"    <span class=\"h3\">",
"     Influence of anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sigmoid and transverse colon are both mobile on a mesentery or \"mesocolon,\" which can be affected by manipulations of the colonoscope. Most colonoscope looping occurs within these segments. Another factor that predisposes to loop formation is that the transverse colon of female patients (and less commonly male patients) may extend down into the pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the descending colon and ascending colon are usually relatively fixed in the left and right paravertebral gutters, respectively, these portions of the colon are mobile in a significant minority of patients. As an example, there is no fixation at the splenic flexure in approximately 20 percent of patients, which allows atypical colonoscope looping in the left colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the normally mobile sigmoid colon may have decreased mobility due to sigmoid adhesions that can result from diverticulitis, endometriosis, or pelvic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066177988\">",
"    <span class=\"h3\">",
"     Looping and adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have looked at the causes of difficult colonoscopy. In a series of 500 patients in whom fluoroscopy was used, 16 percent of cases performed by experienced colonoscopists were categorized as difficult examinations (defined as no advancement of the colonoscope tip for at least five minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/3\">",
"     3",
"    </a>",
"    ]. This was due to recurrent looping in 80 percent and to sigmoid adhesions in the remainder. The colonoscopists were frequently incorrect in identifying the site of looping, and in 30 percent of examinations, they were mistaken as to the location of the tip of the colonoscope.",
"   </p>",
"   <p>",
"    Looping also makes the examination more difficult for patients as pain episodes may correspond to looping seen on MEI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/4\">",
"     4",
"    </a>",
"    ]. The pain is greatest with looping in the sigmoid colon, particularly in women and in those with preexisting symptoms of irritable bowel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066177995\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other risk factors have been described for difficult colonoscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema, there is a correlation between technically difficult colonoscopy and a long transverse colon or sigmoid colon adhesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/1,5\">",
"       1,5",
"      </a>",
"      ]. These factors in part explain the higher rate of difficult colonoscopy in women compared with men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/1,5-7\">",
"       1,5-7",
"      </a>",
"      ]. In a review of 2194 colonoscopies performed by a single experienced colonoscopist, the respective rates of difficult colonoscopy in women and men were 31 and 16 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Colonoscopy is more likely to be difficult in older women with diverticular disease and adhesions and in men with constipation and a long colon. CT colonography data confirm that \"difficult to colonoscope\" patients tend to have longer colons (particularly in the sigmoid and transverse colon), have more acute bends, and are more likely to be female [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178002\">",
"    <span class=\"h2\">",
"     Lesion localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise localization of lesions within the colon is particularly important when surgical resection is required for a malignancy or a lesion needs to be reinspected at a later date. However, even skilled colonoscopists can misjudge the position of the colonoscope tip. It is easy to become confused about whether the tip is in the proximal sigmoid colon or at the splenic flexure, and the mid-transverse colon or hepatic flexure may be misidentified as being the cecum.",
"   </p>",
"   <p>",
"    While a number of visual clues are commonly used to determine the location of the tip of the colonoscope, they are often misleading. As examples, the triangular appearance of the folds that are considered to be typical of the transverse colon may also be seen in the descending colon, while the bluish hue associated with the hepatic flexure may also been seen at the splenic flexure (especially within a long sigmoid loop).",
"   </p>",
"   <p>",
"    Other clues such as the length of instrument inserted, transillumination through the anterior abdominal wall, abdominal palpation, and the responsiveness and feel of the instrument can also be misleading.",
"   </p>",
"   <p>",
"    Imprecise localization of a lesion can result in incorrect preoperative information being given to the surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/8\">",
"     8",
"    </a>",
"    ]. This problem has led to the development of methods to tattoo important findings for easy identification during follow-up examinations or surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30519?source=see_link\">",
"     \"Tattooing and other methods for localizing colonic lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178017\">",
"    <span class=\"h1\">",
"     COLONOSCOPY TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy training relies heavily upon apprenticeship. However, such training can be frustrating for both the trainee and the instructor. The trainee often finds it difficult to appreciate why certain maneuvers are indicated or effective; the instructor may be unable to assess why the trainee is \"stuck\" without taking over the procedure, leaving the trainee to act as an observer.",
"   </p>",
"   <p>",
"    Fluoroscopy and magnetic endoscopic imaging (MEI) help to address these frustrations because they allow the instructor to guide the trainee without having to take over the procedure. Fluoroscopy has a number of limitations, while MEI is not widely available, though colonoscopy simulators are being developed that incorporate MEI. (See",
"    <a class=\"local\" href=\"#H1066178081\">",
"     'Colonoscopy performance and training'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178024\">",
"    <span class=\"h1\">",
"     ROLE FOR FLUOROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The problems associated with performing colonoscopy provide a rationale for the use of some imaging modality during colonoscopy. Fluoroscopy increases confidence in lesion localization, aids with loop reduction during difficult examinations, and can be a useful tool when teaching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, fluoroscopy is not routinely used for multiple reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluoroscopy can add time and expense to colonoscopy, exposes patients and staff to radiation, and is not always available.",
"     </li>",
"     <li>",
"      The area visible on-screen covers only a small part of the abdomen and may therefore give a misleading assessment of complex loops, especially when the patient lies in the conventional left lateral position.",
"     </li>",
"     <li>",
"      The two-dimensional radiological image does not provide an impression of the three-dimensional configuration of the colonoscope shaft loops. As a result, it is limited in its ability to guide rotational maneuvers used for straightening loops.",
"     </li>",
"     <li>",
"      Because of radiation hazards, fluoroscopy cannot be used to confirm that the assistant's hand is appropriately placed when applying pressure to the patient's abdomen to control loops.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Magnetic endoscopic imaging is an alternative to fluoroscopy that addresses these limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178031\">",
"    <span class=\"h1\">",
"     MAGNETIC ENDOSCOPIC IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178039\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;With magnetic endoscopic imaging (MEI), electromagnetic fields are sensed by small coils within the colonoscope and larger ones alongside the patient, producing a moving image of the colonoscope configuration on a display monitor (",
"    <a class=\"graphic graphic_movie graphicRef52473 \" href=\"mobipreview.htm?25/62/26605\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83348 \" href=\"mobipreview.htm?6/40/6785\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83349 \" href=\"mobipreview.htm?31/30/32227\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first prototype, the transmitter coil assemblies were outside the patient, and miniature receiver coils were in a catheter inserted down the instrument channel of the endoscope. A number of key refinements resulted in improved image representation and overall functionality. A commercial version of the magnetic endoscopic imager is now available (ScopeGuide&reg;, Olympus Corporation, Tokyo). An improved version with several new features is under development and currently undergoing human trials.",
"   </p>",
"   <p>",
"    The current ScopeGuide is a standalone unit with a receiver dish that is positioned alongside the patient and is connected to a dedicated colonoscope with built-in transmitter coils (",
"    <a class=\"graphic graphic_picture graphicRef83349 \" href=\"mobipreview.htm?31/30/32227\">",
"     picture 2",
"    </a>",
"    ). A coil catheter can be inserted through the",
"    <span class=\"nowrap\">",
"     instrument/suction",
"    </span>",
"    channel of a standard colonoscope, although this is less ideal because the catheter prevents suctioning and is too fragile for routine use. However, because the transmitter coils are incorporated into the dedicated MEI colonoscope, MEI colonoscopes are bulkier than standard colonoscopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178046\">",
"    <span class=\"h2\">",
"     Image display",
"    </span>",
"    &nbsp;&mdash;&nbsp;Software calculates the three-dimensional (3-D) position and orientation of each receiver coil, and the data are displayed in real-time as a computer-rendered 3-D image of the colonoscope shaft configuration (",
"    <a class=\"graphic graphic_movie graphicRef52473 \" href=\"mobipreview.htm?25/62/26605\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The shaft configuration can be displayed either in anteroposterior (AP) view alone or in split-screen view, combining AP and lateral views side by side. The split-screen view helps to clarify the colonoscope loop configuration in 3-D (",
"    <a class=\"graphic graphic_figure graphicRef62224 \" href=\"mobipreview.htm?20/49/21278\">",
"     figure 1",
"    </a>",
"    ). The monitor can also be configured to maintain the AP view despite changes in patient positioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178053\">",
"    <span class=\"h2\">",
"     Hand marker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted abdominal pressure applied by an assistant can be useful in managing colonoscope loops. Using an external coil held in the assistant's hand, it is possible to determine the position of the hand relative to the colonoscope, as well as the effect of the applied pressure on looping (",
"    <a class=\"graphic graphic_figure graphicRef62224 \" href=\"mobipreview.htm?20/49/21278\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178060\">",
"    <span class=\"h1\">",
"     IMPACT OF MEI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic endoscopic imaging (MEI) helps with loop reduction, application of abdominal pressure, localization of the tip of the colonoscope, and providing instruction in colonoscopy. It may also have a place in competency assessment during the credentialing process for colonoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178067\">",
"    <span class=\"h2\">",
"     Loop identification and reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct loop identification is required for a successful reduction of looping during colonoscopy. However, endoscopists frequently miscategorize loops, especially if they are complex or unusual.",
"   </p>",
"   <p>",
"    In a study of 100 consecutive colonoscopies done with MEI by experienced colonoscopists who were blinded to the imager view, various looping configurations were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/13\">",
"     13",
"    </a>",
"    ]. Despite skilled and careful insertion technique, loops occurred in 91 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef55708 \" href=\"mobipreview.htm?10/32/10764\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The endoscopists incorrectly identified the loops in 69 percent of cases, with less common looping configurations, such as counterclockwise spiral loops, being incorrectly assessed in 100 percent. In addition, when abdominal pressure was applied, it was generally inaccurate, due either to hand misplacement away from the apex of the loop or to inaccessibility of the loop deep within the abdomen.",
"   </p>",
"   <p>",
"    There are numerous loop configurations that may occur during colonoscopy (",
"    <a class=\"graphic graphic_figure graphicRef75180 \" href=\"mobipreview.htm?28/29/29151\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78533 \" href=\"mobipreview.htm?40/63/41982\">",
"     figure 3",
"    </a>",
"    ). The following examples illustrate how MEI may aid with loop reduction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An \"N\" loop as seen from the front or AP view has been said to be the most common sigmoid looping configuration (",
"      <a class=\"graphic graphic_figure graphicRef75180 \" href=\"mobipreview.htm?28/29/29151\">",
"       figure 2",
"      </a>",
"      ). However, many supposed N loops have a spiral component. MEI can help identify this configuration, which requires the endoscopist to \"push through\" the descending colon to the splenic flexure before straightening the colonoscope with pull-back and clockwise torque.",
"     </li>",
"     <li>",
"      A \"reversed alpha\" loop consists of a counterclockwise spiral (",
"      <a class=\"graphic graphic_figure graphicRef75180 \" href=\"mobipreview.htm?28/29/29151\">",
"       figure 2",
"      </a>",
"      ). An endoscopist without MEI often does not realize it is counterclockwise and is therefore unable to remove the loop with conventional clockwise torque. Once recognized, pulling back with strong counterclockwise torque straightens the loop. Counterclockwise torque is then applied during further insertion to prevent the sigmoid loop from reforming.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178074\">",
"    <span class=\"h2\">",
"     Tip localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEI aids with localization of the colonoscope tip, which may be important for confirming cecal intubation and lesion localization. Contrast studies following MEI-guided application of endoclips in predefined anatomical locations showed good correlation between MEI-defined and actual anatomical clip locations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. However, it is possible to be misled by the shape of the instrument alone. As a result, the typical features of the cecum and ileocecal valve should always be confirmed before concluding that a colonoscopy is complete. Nevertheless, the new generation of MEI currently under development has the potential for image recording to help with documenting complete cecal entry, an increasingly desirable quality-measure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178081\">",
"    <span class=\"h2\">",
"     Colonoscopy performance and training",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have assessed the impact of MEI on colonoscopy performance with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/15,18-20\">",
"     15,18-20",
"    </a>",
"    ]. Some studies demonstrated improvements in parameters such as cecal intubation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], loop reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ], external pressure application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18\">",
"     18",
"    </a>",
"    ], pain scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/19\">",
"     19",
"    </a>",
"    ], and insertion times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18\">",
"     18",
"    </a>",
"    ]. However, improvements in loop reduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cecal intubation rates did not always result in decreased procedure times or sedation requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18,20,21\">",
"     18,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of MEI on colonoscopy performance appears to be greatest for trainees and inexperienced colonoscopists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ]. However, there is also evidence of some benefit from MEI for experienced colonoscopists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/15,18\">",
"     15,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot trial, a single beginner colonoscopist (15 previous colonoscopies) performed procedures under supervision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients were randomly assigned to have their procedures with or without MEI. Improved loop management was noted when MEI was employed. A plateau was reached after 50 cases, when 90 percent completion rates were achieved. Once that plateau was reached, no difference was seen comparing cases performed with and without MEI.",
"     </li>",
"     <li>",
"      A trial of 296 colonoscopies looked at the effect of MEI on colonoscopy performance by a trainee (200 previous cases) and by two experienced endoscopists (&gt;5000 previous cases) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18\">",
"       18",
"      </a>",
"      ]. The trainee, when using MEI, had significant improvements in cecal intubation rates, insertion times, duration of colonoscope looping, number of straightening attempts, and accuracy of hand pressure. The experienced endoscopists had similar but less marked benefits. MEI did aid with cecal intubation in eight difficult examinations, although there was no effect on patient pain scores or sedation requirements.",
"     </li>",
"     <li>",
"      A trial of 152 consecutive colonoscopies performed by 10 staff surgeons compared the utility of MEI with fluoroscopy. Examination time was significantly shorter in the MEI group, while avoiding radiation exposure, and completion rates were similar, but low, in both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is also evidence that using simulated MEI during training on a virtual reality simulator can produce training outcomes for novice colonoscopists, equivalent to those of one-to-one expert bedside teaching.",
"     </li>",
"     <li>",
"      A multicenter randomized controlled trial demonstrated that the performance of novices who had 16 hours of training on the colonoscopy simulator matched the performance of those with equivalent time of standard patient-based colonoscopy training [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178088\">",
"    <span class=\"h2\">",
"     Credentialing for colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More robust and accurate methods are now being developed to assess competency at colonoscopy. Studies have demonstrated that MEI can be useful for rating competence at colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/26\">",
"     26",
"    </a>",
"    ] and that the use of simulated MEI may have a place in the credentialing process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30598/abstract/27\">",
"     27",
"    </a>",
"    ]. MEI is now used consistently as part of the competency assessment during accreditation to perform bowel cancer screening colonoscopy in the United Kingdom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178095\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of colonoscopy with magnetic endoscopic imaging (MEI) are the same as those associated with any colonoscopy and include adverse reactions to sedation, perforation, and bleeding. There is minimal radiation exposure related to MEI due to the field generation method that is used. The strength of the fields produced by the Olympus imaging system is significantly lower than the fields considered acceptable for continuous public exposure. The total radiation exposure is less than that generated by a television monitor.",
"   </p>",
"   <p>",
"    There was a theoretical safety concern that exposure to magnetic fields could be harmful. This concern was based upon limited data suggesting that exposure to magnetic fields arising from overhead power lines or cellular phones could have adverse effects. However, it is the electric fields, and not the magnetic fields, around power lines or phones that are of actual concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1066178102\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging during colonoscopy may be helpful in multiple settings. It may aid the endoscopist during a difficult colonoscopy, it may help with lesion localization, and it may improve the teaching of colonoscopy. (See",
"      <a class=\"local\" href=\"#H1066177967\">",
"       'Problems encountered during colonoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1066178060\">",
"       'Impact of MEI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic endoscopic imaging (MEI) operates by sensing electromagnetic fields using small coils within the colonoscope and larger ones alongside the patient, producing a moving image of the colonoscope configuration on a display monitor. (See",
"      <a class=\"local\" href=\"#H1066178031\">",
"       'Magnetic endoscopic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of MEI helps with loop reduction, application of abdominal pressure, and localization of the tip of the colonoscope. It has been shown to be useful for trainees learning colonoscopy and may have a place in the credentialing process. (See",
"      <a class=\"local\" href=\"#H1066178060\">",
"       'Impact of MEI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/1\">",
"      Saunders BP, Halligan S, Jobling C, et al. Can barium enema indicate when colonoscopy will be difficult? Clin Radiol 1995; 50:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/2\">",
"      Saunders BP, Phillips RK, Williams CB. Intraoperative measurement of colonic anatomy and attachments with relevance to colonoscopy. Br J Surg 1995; 82:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/3\">",
"      Williams CB, Macrae FA, Bartram CI. A prospective study of diagnostic methods in adenoma follow-up. Endoscopy 1982; 14:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/4\">",
"      Shah SG, Brooker JC, Thapar C, et al. Patient pain during colonoscopy: an analysis using real-time magnetic endoscope imaging. Endoscopy 2002; 34:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/5\">",
"      Anderson JC, Messina CR, Cohn W, et al. Factors predictive of difficult colonoscopy. Gastrointest Endosc 2001; 54:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/6\">",
"      Hanson ME, Pickhardt PJ, Kim DH, Pfau PR. Anatomic factors predictive of incomplete colonoscopy based on findings at CT colonography. AJR Am J Roentgenol 2007; 189:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/7\">",
"      Saunders BP, Fukumoto M, Halligan S, et al. Why is colonoscopy more difficult in women? Gastrointest Endosc 1996; 43:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/8\">",
"      Hancock JH, Talbot RW. Accuracy of colonoscopy in localisation of colorectal cancer. Int J Colorectal Dis 1995; 10:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/9\">",
"      Saunders BP, Macrae FA, Williams CB. What makes colonoscopy difficult? (abstract). Gut 1993; :T197.",
"     </a>",
"    </li>",
"    <li>",
"     Cotton, PB, Williams, CB. Practical Gastrointestinal Endoscopy, 4th, Blackwell Scientific, Oxford 1996..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/11\">",
"      Waye JD. Colonoscopy without fluoroscopy. Gastrointest Endosc 1990; 36:72.",
"     </a>",
"    </li>",
"    <li>",
"     Bladen JS, Anderson AP, Bell GD, Heatley DJ. A non-radiological technique for the real-time imaging of endoscopes in 3 dimensions. Conference record of the 1993 IEEE Nuclear Science Symposium and Medical Imaging Conference, p. 1891.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/13\">",
"      Shah SG, Saunders BP, Brooker JC, Williams CB. Magnetic imaging of colonoscopy: an audit of looping, accuracy and ancillary maneuvers. Gastrointest Endosc 2000; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/14\">",
"      Shah SG, Pearson HJ, Moss S, et al. Magnetic endoscope imaging: a new technique for localizing colonic lesions. Endoscopy 2002; 34:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/15\">",
"      Cheung HY, Chung CC, Kwok SY, et al. Improvement in colonoscopy performance with adjunctive magnetic endoscope imaging: a randomized controlled trial. Endoscopy 2006; 38:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/16\">",
"      Ambardar S, Arnell TD, Whelan RL, et al. A preliminary prospective study of the usefulness of a magnetic endoscope locating device during colonoscopy. Surg Endosc 2005; 19:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/17\">",
"      Wehrmann K, Fr&uuml;hmorgen P. Evaluation of a new three-dimensional magnetic imaging system for use during colonoscopy. Endoscopy 2002; 34:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/18\">",
"      Shah SG, Brooker JC, Williams CB, et al. Effect of magnetic endoscope imaging on colonoscopy performance: a randomised controlled trial. Lancet 2000; 356:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/19\">",
"      Hoff G, Bretthauer M, Dahler S, et al. Improvement in caecal intubation rate and pain reduction by using 3-dimensional magnetic imaging for unsedated colonoscopy: a randomized trial of patients referred for colonoscopy. Scand J Gastroenterol 2007; 42:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/20\">",
"      Saunders BP, Bell GD, Williams CB, et al. First clinical results with a real time, electronic imager as an aid to colonoscopy. Gut 1995; 36:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/21\">",
"      Shah SG, Brooker JC, Thapar C, et al. Effect of magnetic endoscope imaging on patient tolerance and sedation requirements during colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 55:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/22\">",
"      Shah SG, Lockett M, Thomas-Gibson S, et al. Effect of magnetic endoscope imaging (MEI) on acquisition of colonoscopy skills. Gut 2002; 50 (suppl 2):A41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/23\">",
"      Holme &Ouml;, H&ouml;ie O, Matre J, et al. Magnetic endoscopic imaging versus standard colonoscopy in a routine colonoscopy setting: a randomized, controlled trial. Gastrointest Endosc 2011; 73:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/24\">",
"      Jess P, Bulut O, Almasi A, Waaddegaard P. The usefulness of a magnetic endoscope locating device in colonoscopy in daily practice: a prospective case-controlled study. Surg Endosc 2009; 23:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/25\">",
"      Haycock A, Koch AD, Familiari P, et al. Training and transfer of colonoscopy skills: a multinational, randomized, blinded, controlled trial of simulator versus bedside training. Gastrointest Endosc 2010; 71:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/26\">",
"      Shah SG, Thomas-Gibson S, Brooker JC, et al. Use of video and magnetic endoscope imaging for rating competence at colonoscopy: validation of a measurement tool. Gastrointest Endosc 2002; 56:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30598/abstract/27\">",
"      Haycock AV, Bassett P, Bladen J, Thomas-Gibson S. Validation of the second-generation Olympus colonoscopy simulator for skills assessment. Endoscopy 2009; 41:952.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13926 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30598=[""].join("\n");
var outline_f29_56_30598=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1066178102\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177960\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177967\">",
"      PROBLEMS ENCOUNTERED DURING COLONOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177974\">",
"      Difficult colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177981\">",
"      - Influence of anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177988\">",
"      - Looping and adhesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1066177995\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178002\">",
"      Lesion localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178017\">",
"      COLONOSCOPY TRAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178024\">",
"      ROLE FOR FLUOROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178031\">",
"      MAGNETIC ENDOSCOPIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178039\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178046\">",
"      Image display",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178053\">",
"      Hand marker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178060\">",
"      IMPACT OF MEI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178067\">",
"      Loop identification and reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178074\">",
"      Tip localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178081\">",
"      Colonoscopy performance and training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178088\">",
"      Credentialing for colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178095\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066178102\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13926|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/49/21278\" title=\"figure 1\">",
"      Mag colon AP image",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/29/29151\" title=\"figure 2\">",
"      Sigmoid loops examples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/63/41982\" title=\"figure 3\">",
"      Transverse loops examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13926|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/40/6785\" title=\"picture 1\">",
"      Magnetic endoscopic imaging display monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/30/32227\" title=\"picture 2\">",
"      Equipment configuration for magnetic endoscopic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13926|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?25/62/26605\" title=\"movie 1\">",
"      Magnetic imaging colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/32/10764\" title=\"table 1\">",
"      Sigmoid and transverse loops",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30519?source=related_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_56_30599="Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death";
var content_f29_56_30599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30599/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/56/30599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrhythmic death (SCD) is a common problem that usually results from ventricular fibrillation (VF), which is sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ICD has become the primary therapeutic modality for the secondary prevention of SCD and, in some groups of patients, for primary prevention. Other nonpharmacologic therapies include ablative surgery, transcatheter ablation, and, in selected individuals, cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical trials supporting the efficacy of the ICD for the secondary prevention of SCD will be reviewed here. Recommendations for the use of an ICD for secondary prevention, the clinical trials of ICD use for primary prevention, and the general principles of ICD use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Our approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H4#H4\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Secondary prevention of SCD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD is highly effective in terminating",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    and in aborting SCD. Initial uncontrolled studies suggested that an ICD reduced the SCD rates well below that seen in historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Some of these studies used a discharge by the ICD as a surrogate end point, assuming that the patient would have died had the ICD not been implanted. Such reports showed dramatic benefit from the ICD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/8\">",
"     8",
"    </a>",
"    ]. However, these findings must be interpreted with caution because of bias in patient selection and in equating shocks with death. The latter criterion will overestimate the mortality benefit of ICDs since VT may be self-terminating or asymptomatic.",
"   </p>",
"   <p>",
"    Despite their limitations, the initial uncontrolled observations provided the rationale for performing three randomized controlled trials (CASH, CIDS, and AVID) to determine the true benefit of an ICD for secondary prevention.",
"   </p>",
"   <p>",
"    The non-SCD rate is increased in survivors of aborted SCD who are treated with an ICD, most of whom die from heart failure (HF) resulting from progression of underlying heart disease. The ICD would not be expected to reduce death from HF or non-cardiac causes; what it may do is shift the cause of death from SCD to non-SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As a result, the only appropriate end point is total mortality. ICD therapy is generally not indicated in patients who experience SCD that is due to a reversible cause, such as an acute transmural infarction. Therefore, patients with SCD secondary to a reversible cause were not enrolled in these randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As will be described below, a significant mortality benefit with an ICD was noted in AVID, while nonsignificant trends toward reduced mortality with an ICD were noted in CASH and CIDS. The lack of significance in the last two trials could have represented a beta error as the trials were underpowered to detect a significant difference of the magnitude observed.",
"   </p>",
"   <p>",
"    A meta-analysis of these three trials and a fourth much smaller trial found a significant 25 percent reduction in mortality with an ICD compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (hazard ratio 0.75, 95 percent confidence interval [CI] 0.64 to 0.87) that was entirely due to a 50 percent reduction in sudden death (hazard ratio 0.50, 95% CI 0.34-0.62) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/11\">",
"     11",
"    </a>",
"    ]. The absolute reduction in all-cause mortality was 7 percent, meaning that 15 patients needed to be treated to prevent one death. An additional finding in a second meta-analysis was that the mortality benefit was limited to patients with an LVEF &le;35 percent; there was little or no benefit when the LVEF was greater than 35 percent (",
"    <a class=\"graphic graphic_figure graphicRef67116 \" href=\"mobipreview.htm?27/34/28206\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CASH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cardiac Arrest Survival in Hamburg (CASH) randomly assigned 349 survivors of cardiac arrest due to documented ventricular arrhythmias to an ICD,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/13\">",
"     13",
"    </a>",
"    ]. All patients assigned to antiarrhythmic drug therapy underwent predischarge Holter monitoring, electrophysiology (EP) study, and exercise testing; the results did not affect therapy assignment determined by randomization. Assignment to propafenone was discontinued prematurely when interim analysis revealed a 61 percent higher mortality than seen in the ICD patients.",
"   </p>",
"   <p>",
"    After a mean follow-up of 57 months, there was an almost significant 23 percent reduction in total mortality in patients receiving an ICD compared to those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (36.4 versus 44.9 percent, p = 0.08); the benefit of the ICD was more evident during the first five years after the index event (",
"    <a class=\"graphic graphic_figure graphicRef59549 \" href=\"mobipreview.htm?14/26/14765\">",
"     figure 2",
"    </a>",
"    ). The secondary end point of SCD was significantly reduced by the ICD compared to drug therapy (13 versus 33 percent). Crossovers (drug to ICD and ICD to drug) occurred in 6 percent of patients, and amiodarone and metoprolol were discontinued in 9.8 and 10.3 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     CIDS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Canadian Implantable Defibrillator Study (CIDS) randomly assigned 659 patients with resuscitated VT or VF or syncope deemed to be secondary to arrhythmia to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or an ICD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/14\">",
"     14",
"    </a>",
"    ]. After a five-year follow up, the total mortality with the ICD was not significantly reduced compared to amiodarone (8.3 versus 10.2 percent per year) and there was a nonsignificant reduction in arrhythmic death (3 versus 4.5 percent per year) (",
"    <a class=\"graphic graphic_figure graphicRef68588 \" href=\"mobipreview.htm?43/10/44206\">",
"     figure 3",
"    </a>",
"    ). There was no difference in outcome based upon the presenting arrhythmia. At five years, 85.4 percent of patients initially assigned to amiodarone were still taking the drug (mean dose 255",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    however, 21 percent of these patients received an ICD, while 28 percent of those initially receiving an ICD were being treated with amiodarone.",
"   </p>",
"   <p>",
"    The data from CIDS was analyzed to identify risk factors that might predict benefit from an ICD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/15\">",
"     15",
"    </a>",
"    ]. A multivariate risk model identified age, left ventricular ejection fraction (LVEF), and NYHA class as independent predictors of risk, and based on these parameters, quartiles of risk were constructed. Patients in the highest risk quartile, who had &ge;2 risk factors (age &ge;70, LVEF &le;35 percent, and NYHA class III or IV), had a significant reduction of death from the ICD compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (14.4 versus 30 percent); there was no benefit seen among patients in the other three quartiles.",
"   </p>",
"   <p>",
"    Over a 6.3 year follow-up, the cost of the ICD was Canadian $49,115 more than that for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ; since life expectancy with the ICD was 0.23 years greater than with amiodarone, the cost effectiveness of the ICD was Canadian $213,543 per life-year gained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/16\">",
"     16",
"    </a>",
"    ]. The cost effectiveness of the ICD varied by patient risk-factor status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/17\">",
"     17",
"    </a>",
"    ]. In those with &ge;2 risk factors, cost effectiveness was Canadian $65,195 per life-year gained compared with Canadian $916,659 in those with &lt;2 risk factors. When these data were extrapolated out to 12 years, the cost effectiveness in those with &ge;2 risk factors ranged from Canadian $40,604 if ICD benefit continued to Canadian $52,715 if ICD benefit decreased. In those with &le;2 risk factors, the cost effectiveness was Canadian $322,240 and $549,030, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     AVID trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Antiarrhythmic Drug Versus Defibrillator (AVID) trial enrolled 1016 patients who were resuscitated from near-fatal VF or who had undergone cardioversion from sustained VT and had either syncope or other serious cardiac symptoms and an LVEF &le;40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/18\">",
"     18",
"    </a>",
"    ]. The trial was stopped when a survival benefit was noted in patients receiving the ICD compared to those treated with d,l",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . The unadjusted survivals for the ICD versus drug groups were 89 versus 82 percent at one year, 82 versus 75 percent at two years and 75 versus 65 percent at three years (",
"    <a class=\"graphic graphic_figure graphicRef82697 \" href=\"mobipreview.htm?20/54/21357\">",
"     figure 4",
"    </a>",
"    ). However, the unadjusted improvement in mean survival was only 2.6 months (31 versus 29 months with amiodarone), a difference that was reduced by 15 percent when adjustments were made for HF and the LVEF. Not unexpectedly, the major effect of the ICD was to prevent arrhythmic death (4.7 versus 10.8 percent with antiarrhythmic drugs); nonarrhythmic cardiac death was equivalent while patients treated with drugs had an insignificantly greater incidence of noncardiac death, primarily from renal and pulmonary causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of mortality based upon the LVEF further supports its impact upon outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/20\">",
"     20",
"    </a>",
"    ]. In patients with an LVEF &ge;35 percent, there was no significant difference in survival between ICD and antiarrhythmic drugs (83.4 versus 82.7 percent at two years) (",
"    <a class=\"graphic graphic_figure graphicRef81890 \" href=\"mobipreview.htm?7/57/8094\">",
"     figure 5",
"    </a>",
"    ), while in those with an LVEF between 20 and 34 percent, survival was significantly better with the ICD (83 versus 72 percent). Among the relatively small number of patients with an LVEF &lt;20 percent, survival tended to be better with the ICD (72 versus 64 percent), but the difference did not reach statistical significance.",
"   </p>",
"   <p>",
"    An economic analysis, performed on a subgroup of 237 patients in the trial, found that at three years the total cost for the ICD was higher than for drug therapy ($85,522 versus $71,421) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/21\">",
"     21",
"    </a>",
"    ]. The ICD in these patients provided a 0.21 year survival benefit over drug therapy. Thus, the cost-effectiveness ratio was $66,677 per year of life saved by the ICD compared with drug therapy (95 percent confidence interval $30,761 to $154,768). This value is only moderate cost-effective.",
"   </p>",
"   <p>",
"    It is likely, however, that the cost-effectiveness of the ICD depends upon patient selection, taking into account age, underlying heart disease, LVEF, type of presentation, and likelihood of recurrent ischemia. In particular, patients at lower risk in AVID did not benefit from the ICD compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although survival was the primary end point of this trial, the effect of these therapies on quality of life is also important for understanding the impact on daily life. Overall, the ICD and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    were associated with similar alterations in quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/22\">",
"     22",
"    </a>",
"    ]. A reduction in physical functioning and mental well-being was largely related to the occurrence of sporadic shocks from the ICD and adverse side effects from the ICD or drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effect in the community",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the data from the above randomized clinical trials apply to routine clinical practice was assessed in a report from the National Veterans Administration database of almost 7000 patients with new onset ventricular arrhythmia in the setting of preexisting coronary heart disease and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/23\">",
"     23",
"    </a>",
"    ]. An ICD was implanted in 1442 patients. At three-year follow-up, the patients who received an ICD had significant reductions in all-cause and cardiovascular mortality (37 versus 55 percent and 23 versus 36 percent, respectively, compared to those without an ICD adjusted odds ratio 0.52 and 0.56, respectively), with no difference in noncardiovascular mortality. The benefit occurred despite a significantly lower frequency of use of ACE inhibitors, beta blockers, and statins and the magnitude of benefit was similar to that in the randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect in elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival benefit from an ICD may be reduced in elderly patients compared to younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. This was illustrated in a meta-analysis of pooled individual patient data from three major randomized trials (CASH, CIDS, and AVID) comparing ICD to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/26\">",
"     26",
"    </a>",
"    ]. The analysis included 1866 patients of whom 252 (13.5 percent) were &ge;75 years old. Over a mean follow-up of 2.3 years, older patients were more likely to die of non-arrhythmic death (8.7 versus 4.0 percent per year) and arrhythmic death (6.7 versus 3.8 percent per year). An ICD significantly reduced all cause and arrhythmic death in patients &lt;75 years old (all cause death HR 0.69, 95% CI 0.56-0.85; arrhythmic death HR 0.44, 95% CI 0.32-0.62), but not in patients &ge;75 years old (all cause death HR 1.06, 0.69-1.64; arrhythmic death HR 0.90, 95% CI 0.42-1.95).",
"   </p>",
"   <p>",
"    These results suggest that ICD use in elderly patients should be individualized. Patients without significant comorbidities may benefit, while those with significant other illnesses may be more likely to die of non-arrhythmic causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Etiology of heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of the ICD in relation to the etiology of the underlying heart disease was evaluated in an analysis of 3117 patients in the AVID registry with coronary heart disease or a dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/27\">",
"     27",
"    </a>",
"    ]. Despite differences in clinical characteristics and other therapies administered between these two groups, the two year survival was equivalent (77 versus 78 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect in heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large randomized trials have shown that patients with New York Heart Association class II or III HF and an LVEF &le;35 percent have a survival benefit when treated with an ICD for primary prevention of SCD. Among patients with advanced heart failure symptoms and a QRS duration &ge;120 msec, the ICD may be part of a combined device that also provides biventricular pacing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ICD also prolongs life when used for secondary prevention in patients with HF. This was illustrated in an observational study of 603 patients that was based upon stored data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/28\">",
"     28",
"    </a>",
"    ]. The occurrence of VT at a rate &gt;240 beats per minute, which was assumed to have resulted in death had it not been terminated, was used to calculate hypothetical mortality curves. The potential benefit of the ICD was estimated as the difference between the hypothetical death rate and the observed mortality. In patients with NYHA class I HF, the estimated benefit increased over time (15, 29, and 36 percent at one, three, and five years, respectively). In those with class II or III HF, the estimated benefit increased until the third year and then remained constant (22 and 24 at three and five years, respectively) (",
"    <a class=\"graphic graphic_figure graphicRef54306 \" href=\"mobipreview.htm?26/54/27501\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect of shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of shocks may be an independent predictor of poor outcome in patients with an ICD. In one series of 421 patients, for example, the four year mortality after adjusting for LVEF was greater in patients who received at least one shock (17 versus 11 percent for those receiving no shock); this difference in survival was significant only for patients with an LVEF &ge;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/29\">",
"     29",
"    </a>",
"    ]. The four year mortality was also higher in patients who had multiple shocks (33 versus 20 percent for a single shock), with the difference in survival being significant only in those with an LVEF &lt;35 percent. The combination of a low LVEF and multiple shocks identified a subgroup with a high mortality 16-fold greater compared to those without these features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of electrical storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical storm, defined as &ge;3 distinct episodes of VT or VF within a 24 hour period, occurs in 10 to 20 percent of patients receiving an ICD. Data from the AVID trial suggest that these patients are at increased risk for cardiac nonsudden death (relative risk 2.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/30\">",
"     30",
"    </a>",
"    ]. These patients may benefit from more careful monitoring, with consideration given to other therapies aimed at reducing nonarrhythmic mechanisms of death, such as ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H20#H20\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Electrical storm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mode of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ICD reduces total and SCD mortality compared to medical therapy in some patients, mortality remains substantial. Several studies have suggested that a majority of deaths in patients with an ICD are the result of electromechanical dissociation and not a recurrent ventricular tachyarrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30599/abstract/31\">",
"     31",
"    </a>",
"    ]. This issue is discussed more fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Mechanisms of death'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of an ICD for secondary prevention both overall and in patients with heart failure and cardiomyopathy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link&amp;anchor=H19#H19\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Our approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H4#H4\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Secondary prevention of SCD'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/1\">",
"      Akhtar M, Jazayeri M, Sra J, et al. Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation: ICD therapy in sudden cardiac death. Pacing Clin Electrophysiol 1993; 16:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/2\">",
"      Mirowski M, Reid PR, Winkle RA, et al. Mortality in patients with implanted automatic defibrillators. Ann Intern Med 1983; 98:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/3\">",
"      Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. Ann Intern Med 1987; 107:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/4\">",
"      Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988; 109:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/5\">",
"      Kelly PA, Cannom DS, Garan H, et al. The automatic implantable cardioverter-defibrillator: efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988; 11:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/6\">",
"      Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989; 13:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/7\">",
"      Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/8\">",
"      Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation 1994; 89:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/9\">",
"      Kim SG. Implantable defibrillator therapy: does it really prolong life? How can we prove it? Am J Cardiol 1993; 71:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/10\">",
"      Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995; 92:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/11\">",
"      Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/12\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/13\">",
"      Kuck KH, Cappato R, Siebels J, R&uuml;ppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/14\">",
"      Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/15\">",
"      Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000; 101:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/16\">",
"      O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001; 103:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/17\">",
"      Sheldon R, O'Brien BJ, Blackhouse G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001; 104:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/18\">",
"      A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/19\">",
"      Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 1999; 34:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/20\">",
"      Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/21\">",
"      Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002; 105:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/22\">",
"      Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/23\">",
"      Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol 2005; 45:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/24\">",
"      Panotopoulos PT, Axtell K, Anderson AJ, et al. Efficacy of the implantable cardioverter-defibrillator in the elderly. J Am Coll Cardiol 1997; 29:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/25\">",
"      Narasimhan C, Dhala A, Axtell K, et al. Comparison of outcome of implantable cardioverter defibrillator implantation in patients with severe versus moderately severe left ventricular dysfunction secondary to atherosclerotic coronary artery disease. Am J Cardiol 1997; 80:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/26\">",
"      Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/27\">",
"      Ehlert FA, Cannom DS, Renfroe EG, et al. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry. Am Heart J 2001; 142:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/28\">",
"      B&ouml;cker D, B&auml;nsch D, Heinecke A, et al. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation 1998; 98:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/29\">",
"      Pacifico A, Ferlic LL, Cedillo-Salazar FR, et al. Shocks as predictors of survival in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 1999; 34:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/30\">",
"      Exner DV, Pinski SL, Wyse DG, et al. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation 2001; 103:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30599/abstract/31\">",
"      Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39:1323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 922 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30599=[""].join("\n");
var outline_f29_56_30599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASH trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CIDS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AVID trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effect in the community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Etiology of heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect of shocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of electrical storm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mode of death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/922|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/34/28206\" title=\"figure 1\">",
"      Meta analysis ICD v amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/26/14765\" title=\"figure 2\">",
"      ICD versus drugs CASH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/10/44206\" title=\"figure 3\">",
"      ICD versus amiodarone CIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/54/21357\" title=\"figure 4\">",
"      ICD versus antiarrhythmic drug AVID trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/57/8094\" title=\"figure 5\">",
"      AVID subset analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/54/27501\" title=\"figure 6\">",
"      ICD reduces mortality in patients with LV dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_56_30600="White plaques of VIN";
var content_f29_56_30600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72661%7EOBGYN%2F78650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72661%7EOBGYN%2F78650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia (VIN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Raised whitish plaques as a manifestation of VIN.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christine Holschneider, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 411px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGbARYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmo7BWABBUe1XYrTywpVdwHrV+C3ZzhQMdsmlm8xFVXCrz/D3rkubOLRnsoGVAIGfpTPILuN+eeABV0wsq7gOvv3oK7UPG1wOvcUuYtRsUZhDCCLhgr+gHFZqCWK1cDCbTluOR+NWr+4EahL1RKs/yhl6g/SsqS6SCNyJX4I5KFuPfuKZpFXLiRHvhoXHDg859CKqlPMuZbef91KOUdeWPH+eKle+t57FDHOYXbgMi7kZsd/SpZHuxbWtxLDH0AYg4JPQkUajsYC2Eulyq0sYmtGYq+Bhtp6ZFXrO3tX051+0lArEx7cnZxxj0rZuI4ZnUTkh5xwy5AJHYn1rPht5bPUnMXz2zgbmC/db3p37iS7GLsvImSS7jiEWTtnDcH/DirMGoXNxdbYJR56FVZ3+6yHufb+VbFxskeW1ePdA67skd+9Z8Wni0vCLeMMJV2sxOCV/+tTUinHqX7C2aO6urN5ldCflaM7kP0zV6V0SRYTMySqPlKdvYisnz4reIyNHvmtG4bdyR+H41ZuL21uI45TE6xEjMvdM9DnuKCLdizJcy2dxDHOnmWsow3OetWFIaOSZRvuVONqnIIz6fSoZrmO1UCTbI4+VCwDHP0+lTQQM88L5Do4I+Ufez347Uc1ty404sz7ud54ntwWZCQ43LnA9M/hVAI8lvJdbNzMQ2c9Qp/wABXQ6zbiysg9rAGZRgrnGB7e9Z0wzaGK2jiABCKqnIOPf8KV76myppLRFPBWRmZgocF1BIPHrRa6g1zbWQ5W3wTLIxA3qByfp0qgk0iIXeIuWg3RI3pgHH0/xp+jWCf6ObtjJKpwUzlYyRn8OlCIqKyNoRpLE7oAsTguikcMSetTTxqY1duWRcFgDnJx2/Kq9xOkc0TxTDzo1GUU/Kc9/0NZZuZws52edJI33T2PvTMoxctUak6R/ZHhLkMoA3lMZJ9/wqCKeZ2jicBfKYDlgx9s/zqi9w87lYo2EyLgbhhSeM+5//AF1JGWkeQHCfLsdgMHP1p6DcJGk18bcFblgCW+8gI3MT2FW4AZHzOoaEDO0nkn3rMWNLO1BtD8zH5izcHGPWrEGpMkRFvGryI54nO3kc5B79aW4+Xl1L/wBtSO7hEMLtIR8ynoCfU1ZmVUZJpnUrECSQ2Av4d6yZ7ofbnljJlumjyYs8KMdcfU1YiWW4jhLZiJ5lYc4x2GfelcnlHXMkwllEcCGR1BBdsAjnGf1qZGtntEKbgV4MgGQT7Gq1ukMt9NI0onCEq67uefUdqsQy25iJV1to4D86scA45wO3cUBy21LAlWK2gEKmQMA5YDJ57mrcUyoELsXiHJI/XtWbDfxbT5Lxwq/35UUFTz03Y59KrxKl7qMaFbiKTkB1k27Rz26/mKZDjc6U+TcxJI4JDjIXb1FSGFXtHe1i5Hy4XknmqVzNJI5WJ2OFABP+RU9sZvkRnCxgbueKaepm4tJCQmGN2y6RNjBVlz+NFaNvYpcsxIUMPUnNFNX6IbXdlWxhUqGkJXjjHSmykM+zbuGeKuQIdmJGGPRRTHeJWOD15xWCN1HUzbmJyo2lUPbNQXEMksEi+bj3xkCtaWBZY+ck5z71RnyH2RBiGGPalexSjdHPQR2zStDHIJSnzMxOcfSqsksKagCFYMpwTIRtYHoQavbPsGsqs8SuJVKeYg4HTGaS9gMbMIIxNE2Nxfg07lWsZUSR21+okG52bkqvykH+9jj8avSvCYXM0rbQxC5Pb2qC7ubiNGdURYo/vIF+Yj/PpWULi8uruKSDYID1U8AN6g+tMaXMXNPvXszdLM0l7EPmgXaeB6An/PNTNrFpJBGsSEMzfNEV2sPcg9akW3O945JplfbnKJkZ9j37VUureSceZvk8+HgJsxu/Gne5KjroSiWOOcyEEoy5Zhyce1VU1BbmGSO0VkaA/MDySO3NaelqkEAtWgUMwJ27s4BPr0qvdPLbyuyWkQUYGVPzbf6mhMvluzBYrcM5gj2Pvw+e57NWzp9u8kbQTlTEeAMYAGOlV/MtolaSLzFdjlhj1x/jUgl+0wwhPNB3qVAO09e478UmX0SSHQ2c0enlSgMqHYoxneAeBn1wMZrqNJtfKlWRpHUbBhRwqewqlpSJG7B9xkLFinYD1rZcJC6NtIXHzKo6n60ndgkhz28csu1CHwcEnnNQanYrb2Nwtmh8w7gCBjBI5x+JrX0SJbu9WSSLfFHzsWTaqnHVvWrGuRLgoijJJOIweOa2hD3Wwc3zKJwUdmIjE7DDpGuBtz8vf/PtUV1bG2uLmUSoIHKuAB82R1H0wB+tajlrSUM6vtIZOmcc8VWvf3lnN5qgvn5cLjg1kmOceZ2Mpv36lwsTAMGwTjAGKjc5kCgADAAGO/rUSwxwFlRSpbnj+I8f0FW7dhtJmU+x3YANMSSWhFbAxTiJpIwGOQX4A6YHH5VLcSGFCDuEn3cxgHfz26ioklRH2OwVmIAGKz76EyzGETyjzF3DDYHB9ug/xpoGia8lup7mGNyLeKFd7n8flA4/OmQGCaSeFoFuGU8vId4B9BnjNQS2dyYsPdFiQdxfoB6AD8Oc9qfCBbQt9jd4/N5I8vd3xkDt1J4FUZNM1dPhgW8Vd80coHDDLDHvxitQAXOptHaXZ3qoEitgKAf4VHT6k8/SsW4vUggSGBA07KQNxPX370ui3O0xBMF5CVlmYHL8nuBx070EtG2ryafBdKwhtY5DlXVQdrE46ngDn+dWIrWyu7NzFBFdlHyz5V2JHfJ4qtd+UFw+J4zgBHA2lu2KsQXkMdxFDA8RkI5Qv06dqm9x26oikSeG4WGZ4Vt1yVCAthsdTwP0q7HHbJHEku2JgM+b/e+tQxJE980lxIp8o5EbfdJ9PerU+0yo6RAwA4bAyB+FTcGhqXAmmJtkDRhtrO+QCMA/L61rRXEUsqcM+BwMdKwZXDSq4uVUMwVQcqAMY4AP0rdgm8uQFVXIwCRxmrW2hlKLT1L8byLgh+oxlu9FMe581iWZVPXbniiqvYjckV1VW4HXHuaiMZHRMSYznPSpxAIo2klG1RnnrVZ5sI4QsD/Oue5vYqTSSxqGyDzjHtVS7naEq8Do27khj0qzcYaP5QPMX73oaydYgDwxSeQSV9Djn3pFpGdcX722rLvQyRuCQNw/z3qB9TaOVkSOTyyc7iuApqzdWkFzaRvK5imPAJH3fYGqd/bJFZeXHOxhHzPlxkHNUtSrdxb3TzfzeaIWhl/56tIwyB9Dj86IIkgDRqQzBC4YjI6ngGsu31lI5o4o5bh1II2wwlx+fT0yKnnvHlwxglEJ+5I3Az7gdKpJ9QsuhoRam7WYnjiuIy2ACEByT061XL3Tyo9wxBjyNoGcenPHFV7VpI7KJjfY2KFZCmQOcEg9qnt0+1xyH7UXZWxu4y4obsVGHcnWNghZgsEfG9IzkD1GRSWiuUkjmOE3ZV+pPT06VYWMC0CwOqIQCWYZz6iom/ezuYWG5NqlTyMnnFK9yrWKVxbhXyjOFJLEHB3UkCgurbCSrZHrUk0gbhkUEjd16/SobS6BkbKEEIJCzH17fpRYa1NeCYxSBlT5pOM9cc//AF619jTAoh3PkLknAX1JrIt5R58UUC5lk+ZuPuj/ABrp7KJvMtoRs3k4Bx796LNk7Gvp2mw28SySop/vFc7jTNtvqFwUicqocIvrnrT9du3tU8qFgdo+YqvX1rD0688m+YKpVEBcFQck44/Wt5SUGokQg5pzNDVLP7PMyn5ucZPrXN3hjnwpbAYH8K29XcXrpcmSWNivIb+Ju+ev1rnCOJIVjwYydzE56+/+elYNa6FJtWuZM6pGwETBsc8npUNv5s0xKMGjX5mORj61duFDEsuM4yMVDaecm1l3Ag/w8VcVdFvTWxMsSyBNmd3qWXHrx+eKmFhaGYSXM82QpwyJkZyMcjqKniAupIxCrI4AJY4wDjnnoPrTJopEeYxLF5YYB3ilIzkH8MfhVqPUhy6XMbVoFYb0iWSMtgMSdrHAwOemfaoP3q2rMtqw2HagZ9wPfr25rQnso0JkgAhcqXUBjICd3PA4z7mst7aXyXjeFcSEOFT1PtjLdM81LVioq4tkt6qtFdBg8o+dxICNvf8Az70lveSm+jjEMq26dNgBVyuep/HpxyavSuruFh+0rIYwBvUDn6AkD+dRMG8pYWcFGwA7HHPH/wBcUXsS43RbsrpvnS4jCAE7EY8d/T39K0bZrcjazLu3bQ6qAd3XJx9ax92UVYYQQgwADwT149BVyVxFEigO0szAE4+XJ98cdqT1Fym6Z7dUwwQyDGJAOWPpUEV248m3IbezFSYgWXHufy/OsUyvFcXNs7o0Y2vhj29Pr/iK1oriN2jliLxIqHk8K2P0pWM5Is3BhF2WlHlyoRtVU3ZHvk06S7jBPmNiNsjaTyfXiq+mp5073NwvnZOACMAenarF2W+zSCwMUbbhuXYADxVrYylqy5a3UBPlhkCBQREMMF9+KKrwWkdvJ5piUtIoyCA2Pxoq7oxcX0OknfdKY0U5HJLD+XtVR2WWRkcKQeCScYq/MdsrLkKedxHOay5UT7PIQ21+xxXIzsSSRn3QaBGIG7GQO9Zts10yhr8oMkqPLJAp13NMCkAxIjHGR6/nVWRIzcfZovMjdPmJUE5PvQkVbqWVdIpjBPOJNw+RW5bH+faqc1gWjlmJ2RgZKk5wMjnnvWhZ7bjJnba0A5JGD+VPugrI5iAkVV3j1PtTQ/UwTLaR3KSoWLIoAUKcMfy61HHqTwzOZUElmzYMSdVLdz3xWlBb2W871aNmAIWTAJb6elQQwWkt35EGz7oLo/AIz+uPaqRTsZ0KLDOVjB+zkHNo7MoVuuckEc+3FTeXHLKjW8bCTcFbgBVIHftjFXI9R8l3t3hVp7fOTxhh2xUM489gCqwoSTsBJMnA7dh/hSuacumhbSN2keWMghiBhiOPpUcxfdEFjDyKDukX8unrTFPlDcVaN1UYLtgZ4yRVvTwftATyxlvlBU5ppEuXQoJp/mP5s8UsR2BSCc8eg/Km3EImneVjiIAY9sVuziOGHZLMxI6biSQT1zWdLhYgwON3O3+9TGnoO0CMSStK6tvkAKn0B/8ArDp712GnzRWt8ZpFXKIzKG6Z4A/z7Vy/h9ZJLyUozLGqjCgZwa2dUuC8kSqmSkYz9M5wTVx017GL9527kN/cSXci/P8APLnHOAB6VFp7bL1cgMEwrKehHvWfBcMwjkePjfuyOKablUvsgnEg2t71g25O7O5R5VY6PVo5oY2CSiW3SQqrD5toz29M+uK5W9LwtOC6rJkCMA5Vs/Mc+/I/Wut0Tz5LGZGC7nBAPXAGQQfyzWAlqpt7yGcFX6Aj+LjI/oK1ics7K/kYNtPlpFKN13cngmtCRUdF+YjHz5Bxjg8fzrLgl3Aq6EFcHoc49etaQVbt2dP3TMMbAMnt0yeT7U7WEpXI1D7I5UlyrMPu7sficdKfpMX2ucRRR+cqNtYLgBevX6dKfJMBbAyZ4GBkZA6kng8fiKnMbfZXMiMGdd3nK4Rtx7k457fStoNbMzmm9SeSG1Fmj2ShJlyrbjySDzx+frXOzNKdSJ+0DKsVYY5wORt9hmuonv7qNYGfSobjy03SSKC2T6vzgflWUsKT6e8iW4ZBJ5gi5BQE/wAPcgA9PwpzhZ6Exm1uZZinlkQ+bPcvECxJH3QT3B5xzj8KpBfs0kMk5hijlYu207kjIAA56gDnr7VYieeJfPUJlvk8vOcndxuyODxntiidY2ae3YBXkLPjd8pGBn9T/nFZNWNYyT3LUziQG4gkj+0PmRGLFDu4GcjPr/npTYLy5ljtFa4SZmOQxXDM3U/U5AqqFa3Qx3EsCzPGSiLgIoGASfzBp8EkJYPGYJpIk2B93fHqOB+P5UkErblq2ZoFvmnX986F1OM9B0/HitNbiOFEFw5yUGwBSAM+tc1YsGuSZZ3aADaJCpKsw4+Xse3Tqa3YAsEBkuVMqsgMakEH684xSegnqXFfzz9jkmMG3hpAxIT/ABNWE0pLoxxSXZuEiYSMA+AR23AYz2x9Kq2BTa9vIyhG+cy4zgkdPzzW5pBt5ba4eNWiCgBAAAGHc8U0zKcBzifB2yIqKcfMuaKTRRA8U2AfLL7ssDgn2oosZ3UdDZk5iYgEvjqe1YmpGRIGhRFd8ggFsf5710MiHIhY4U8k5/nWPfRx8gqA27IAFYo2v0Od1ZxZpbMrKLgtwGOFI9KhtJzc3EjRyeU5zwVzz2Ge5rRv5kmMaDho+DgA49qr31nDDD9ogLgDDBEyuT+FUXBaElm0sUZRg3mxrknaBn8f8aWfa9yo38sPMJJO3r0qXS0H2cSMxdnJz5h3c0pVxGp2opZs5I7HqMCkW9BlzJFHZzSwpG+0fN/WsTWTDIAbYkTwOGCY254ycfhV8O0VzGyeXIjHy3I4yexxVe6Mn2qO4C/vfNw230AOCB3HShISdmQ6fAJ7yGSRDHASfOXOMLjt6nPNaqWdvHE80W8qWIjZuTjvVQXEhuESWOKPcWbfu7dsCn2BlE8vmOGUNjdjBA5xx+P6UWKlPQlkRkiaefADD5Q4zgDp+NWdBZ3Ly7CI2wFYkLjHcZ70WkM17eSXMRQWtuQCzHr7/rVrVrgXWnvtAY7tiyN/EcckA9q0RiZF4yzX0oDghMs+453MffvVdZ1uYjuG0g5yAewqeO3E16s1uAoQZIQcZPT61VtrSaOOaOUbndsLs649PrQy0zotAb7NbGZlDtMxHPU5B5/DrUGpuVjnKSYVjsGDV3TQhRYWY4jyxz2rntakYizijO0uWlY+xPH6U0m0SpJSTKc1w8MkSOjlO3HWq0k2292Y2rvAIz05ruoYZJbOF2AMip1Kcgdv61h+LdP22FvdRhBcBuSo68jr+NOWHcVzCp5hGc1G250GmyyWLRRMyi3KmVSeSSRjB/z3qtq9vCL2TzwPNtz88RHO4HBH4c/lVLSpf7Zn8rKxuiKrDryAM4q3f2BtpIzuWSUgOzhsg5GRn3qNkdCSbt3ONvw5kkjgUK6NuUY6Anp9OKsWu5p1hYiM/e5OOf8ACrHiGAWt+97br8kiDGDgbh1x+FUd0haIkqXYbVzzz6f59atu6uYJWZrPCsTl4osFnyyPxheMc4wT1q3bhWLxPLGtwmNiFFKsuAMhu2PTtxTJGkZIpnT95xEoK4OOcH3xjr24qwYAWgtrhBkAOr7R3OMknt/hRGQ5LqMtLiS6WdXiS4x8rhv4B22/p+VQarbvBpe3btYPuEiZBC5+6ecfjTJLcqrXEcjRsTs8yNztQ54zjIxVi1kvspDNtwhCrMrbxLjtg9D9f1rdSTWpg4u90Yr6S9xcSAxXdwAmU8pDtyc5yQPQnnn69apPClpcIxijkCoE+ds7emTx+Fdo0LXQuJJNOtV3qEcJujAUc5G3j9KwNXWHzBLLYxLZhjvjhuMYGDjceoqZxW6KpSezRzcot9QnRYyQ6OQzMMqAM9Pqe3tTLa7uDbOtlbeYgO5V2HhevqPrWkk9vFOsKWjeSF6IWdY1989CevH6VA15hVW1NsY3fLhGBKL0AIAOWPofTtWRq13Leg20kUUc93IN21j5bxoVTJ56E45Of8a27Sa2ljSRkUNsJYkkE88YHbt/kVkpLLdgSW4uI1bghgV3HOe/HYdvy61UtbhvtczPfKZsnfAFGVwccjn/AD60PUk6BoY3nhkfzJEYE7FPOOg4A5HAqVGCWl2LZUjQOMKeM/lz/Ws/UrmCzkt2hnWW8YfwLjAPU5psFyHeWS8kMduACWx154LH64qLWZbldX6G7Y3EZsbcSwBm2DJ+bk9z1zRVKzeOUSKJcsCDkdNp6fjwaKvUwsjsZg3nnkBC2CW4xUOq7c28h5Todvb3rQlXDMA25Cc1nXMEYvQwhU+YAcngAVzou1zHnaza8uS1uHlIwWQZGO3NV0IjiNsrgyE7hvPzAHtUuofabeZ5UjR7eIgnHXB9vSqqzW99cXMyIrMVGVYEH6YPatC47EsatEoMb+YzAY3AcH8Kjud8lyPOWR8KNowNoYHqD1FFpDGY2haJY2X5lHQfhTbt0gESLK7JvGGTBznoCRQNlea0ZrmTdISqcl1yuD2Bx/OqtoIrO3SScuzKCFmP3nyecd/SpkHli4S4ikaGV8bnOQSR069DxVe2EzXJtpFSMDCoAuSCDyB+AFMByutuWCrLM7HO5huIA7Ad6kW3vby9DSIwt3bcxwcn2xV2BZoC0pILhcfJ82fYVrWoecW4fKyHPK/dUDk5/lS9BeZKLWG3eCMgrAMmRM8EDnn68VlTSSX99mKEJCCQkIOcDGSSSfQVduZLiGA+bsaWSUYLN8qx9ASPrSvH5N2qQSFnMZ9CCSMtj8j+VUlbQRURk+yyMUZQxUhsYG05wP5VFFIr6ikaHLn5yR6np/Orl7JLJe3VskaAKoXOcEKDzgevFVtGhX7VM5XLyHYGxgLgcn64pxXM7Izqz9nG7HbpLWaYLyHiZRz04wf0zSW+nw3OulW3/wCjRKHXHGMdvc59qr6oyvq90I33+VGWDAjBOR1rS8DtJq2u6jKUO1HVtoPLcYH6fzrohDlVjkdV1I3O0srSNIpZZlxHCm5YnBI9gf8A61cNrFzZajpM8tpMYnEiuYGGOoJz/wCO/rXSeMNVubzyrS0aWCArlht2kj/9ZrgL+0MeoXwucnYBscDljjpwK3lKNnEzhRlZTQ3Sw9pq7sGIEsWAV45xn/GulknMNo3nSiczxhQWblcYC/kOMVj6hGlpptlOfllVUkcdRxw2PqK1Yo4XtGLDfhSeec85x/ntXncraPaU0nqYvijC+RE6hGRPLbkHJHAbj2x+VUtNtke0hFw2NrgjPQnOBnv0NWbqKO+mFuy7WG4AKchRuG0fqaZZRvALlGVvMgTkdec4x+ZAqktDGejNGJ5XESczeWFy28DAYZGAR1GCD9a0dPmIVE8rz5Bz5vdfT6ZqjYWaSSbC2XY4XryQPy5Of0ra0WGBZXEhYEqY27BDg4P55HWpTdytLXFaG3ubTzMmK6wQ6v8ANnvnPp7+xrOWzuCifbLQSxltj7Bgrjv7iulvJ7YI0FqvERG4tjtjpj6CjbLJboy5dei5c/KDxwM8H3rcz6GFOJYbtEtIxNC2D1X5T7//AKqz7pEkMqzQwrNnBVpCN3+7nCj861Lu6kis1RZiZ/us4T5sf72CP/rVmRNarNcW98ss6bDtB+XDdM5bt06027i5bbHL6jB5dwyy3UH2dUBlG4vkdhgHH8/xqGa5KwowkQQY3bFh2MwPRcHocDsR1rUXAsF8zTgsJYsJPmLeuAB8p5xz1qneXRigMpgdimQGaPJTOABzg5yR6Vky2+5BaPKpj824lSeT7tvHGPkQZHJ5J4x+fSsx3eKSS0hhMZmkaR7mZTGx3H6kgex5rUsIZJ7WSRYop2uVUsxBVmBzyQvPPGF4+vrDO9iNRjtXt2k2IBuXaFV/7uSWxjpxn6VZzy1ZHZ6HAsFxOZ1fBA3Z3qTgdyARj1rThtIpLCI3MGwp8yDJAfAwMEYJzVoCCSHYkBDHiSPORz17frirWEt7ANFC7lVKqzH5hjgAVDepdnZDLC3t5AWhmcoOMxo2T9ePrRVk29xHaxfupEY54UMW6nrjgdaKLkNHoBj8xfukAcexrM1KGVj5Lx7ipHzZ/lWxcXsbR5jD57IRt5+v9ay7z7TtScOASwUgDcFHr7muZG8dTL1aDfbKSzBkBDdunasSxsjIArM+H4yvABHatnUFnjuj5hZwy72J4H5etQi0RLcgSKHB4JGB7dKu5rHRDbwJbwo7K0pjUjaCcnHXrVC4gS6WGW3iSCTYCfMGTn8Dx+tWJrlY51iMJHm8mQZ5b/OKpSSrHGS4QPE4PDjnnp/I1SId9zKuroSK9qRtuFdNxTsQ4JH0xk84q7AsCRSTs5MmQGlJOQT3P5GqPkvNqckrtsjLD92wBZlOcHjgjPrWxp9vbPcR2wjIiVmZmx989BkH0z096phbS5esrqOdAIZ0kAbcsa5Gz2+nvmrnzRw/O/ltMCkfkjBDHnOaoJapClysLssZ+RdqhcfSrItGjt4osuTghGJO4e/5ZoQNrYTTNPdb0JO++12BSWPfrzVu5SKbUreMOwKsGcI+0gAEYGPY/rUtnatbaMp3eazId395mB4/TNUo3H9qKYiJbkoclTj5ue5/AUmx2TJGsobU3kjO7tj5N7M+7JwTkk4rOsyysERHY+WW3RsUA56n1xkDHfFWLiD/AIlhRyguJWXndwOM49+T+lSTWRtrgQuybkVsqMg4XkE49evet6C6nm457IzBDAia29xtaYkeV9ec4/Srnw7u7iw1rUlhiimuGjVxGzY3cHp+lJaWUV7YajcyjMwnRVJOAN3X8etYuludO8UtdQsp2uFK4yCNo4rZ+6lInDRU7wOn0fUL2/1XVZdReN523Q+RtyFA5wB29c06/mWSyvGRI1kaSPHHJUhucflmrfhM2T69LPJsV8gnecKT9af4vRLNIBDBsEbkTFCWLRH+LGO2cVnJOUWzrU4wqqCMDxChbRYEySiwbRuQLnryOORUdnK8ULvHIqKYQRgdcgY9uela+rWfn6NbtCY2g2lRIFAyMdDjvUFogOk2Zdyq3FusRk2ZUAe/4VnBN3NpSUWjCeLZvkj3M4ZWLZ7d81C7ypA88nyi4YOG7ngZH5g/nXQ2MfmabqMQwsxTb90HoDznqOfSuZtrtbmyWCU70ibKKxxuUjpVOPKhN8zb7F3S72KUKyK0qBWDjbypGR0PbOPwrowQlr5iHEvCOuMFwc8/p19xXOaVIV3ARFUOEwo6HIyMfTNdGtwAbaN1RHtgAzY4bI4P146VzW1OhaIvWgtzKqo23eolIPIbIBx+Rpy3lzFKQ6SWqQkykxkHzAPukknjHPGP5VCjSXPmRRYOHHldsj25wP1/StUabKltDdXLRq6sGWIuSWHccfzzW1Nt7GVSOmpz2stcSoLqTcbKYmNgsgfdkA7uOvDdazLqKOyvJGMb3AdP3TIudg9Dnr2/Kuq1QWlvos1vZrG8s6K5YKnyuQCCQB0zjg5PY98c3BcsYikhj2BsIFZl8vnG1vbr/wDqrWSSMotszrizjjaMwRK4JEkflmMbOOrMAOevT/69ZV8kJjuEbb5cjF5ZUYuSy4IH16eorev7GafK7YppS5z5km1VX0z19fzrOksLazgjW6iCwSHzMK4PY+nPBIPSsrjkrIxbaK4gihaGFbgSxqJQ0wEb5Py/UAHGMimS2kFrdsPLZLrONsLBAPbcOCPbqK2HtlaETBSLdjsUeZ1PTdjGMfjUC2w3TRzOswKcCRQ5B6AAnp+GKVxKCE0+H90JoTOYyVLljnePUZzx15FXcJOIPNdkRJBIyFsBl9Kp3U0K7Ud1hhgUbod/p0BIxz07dqkaLzYIXkYLEuCC/ViQflUUgb0N9dVkMzyNsVDwolIP1xiis7S4YruJiqTuuckKSvP9cciimmYSirnoV1am4McshZdqlMdsHr/Ko54Fa2baxYpjbnGSRWo0jw5QKAW9ecVnQRxkSsWI+c5Y+tctzrinczm3XUjK5VQE529fpmslZQxSNosOuVYt1NaksCQNcTs5MZ7bscelZtu63EDRvuQBsFgDkfn7VSNltZFS+jM0k8cm5ARuQDuPYis2VIpLdrjLRsgEe8nJA75961y0KXAIchmUrsYcnHXOPzqnIJo1n+9FvXcGwcH06irTJsVblJEjtc7ZmlcwhgMnIXIJPcf1qzHF/orlrhfOhJICDhuM56nvVIXitFGskhZIpNzMqZIPTPy9qWayS9llVPPVpNrARMCrgkZPsePXtVCkizpt81yGSSIpKSN7DkZ4ret3tpbuzEpKyQptjZjwDkkk+3NQizt4LeSRpEIbK7VPQ8AZ/KrtlpbxsfNKSg7G2NzkY5/p+tDZC1dy7qCC2Vfm+bpsRdwxjqMdves23DxzI8i/Kh654HXnHsM1e1G1jd1eMyrA+4BWJO3HHGe3GKzBKtmzJMFf9zIwbJ/iwO3frSk9bFr4bmLqHm3WnoUyA0gZdp/vHofwUVpQ2jGSSRXBnYLCrZxgDAH4n+tOeNHKL/q4vPQMP7pVV3fkc4+tX9WmittO8nTXDzBmkMvQnCA4x049fetqEuW9zgxdJ1LWMJLprWyntlfcJLoHf9AM/wAqzbT/AEjX7+4jjk2MWkUZyQe2cD17471b2m2W1jZhIznzcgf3sf0NW/DVtHfHUJZA0j58zdnG0bup7nrW9STklEeFh7O7NrwboL3GlO0zjzGcl4+AQM4wPfirvjCRkstPvJ7NJjA/kuMkEqR+v3RWrpVqsPltcyyQtcgvFKCOeeRz0P1rl/FGvm91iHShIZZIH3yjG0Zxj9f6VcUuQUuaVdE5g0vUPD1ylpmwkZhJ3Idhxgg9Dg9utZkPnQ6fa2jbRdWx8s5OAwyNpB79cc9KsapLZx28BbyllXnagO5h3P4VUbVIdVtDb2IjS5tzvWQttLgZJX3/APrVinZ2R0VIaX8zSt0hWztLtWWA3EyxykvgKN3UAHdjg5PHXjpXm3mpFOyKuFU7h2xkf5FdvqtzBLp1pc75IrR9yxhypKjGFH5gCuN1BrVVHm70vFkyxY/KyY4OPXP86VRbIdLZtm7oKWxuYJZboBihkyDzv52j88VsEzG4khYx5DNGXLAEbSOfr1/OuI0O8aFtiqvHXGCCM5wfxxXRWV5b3mrTfb45BFI+QyAliThjxn3rm0bsdLTSudRZmVY4Tcq0bEht4I259eO3Xj3rYW5nmHlGJ1gUkmRB/EexPYYPA56GsDT2EkEvmOoVCEUFtoIPP5Z54rQaxv7GxN29nJKryKw28B1Y4wB1PBz14xzWlO/yJnbruT3M1rJmFCTbquEKgZbr2J4HPUn865zEFpd+eqGJpGG6McqAc/KB1Ppz1Fbk8j7XaV1WdMElAoVQO2AOSOMtk+lZLoTJP9oJDcy8ZYMee1aOVkZ21MnVbpdrIjBTMwwEUKqj3I6dKSO2SOY/aIRO5GNrEYB9cZyP5U+NRPHdTXIIXy2jjDINoB28noDyGHPv6U/901wZfs/lpJzGqtgDsFH5fpWdrg2k7MzCiiaWGNF8pXGEU4IBHOfbOajjSJCrs2+Y5xtyFVckAD3x1zT3j3yXDwhXY8eavVBgcfgcmoraFkkiM6IWhjGVHT6fr+n1FJkqV0R2tmtvOHuBHLNKxICk7QOefftWg0JSIG6xPL97Hl8Lx2568enerrRYdUlC7uPmUdB3xVvT7d/PCrsYSZcBeSmABjP5/jQmZS0KOmpK9u/mMLTD7V2qBkfSiupsbaC3jJkPnSOdzFxn/PSimYt6mzc+XZhGd22s2Arckk+pqNsSgIGAy2Tt4OKu3kSzIplUsMBlBBAzkc/oapvKkd2yiInYgkbZyCfpXIdsTPdIN00Ct5nl878cZ6gDPeqs8pCylo1XK7TyBz2OKtXTxyTGXlHkIYIfTFUNQYTyQuigyEeX5fXseTVG621KG0WzoTseWVSQD0rPlE7Mv21FKJgZHQjPfOdvsRmtlI47lTbExrOgyyZ6HPQGqWo+RPA7PA4bhGbaUYc8HOORVJidjn7pJbRrh45redGfcITh2UevUdqswXcsk5KwS+bjaIIlyHx7jvj+lWruAwWM8IkuRKB95irdefqD9BVrQdLWGxKSSthzvJRj0Hb+fNaXFdPVkcjrPFDbyF43fIbBJ+7jgfoK6DWi9zPFFZqYfsybpnLHLn8+pzimaTZWsM91KHCYUSQKMFj+P1qzFdPHp7tcKXndiW56seufpn9KZnuyOSaVbBGmyRtJXHpnt+VULlElZFiPLRpnvgcH+WPzrUmZHsGSMmREyNxJxzwSM9BVT7EROptWJd12FQOwwM1k9zRqyKuthIr2CFGVlnlDl1HB459uc/pTdbhjWKOKP5kkbYMDuzHt9COPalvSo1GzDKfLUscAYAAI6flmq97FLNcxwMAqm45G7HKjjH55/GqjvYza925FeW5mubuWJMwLH5cRxjHYH24P60vhqXyNMuRkbpVEYxxkZ/WtS4lSPwldum0M8pBbndnGMDnH6VgeGWWVY1YKTwDxx6V01HZpmWHtyO56Tp1ul1pkBnOWX+4OqYHPHU9eMcfjXjOuagLfx1dzxNm3eYKp9QMA9efWvZ9Uvraw0dYVSKKREUo8TH5iMA5I46ZryDW9Pin00ajayLL5jbyCOVJOcH/EevXrWjkuUnDJzm2Wb26Vr65EblFcAfMOvqKwtRtP7I1OCWzuVmkVllXyz8uPfHQ+1QJeuLtjl0YrkMzZx8uCPp1q3JKsumsFIMsYJVgfu85P6ZrjbtI7FrG3Q2Z/shvUht1MMdxIl3aRPtwhMg3qS3YHJ75AB9aw/EcaTXboEAVV3KB3T5iO5xgE/lWxbafe6jpFjeJbiVLaYjzARvZSAWGMcgAAg59fSpfEFjva2nfiESfZ+oXaMdCNoIxz2NbOTMKDV+Vva5gxtDDJ5MaOOd6tnkqQCpPrx1FdJp8cNyQ9w2GCgLjvxjH6Vy+hql7qD+YxiGxivcbgCQv44x+Nb+mwx3k8YWT94GJwGwD0Pr7VjJa3OhPoaN5eW1uYZ7h87G8tVJzv5GM46+309q6sQ381q13KPsabi+wufMkJHGR2AGcDtntWBDp9t9ttp553jeMbI92TsbPJA/z3+tddrTBJYDEfkbDrlflLYVVGO/0Hp+NdVKD5XqefXrrnSSOWeF2nVWZocYPufoPUelP1MCWNpozmF9qkNnODhQp9Tk7jgnFauo6e95qsOmwWzyXdwSZHZhGFQH7qHOBnGCx9cAZ5rAnP9nSXqxn7VMn7uN4xkEjqE7Djv6Y655U4W3KVbn2KQMbQ7LdmBfcVBPbjqOw+bj6Gmr+9hiAQykZ2jGAPU0+K3m8xlgKecy7meQY5x0A/z1q3DBIrK4aN9pyeAQcjH581lsXrIw9scSS287EEYG5XI3Mcc4HU4B/L8aFnQW0rH55x8ihBk7d3GRz6/wA+tWrlEN6XZGknX5GO7IUZOPbJyP8AOak0y1kheeKGCUJs3o3B+YsM554HJP1/Cp3B2Qo+XMGJZGCnLKhG30A/D/69dTpMcCxOYXCnIDPJgMfbJ5/Cq+lWMlvp5eONDcli5eUEgZPAH0rRsAgiEcTbZpD+8k6bjTukYyu9iCeFFlP2Eo7EfM0eDx9aKfI0MU5Uwm64P3wOPpRU3K5Ga5EyXYMjDYnAQk8VBcGRrgFUHlgFCvcfiOtXwCWlXAkwcluoz9ai3yCIxxKgkQ44Gc8ZHeuZM6OzMnUHjWzeMxfvUI5xkist0xKk0ZcttG4FsY/D862YJhLIbi52RBhhsjAGO/NU44PLeYxnzXZ+Mnonb2prQ3iVUie0ikmVWPmNvA7k9OtUtt7ezStIwW22bjGhwzYHvWy7q2nqGBZFY5UDoc4xVKJUklkEjlVCFSBxgdqtMGr3MzTyhskgnjjM0r7DtOWY9D746ZNdCdCvliSOHEYOfu4ywP19KoadHJZtFcSKBEGIGBzjPH59a7DUb3yIUkSFpzImV9AK1UbnHVqOErI5PTg9rdi0mRgFJ3Hg7e/PtzVu8heJYrYfOZJGJkHIwTxj8AKnjmlf7Vc26LvmUoqdfmPr+Ga0pYZLe1tZZ4pLiVHQMcgs645OAexGOaTe50xe0mZdxartQNv8ocID0J96Ytw1tJ5tsGgG54x824qODjnPSruqRB70w7kCIpJA+neseVxIqBWH3m3HPXjBP8vyrDmszW3OrlOdoGuFLPuZI/kGepJ5/Hn9KrTqHureIMGfbLIcnAUjv+Qq9Apt7hL541fB+SHGOMcE+o+7XO6nd/ZpWlBDTeRhFwTnJya0h8SMZr3WWry4WLwy0RV8FjtYN95iTj8KzfD9u5CDBRT83Ck556HA71a1qG5vvD1taohV49vK8EAAZY1e8LmSOcXFrG0n2VSQ23IIx16H16mtpPmaMYe5Ftmj491BLprPSbePyZWjxLsH3VHt69P/AK9ZVl9oFmNKuJ3bTwdwiborEEbh74/nWl4cnj1WHXNUvpDJJcXEQtnb7xRfNDHoM8nnHHStS+0ia1uLN2jbF2uYSpBDfl37VpK6RdC0VZ7nkviyxbTb4rG26FOVJbOV6jv79KbYTBrQAhRlSDketeh/EXw2lzp17Nc3TRahaRLIkBjZlkjQbX+YA8jA9semOPIra+HlJEcbgSvJ6VlVizanOMrnv/hWygs9FjtAGS5mhjZFZDtAlGA2fpkfj7YrgNehmt55rIbokgkIRs45U5ODnr25zWtpU15q/hlptOvIkv4okgO58kkYZFCjLKcpgMOM56cmsa2updR0zSDcxjMsxDckksMkk9sdse1b1GpQVjzsPzQqybMRoWtr55i7bLiJju5Idd5x6fxJ6dQfTFW9FZba8WcMm1ZNzKQDtIbp79BTLq18kzzzKdgxEMdNoYAfzFVLKAxQM+8kHCnJwQT7Zyeh/Sueb1PRp6rU7LQ9Qk826FzBFJmNtjEAlSxx+Bya6oI8l/bSmV3RYGVIxkYYFdrE59z7cd688ESNqSrFKY/LQZKpuJO0Y/PNdLpWoajdSrFIRAI4WAkSLZhQp5BI9uo/Dsa6KdZKNmcFXCtzco7FvVbvzraRNPYNdXOLf7SDhIot/JH0DE596rCwtbe1mNo4RVXaplYnzG68fix/Sqs0bIitF+7tWKQpGGOCgbcQT9V3c+x9KfbTPdDaHVCScgYwuW3c/jj8qKk2xwgo6IckDT3kVwJI02jaQeCVwen1JH5VaRkFuyxRuTuyjuflDdyPp+XNNmbY6RsY037d0gPKAcYz2696NaS5lihFrC3k4ARUAGTkDJ9fX0/WsLm1rGU8V5BHbm2jEZkl4JXcZj64GOg/Lmrdvpd4liFurpYYguDHAuHfHGWZskDv0FPgi+y3EcM8zqYWwzgZZfp+P+RU11Is7mGylDMpEjkEEn8f8/jRexnZydgXULewRdNFzD9rmLMluXBkbjPQdsCtnTtklviLMrEZLDI/DB6fSqSi31G7tbie0jgki+SNjGNy8YOG9+fzq/NGYlJtCyl8BmRRlx6kHr9amTQlFrcga7jsZjmJGyMEsQBnP86KJbW33Rsd0xKDJkxx04FFSpW0N+RPWx0ETzpdSrIuLcg4UDn8akgiSW1uWVnQBthZe3qAf61NNcxQSyxTuSyHlucDNQJKZQ7yqAJGIAUbRiudMlu+xg62gGkyZjLguAcfMOtRwqybopGjO9Qq4Ygk+nsfpWhcubCy8hI4zbBiCSMce2eaY0EBEUrDfInIA7A9yKq50RTtqZ0yC1tXhhR84+VEFONjA0iHy5CgY+ZyV3YFbFnNA1pcE24F07gByM/KO3PTmodNUODEEchyTvJxintqWndsrWMaz/aUjVPKPTcuQrHvVu/1W0lSGyieRLhCI92PlUgcgE4xkGrtukdvHP0jVuMn0qpMtkls8nkB2Dbs8jfxjr69K2jUSRzzoqU+Z7EGlndJGEzIIVB2+rHjn8asX13cWpuERmLIx2cAHYeuMd8g07RkS58g25ljYuJSByAADx+pH4mneNJ4IDGQ5lnLAHKkHGM4/Q1KV7tBUmlUULbmTdRTNfQQ2UwuIsAux+Uk9cnPPQYIqvNAieXEsbqdxZmP8We340ye3D2q3BLxOPmDKe+c4Hr1FXri+Msjyw5AcL97BPTp/wDX+lYydzrV1oUIoT9nmzLtDAoPmxnODj/0H8qPsFvHJfGaNjIsKiJk/vA4P8q0bfR5ZrOSQsyNy8Zxyx4zx2zVjTrALaW7OwCmQxuGzuz15/OtqKd0zmrVI2smZXivRZbuVrfTlbCIsihc5IcBgGPXjNYOqaZqHhvwfMbq1PmT/KpM/Gc8ZQdTzxnH0Nd14faT+0Lx2yW3bOu7AUYA59q574lHU9R1W00+ysJbuJR558tdxXYORjue+PY+ldNru6OaLd1TltuaeiQaLpfgmxit8m6MRW4OfmDn+IA5984x1FRQXswiRY5CbcEso3H5SRgkDscdx7Vkvo3iiOzd20a6iiTHmPsBIHqFByfwHFUrnf8AY4yt4zSkkeWicgYGOfrnt2qajbeh30Kcbau+pX8eTqumGO3mfzDCUkIdhuzkkY445AI6HBPevHkYLLvXrn06mvQfFWjzW1lHPc4Es6l13Ft4HvkDr2xkVwFrDvuASTsDDdiiTfUJxStY9M8EXMVtbtctAm3yyrSLGQAP4ix/vAZ9eM1Q8JasdWuLxMwpYaa0slsJAuSXOSCQMnGWxn/Cqvi9Ro2lWGn6YJjfX0Qm8tgNyxMMqMj1Byc44x7VPpejadYaOkOnzXMt1cXDqWkUITGp+8Rk4JAJxk9vxqDfKebNKU733LNzOjaPbooYCZzK7EHLAFgNue2eD6ke1ZglV1ACgnJc8ndjgDPbGc9OetSSOguZBMB5dvlipbsSuFTPfknH1PrUaK11+9yVMjHOOODWMvM76Ss9Dd0q3Sectuj5C9MqxxjkflXTt/rAtjBJKzHM0h+bLMM7Sf5/THrVKDTVjtERB+8KEzMRgA47H/PUelbOk6glrYIC2JiuSNuQM55/PgVVKN5WZliKlo3RzOok315Bp9qzxXQ3/eJCjBXJOOcZYVHp0P2i2kCyn92QjqFGS/zHOc/dGR+vpT9Xnjv78SwLHA0cMgWTa2ZCwyM4zjJH09TV3RHl09fsl7Z2k7zKvlTMARCR22/xHHOecHJrqajazZ5S9pe8TR06xF4m20bYRIV80vkPz1HbGKfq89280drZgAO5jY4+/wAc4GOAB3rYtGtbOzS0tHA/ilkJ+6OT/jVGWb7LHv8AlR3X5pQDhBjoD7de3euO6voeirtalC3W3tXkAVpLlsEA8KCMgY69vX/DK6ftS4YzxjGzKcHJP5euaLiBXgibzdhCFtxOCQeePrUi28iGO4YbUPAByQBjuenrSbKir3GRO7uwRCw3khV4Ax25P+cVpySLb7GnRFRx8qISWHHX+f8Aniqd1IIwhRQIiePMAGeP0qEyC4QLmZkjUgOIztX2z/WpK5DSgtkO5kiUZJ57UU7RfMhtnhO/aG3bm45x0opcoczTOplWRdRkZI1eAgYIHI/pSXzwxhElgdkflHXgD6g//rqxLb/aIHkieQSEYxkfjTbbmQfOPl9e1c3N1JitDK1OC2mspIJThyNy/Pzn8awljkkhljaMtM3QscAgV0dxHHHqMk0rKyY+UZ6ev41hTItncSSYcxyNtXGc89K0TN6bsjWtVfAV8IuwbsYLH8e1S7Y1Kjay54XAxn296ZZy4t94hZi3AAOT+lSLAbidd6gCLkfU0i72G3IBjbeDsXg5OBj3qvNCr2oF1L5O4/J5eMHHODWk8JNpKkYUoQQXJ3Entx2rEmBQNCYs+Uql1Ix831H41pGOhz+21sa2mFYNM3IdsqEk5UAE4OBXJ300up6mCzF/JGenJxgGtxbsx232UktuBY8+nX+dZViGt5nljXYCeCeSR/QE/wAqV7KxtCF5Ob3HR3BmliDKzRQhtuVwFYgZp3lrJOyrGzF2XlE6AZycdutV4PMkXyyflknAz7kZNdX4YiEVsyvGHnbLyAt0/wA8dazS5pWLrS9nC5Ue8kLsIwfKTaqnGDjAFXr17QWxWQLEqtvxu+bacH69qsXlrHLYzXCKiKjGN8EZYY5P+fSs+/t4b7S0MESFYUCM3Q4+npXfF20PLVNS1MjQZZGuL6aJJpC07vGQC5wpxk9a5DWvE+px+MojaXUlhHEiq8gUOT84JJU5Bxt7dsjPJrY0uxQSOl7I8ceDtG0sR3wBnHpXG+Lruzt/FEsdrBPJFbwLuZULKoY8FiOBk+veri2o3OqFKMqqT1Vj1KLxSus6BJFq81+1pI4RbiSSBGcjH/LJfm6jt17E1mXd7ol4FTQNOiJt0xJJLgedtBbOw5J+6STz1APauF0/xnc6fbiKzhSBDwxEQDvj1Y898cY4rK1Lxde3E+9Y4U2jA8tVQAewAxWc58x3UsF7O7WiNXxTcf6G7yxxhsEeWsYC4xxyMf5HevOtMtZGukjEqQ+cTteThAR7/lXRiabW9iTu7hjgYXb83oPX61qaHoFleWb2l/8Au5Y3IBVS7dew47c8kdOtSuzMaz5djU8K+HLm1mv9VupbPUblLfkiVXRVJABDHvkAAdainNrHfNHPcI7W2IogwyjOCC65yMAZJz7e4p9uJ9Ls/s9kB9imuD5YZDhjwN564GQMDPXp3q7rfhyLS/C8k8yf6fMwCEHlmJ6Z/H6d6rmWyOPku7t2ucbPCsjBbN127WmkycBcfKPqTxyO7Y7Vr6Hbx3dzBsQhhhSnXgDrn6mst4YV2rCWYR7WDiMoGyM85/T1GCK7fQIZiqytGqRoNuB2rKo7aHVSTauPktpEmZnWRoYcKVHOOcZHtkgUt3dKXi+zKAdhUhsAkBdoGPbg/XnrWksLNHcyyz5ijIP7obs5xgfUVjThheTIPllk4GFbIDEYUn1x0PA61rRjLc5sTUivdJUeytCjXsKyOUCo5BCoctvUn1Hy4HP3uasRzOuDYhY4BhS7dMcZJHp3rOnLyW0dtcLmAvvkQkkLtVUyQPug4z+vudaDTRPaSEnyosbVAXjacgH0/wD1UVtJGWHfNEIp7Rt1lBIZJXABCBgTjvnt171YvWMqfMoRIRgKBnbjHJq3Y2ZS7eW2ZthBIcjt6fj/AJ9KS5t/Jv28kM80kXX+Ed+e1Y3Om1mVoY5p4hcyMJY2IIJ4Z8emelP1C3Z7fYkzoOPmBACn2/8Ar1Lpxe4Ljy/3SjgKRhz6Dv8AjipoIG8hluI42OQQUX5FGOg9T78UNk7Mp3LvLbIHmAizwRyAR3xViCFfJjSXHmEYYg/eJOaY1rOJjNbyIEV/uYzkZ9eMGtBIzJIsqwuqqhXgA8/iOlS9S07bD5tJZwGR/JcAA7TwRj0/KitGOVFtl4DODgrnGKKCbyNRlaC3keJ145Oc4qlI6yWn+hxAzbv9YvKr/jUzSBLuSFn+VuVz39qbIvlKSm5M8fLwD+HSuZAl3Kd1axXVqftG5WQhsLwSQeh9qrQp5sRWQcA+v5dquWMmHYSKSvUZXr7ZFL5EVzeySAuFb+HA+U+oPX9atGl7aC28XkQsJHwoGS0fA/Ko4byXYZJYwkSZ2k9SP7xHarloRGrxO24D7zg8/hUUllGElSOUszqdqHBOOvP500F03qSQnyLA21u5lQDdJIRxk9z09apwW9zfwyi1QYlcq8r8AhSMEfrVyK2RIA8W5XIwzDuB9aZp13Kk88NszzeVhj8wA2n0HfBzWsZGM4q10Zd9ps9mWWXe6ngMq9z2rOnkiFiqxRZkHyiRu5rvr6ZLmz8iMqXcEHJzt4rimsFhKorB03cEfWs6vu6nXhp+0XvbkN1azWlnbyumFIEpyOAfT69K7a1t5IbaO6tTkSRqWh4O44HqK5y9aQxLbSP+4YBNxH3V+lT6NrbWtr5cwUhWKJ6t1AI/CnRavqZ4lSlFMv3MzS3Fzbm2MruMMvQYPHr9aowyzWto8CBNgk2NKExgbRtJ/OorzVZ0v1ax2xq2FLO3f1p0UM+p6e0xkRfKyoJGQSMr/wDX/Guhavc5/gjtoQ2Fm154cIgvwJSWilfyyrKBn5QQccjHWvnTVm8nxpqbWTySwZClpCMkj1xxXtvi3VJfDmjedpzxyPet5UjPx8/IyMdcV4ppIWw8QTpuMkhAZXXjJycn2rVPVRbLwqbvND7mdnVd0bDI7cZpo067uI/OMYhh/vtkZ9hXVW14kchE7R4KkAB1faD14xgfWqt/eWygYb92TwSQSfYe3HamqaWp3SxErKKNMx2tve6Va7ykccLZwcZJx1NdFpVxDaQSR3lutxuRseUfLyc8YOD2/OuU0mRLjXZfPXcyKPLU/wAWemP89q9Ck0lY0+0yOwlZQPki3EcgEL2zyPxxWC3Oat2MiLTbuLTjPqV3awW6yLKlkyBpyA3GDjcM9QvcgH3rI8VX8viPVmypgtYQIY4ZWykKd2JLZZ89gP6CtTxDaXWnyC/1XzTfSDy0WaTHkLs2hpGzu3AYIHr64IrJ8O6LPqeoItrEGdH438Bcfxu3rnnHXoOgrRt9DljZXbG6fbyyX1vb6ahhEWcqx+cnoXYnv7cAA4rpbeydU+ypmWRsdBxT7Dw6NK1GVZJYHZgNvlAgH25962xBd2cUslu6RTDkKwJOPX8ua5JNykdvMox905DVdUutG326uA/X5R396zLe7v3Zbu9vl3OQNwA3b88Zx2+vbAqLV7e4n1fzp8eQ7YZgMZx2FX9M0w3OoSxRsUkA3bJQQVIHv/nFdtOfLHU4K1LnnqOgvBNDb6ehZySXkl65AO7Gecn5uR7j6V01iLWOxFvBIUiU7mD5zknOP17021s1t7WC3N1mOPBlkPGRzwMdOf8APo951trFiJJHbIVVPbnHH51lVqc7NKNHkVkX/tUUUUf2FmxKp3qx4yfb+9/9asqWMfu5BcsePmAGAfYj0welFq8tzBvAiRYjjZtwevSrrySXIUEIojyhA4IOc81i3Y3UbDoFiNuZM4Ytwp/n7fjVpbhvLEEluWOSdy4I/wDrisy/gRRGCszKjb1wcE4zzn061fhlgmZ5Suz+5G+DgUIUo9WSB/JnCAR/Z2JYNggmrNiJ90/KrbydGzzz1yO1IkjTbUlGAoChlODnt71ctk3RFFUoFOcdM9uaaM5DWs45YFXzY1YH72eCKKSO3Mc5MVtAXAwSI8N+Jxziii0WTea2NO4VJAGiRXAGMMcYpLtUWzVriLKZ5GN4/IdatRbWRghJ7ZI6Gnx228lpp96+hGMVyoOaxlx2NshWSGIxg8gDgH3xRewGAh0RVjf5nZRyD9BV6SJ5GbCssQ6EnH8qaIg6sFj3Fhxzxn/CrGpMomYANLDtjmAx87Yqaz+a4iIOZyh3bT/IemazJrdpGksEyLhvvSMAAq/XPH4UsV1Lpl4nm7DGPkWQNniqcSlJO6W5q6e8gtd0+xZIwd4I61lpf7bqd0g2Kg2iVRlgDnceevQDmrF1ePNbXDW8qtJIDgYxis5pJVgy0X7tIghUk4J47e4z61UWlqw5HIR9Us2vFmillLkDBA28YPf3q5DJaiRZIweck7jnJznP61lWsEYBiljAJGAvQjiktWNrGIpk3YJAzWdSdzqp0lFGnNbzakZpokZscYUgfzqLS9O1DMqGJVRiFcNjg9qdoUwkvGSKQh8427sV0Fv+5ku5y0rYI6kEE4+tVSjdcxjiKrg/ZpaHN63bLNA9pHy6cDaOA3oPasfQNdm0/R5tN8hpLpyVjLSYDAkkknPGBXW31uk0Ev7ohjGZd6MR8/GAD1HU968+tbXyobu3lVPOkk3YYlmAHPX8P51tB8ruRJe0hy2OTuJNRv8AWdUs5JvOtbSNgAHUqoBAZgSO5A5HJH1rA0jSoNUurpCzRXCDMMg6ZHX611trYSXV7eKNoN5N+9lDfKQDnHHGM81qSeFWtryC7imV4pVyfLBGM545pSnrc6aKUU0cTb6Rd3OnQ29/9qdY9wLRR7N+WJJYrgt179sCqN74Ss0bfYzzxSYx80h4/Ova9Blwws5BGemCw6j3rM8ZeHhd20s0IRHgUuSpxwBkil7WTerNeWCfLY8x8P3uzX7GG5yLyI7QykNvUd69Htr1pL253mWSKOF9rxqzbHwcMT0ABx+VcV4R8H6rcXb6teRzW1qVZU8sZdo+798DAPua9V8FaS1+IFSMLpS4dmfH75lOQAv90cHJ5JHpxWiTbTRy4qpFXKHhPwnPqN0l5rs8v2OFjMsO7aWYk/O3cnpjnj2ru7XRYrWMDT7aNLaM/KseFzxVy30uEPcl1IjODJgklgOlRazdWqaUSsjLBwysnDAAZzn0rdeZ5snd2iZ/iC9sbW0W6aIPIvRiB8rDpnPpxxXn1/4gmngVYxy+7G3jOe5/DvWnIY9djRLtWaD7sYRzl8nIdgPQH8uSK0dOsLGwuJmIt3RBlGkO7DAYGB09s+/FYtKcvI6Yv2cGnucHIhuRJNNbwI0YAknkcuo9NoyORjpz271raXa/ZrNGt55mS8bY4ZcDBHBz1zyPTr19IdVlW71FFigR7VpA7nGSGJ9PTp+VayXg043kdpbNJNcMFjaOcOsaHBB+ud2QB3rR/gEYta9WQuYGkaw8uR4osByefxz7/wCNSXIMt5Emmw5kJDEueT6k5/P0pxuJLO1e32J9pc5/2268AZz3/WpHgSyUbvllkIIxnGMc+hrmZ1JWEhLySSwqkWScngc49+9TxbROiTynyQm4LtyAf5ioSu+ZUwFA+++M4/z7U+2gabzI0GVGCGK8MvGOvf2NItpJC2Kq940tmVfaANwJKlvxPt6dqms4nvxcEAYRgrZTbt464qO4CRhfIDeaPlfnaCfUdu1OET7EKoZVbkkNtz7YGfendENdSZzLCyufMk24K4cn8xmrf9o2yyBfMxKeCqkY/KjS7eSW1P7tIwpb90cN/wDrqS20pEJZYkRyRkty3+fajUydm9R0RlLMyyeRk8Akciitm0DxDa4wcdcdfyoq0jNz7IuHAJjwVz14qK9ZYIVLozBiFG0ZOaSdtg2qxZ+md2MevFRyTglAC0n95STg1yISV9R+HkhZI85I+6Bxj+tVLSXLPEWDMh5CA4WrgWUfvVUxjPoeKbHGQjSpgt97Hc0ykZ1/B505YfI/QbuOfWqv2RJIJ4niF1Mq4Rt+Bn15/wAav38shl2LHtnkXLEelFjHblAVQxgHGN2Tn1rSMmhuCa5jnpbXyA6H5GRVG1TkyHvx6VdktSsIuQrOmMlAuMenNOhzDq10HVbly+QDzhewya0NSv4IIgmEUyAFjglBkdMimlzMupVcEkupzlkHuZXH2do2Q7fu4IPvTtQDyxGBxsdTnf3qvqM2sWd6z2UZvRcHfhW4BPU+3NGnw6xdPI13YyfMuOFBwfes5U3fQ3jWhu2c7LLeWGoNJbznKkgOK6TSteKWCi5kDvK/zkngD0xVO/thApFxbyxTjqDwKorANQnihsoNsgOAQTgmkpOOhvOMKqUj0KHWYTI1pYBCWX5nc5Cg1zOu6Pb6ZKGRzcPOjZEgPy+/BH1/KnWdlNpcu25VY5XOTuOc47Y/xpdR1F03IxbDqeVA3HPYcVopdznVNL4TlYYIY3jSxyXdsKoGWx6n8e2K3mgnCIQQstmUd4dvB2nr7+5rT0K3sJisQjksIgMGN5fLLn1bg5/E1DrEGkOD9h1J98jhniDA7j07ZHftTUX8RTqxb5UW7qyWXTodUgjKiXJUheN3df8APpVK3thqKSm5Z47NRmRQeDj19B29+la2k+HNTh017N7lord33x2+Nzr756Ae2P61t+HNCOnXFydQSE/MDCCc4GOSRjls9/yxTUVKSsZyrKMHrqjIitL2/wBGeEwwtbDCqiq2ZAOg5AwvbkVbOo2Phy2hN2yxKQAUiABX2x04rS8RSvAcAxxqfnAfGWPPAAPp6/lXkfi6W51HUpp5MNEgyFibKoenJPfvzzz0rZv2a8zCjSVffRHo1z42tpLV/wCz0ZpnBMbt+7VSBnJJ9OvGa8017Vr9oUhhnKrJGFBL9UJ/hHZenX9KhElvHYmZ7qJpjGUeKJndn9mbGFPtnHA4aqDW6i6hlmklkgQKuNw4X29uT6VnOo3udVLDRhdo1vDc+o28csrKh8xQobf83pwP51cu7K4ZVke8kjGSfIcbgM+3rT7SdbCa3e3hACoAzFc+mT7Gp9Tngu2mJm8uSNdyIUJz2x+h/wD11KkxtK+xTFlbIDKJHllOCsKkkKfT2q/suL6aJ0RLOK3iBMgfhTu7Dtxn/Jptv9nks7a4hJF+SE815CSeOOO9MuJA1rG9tFIm04d3GQxB5xn64yO1VzN7iS7bkUNudQ1R7ue7P7tj833i4OOnGOoHp1P0q5HKXvZRM/lIRje4z9O1PghinsA9vavb7SSXUnJJ5HPTFKUlvIUkuJgxU4GV5P8AvD8O3rUsasLC2YXtY3hMaAkbl6k+nNWbNF8v7PvCtgkuTy+PT6f0pYZ5PtcWYIScDCBflIzj86mWG2ndzKIiwbeIypPHrg9qVyZEdjE0MM/2mR5TneuQF47jgVbsw5kXFr5ZGNwZ+gPt3pDcIwZbxGXceNqbgfoBn2rTRcFWDF1IDDIwcY96pGE5O44xuXzE2MH5gO//ANarGcqwI3d8A9KZ1+dUAKioQ0+4KsTHnJK4HbjOadyIq61LsszRsFcLyMg0VPFBuA3YUYzweKKdmTzRRDNtiDO64xycepqCwh8yXa/zIRuz6VJBPFepLDGigg43H19qfFBJbKIo8GVumTkj34rmSK5rKxA14one2WSMqueA+cfUCluXaERrbujs3cg/L+VZd5atGzrOZBKejIP1IBq9plvKlsZZGY8/8tCMiqZpZWuOndlkgjkkLKxzk8H/AD9KigCfaHVD5cRGckHg/jUk13G12GcjcB1C5IHvgcCqyXMk2ueTHbOYZQS0knQAen+OaBraxDYRqbScpIv2glpFLDJf1Gc8VU17W7FdBkQ3IQJlZIVXLlvY/nVzULCz3tHds0YDbkCNjI9KzLq0FnOLmKz32yENiQ7gzHvx25qoy5XcbpKppcb4X0q+k0q2urydlDPuW3Ybdgz06Z6Y7d69BtLh4HEckcUcWMAhic1heGboSJPv/drKc7SG/ecdBkVsam/2WGJ5lAVQcZTeScdOO/5VqpX1RxVIWfKzJ1901GRYY1xsyTIRkE9Mc1F4f8LwR7LxiZj/ABQ7cLnseKdpUMzSXLTB47aTG4SAFz9MdKuRSmwjeHT7kPtGdrjp9azlZu5pByjHkiy9cafZSgyGNVlGQM/Lj86wbqxuVlD2cUZiHUuoABHoTip7rUZjGzs0aMf7ql/xz0qPRtOn1FzcahdvJARjYW2/y/lUXvsaR5oK8noZb+Gn12bzdQ1NYoSOYYCWdv5Y/Wum8PeFtB0LZcWWnr9qU/8AHxOwkl54yCen0GKntkTTgVt9qR9Q3lj9KpaodQkZW0uDzLgkMZbmbEaj/dHLGtYOK3M5uc9E7I6DWNVg063a5lZVAGOep9BiuOuPF8cTebbB7m8lbAAjOxf9kHjJ+lZnii7khsI31K7NzdStztj2IADjAJ5/LArNsdXitGklgj33YhZIRBiRUY9Cc+n0NXKp71kbUcKlT5pask8S6pfSxtPqcqWmEOMtjdjspHX8PxIFcU119qQtahUgUhW+Yjd65PXnoef8Ku33hvWry8W81u8laGZ1k2hg0hOCec9uegx29q2FsIIJoRBKWMS5OY8Hd37nn3rKTdzvgoU4JXMIjdD9miOxWJZ/LQbQT2BPTH51PHZtFZWqxqJo0b5tv3SegFX5IY2Y20DCHapJDcZPpn1qjZ3PkxTWl3dS7U+eMIB1xxmoBSutCw9zdQMR5M4hZAv3TjHscUksljNOgVp8ALy7Agt0OcAbR0pNP1VlkcFknU4JV2Y4HTtzirE2nDl2ZIxJyFBJ6/Wnr0JaS0ehNcaXbx6WtzFdwNKxP7kEEg/UHp7nFWtEke/04rqs6RkktHDGFzn6Y6H1qJLNn09YrbyIlZtvmSy9DjkYHU8/yq5Y6VZ6ZZl3P2i4ZSRInzEnGBwM8DiuiNN72OKdeOzetyK0ZdyQSXMgt4gMQls59s4qWTyIdUaaCSWKAtgHAJHpntUGmSwxB0uId10GJV17enBq/MiC3Mzu/ns3yqVIII5Bx+dZs3T1Ib0zrcLJHGinqAVxx7/40XFsoaKSeNXU4KOB909Tn/P1qaylW4sXe5kPmAhdufugdMZqzAImiAkGW3E5Ck/T/P41NrDuLe3BtJlaSJc/xLnbuHpx0/Gr1oYblRMUbGSArcUy2hBjAuFDydjj7oqx9lSFFI3dOQDjNPzOeVtgVdhXbJLGm7OzAxj8ifyqzFMkbhpGC+26mrB5jLxsC8ZU4JourZ0KRxcru5JOcU1cnR6GnbzB48oquvbJoqnFDEq4YF29e4HpkdaK0SbRi466EcLrFH9ohQgjknA/liiwvWuJhJK2Byck8j8KZBMximtNoWQ89QPxP/66qWtpGIj9qXainIVRjJ965Ubcu9y1Die/eVpVk3DAKnhR6U77UbecoLZ5iDwdwK4+lOhiiiDBzhQudvt+FV/tDRCQ26RksOpBIAp3Ha+hFDGxt55gyRtIxYL1706KG5eFTG7Pt5O5tpNNndI7VRIgeSQhQRgBTnt6VHcxTWiQmVgUccgPggUy7DLmC2GBNEZ5ydyuzkKvboM5/KmRx3S28lvPCzOWOGLY57ZJ6jHanTyrdWyRWAYZOXCLluD0z6H+VVZxFdwDczicc7nbgEdPr+FSy4suwzXdvpCzNceeI8LDA4GV91PUfkMVlza1f3BMrzwrbpz5ZfLHH8/wzV7TYlkO25Ej24/hGefwGf5Vm6hqtrb3cq6fG4kDYIORkdxzk0ud2GoJyatqLD4ovLiclbSRxywOeQPQCqcVzqEs0t1vEbSN8ygglR264zU0R3DzpE2GVjtSMdf0zUdxPGgVEiIHJPGCx/pUuTZrCnGD91FvT7+SOd/tD+amfkMrHA/4COM10lteZje4uZjHbr0VBs3fXHIH5VycTvJtS1tQryHAbOT74q6BY2sTJfwLcM5G4TsTGPfAxn6URuTWhF7bnX2+s6bc2YuNLlt7pCShlySoI68nr9apyvPc3PmW19st9235oi4Y/wCyp4+tZ+kalYzxTNpS7raDo4jEcad+OMAZ/Or091IYUW2lZ2c7ijBWUDscDGcnHOfXiuhQu7o4FBxdip4k0Vru3dlma4jjHLOAoT6HgY9q5SWa20u2AtJCZzlSqqOhGOuK6zUr2CewZCZryZOMjCxR+pAH+e+cVw1xZapKLh/Klt7YDnYOG9ATRONndHdhW3Hlm9EWpNUhksBC8csm3kvs+RT6dhVWO6YQeZJAI4BgZUnJ/SneG3BivN9skvkgPvlPAyeOPejVp5XQPcec7kKUIO0gfT8c0KLauzWXKpOCRmah/rncncpP7skj9eKoJc2zkfbZMhMqFjGd30xRqFzcIkgZoiiHnewLt7D/AD2rL1PULOCOMoLieNvlYHjYeORgdKVikrGlm1mmExuPKjX7oTg/TPJFX9Ou2M0rWsc06jPMnHy/XkZ/GspbyPUTHaWdqYMKMszbi3qas/YHtLhEjlZY2x8gY4/GmtCamq1LUV8txcyW8qyWqowcepHGR/Oup0Y3H2KVoroF1Zgql2cBM4BA79D1x2rm79oWhCXUEaN94Eguyjn9Of0q3pIubomCBmkt1OQVb5VPrW6r2Vmjz3g7vmTsaMdu9zcI9vJiRW5lJAxj2q9erLHcRqZftQjbKsCM/UEVHaW8SWoi+zOzE58xm68+nrmrzW11aGGTaqsBwD0x/Kuc67kkLRSz4VBbqUJ+VsAADpUkOyW4d3iUmMqSxX7vPYn8PWo4LNWCuZBuc7mUnI+tXhbQSSPIgZlHGQKZk2i3CrGTMgyM8qByDVryVliOcYU5G4VXtwVRUG0hPWrEKEr8/B9Acj86owkx0oMZyfnJIOFpdyswJH5mpZSAgUDPYHGadDb73yVwvpmnbUi+l2KIYyckADsDzxRVsRqSQe3pRWnKZcxifY44p2nGwlurDGT+gx/nmoHMUl4mAwwM7GOKtTNKJ0MSBYgOm08n65NMuAsM4kmULNJ0A5LY9vSuU6YytuR3yvNCzbWwgzuHVvp61VtJJxbKvCq33uAc+1XLxS8OFkwrnG0HtUepSvp9tCQm4S/6vb1PufSixcZXVh9+nmRQI021VId1TqMdP1qG7igurbndkdHYj88U6MoYx5ZR3Jy7P39wTWZctH9qiZsuitvdgwb8AAePxpiRPbRXIO22+Xu0u37xPt/SoYNIv4meW6ngETE/M4BYD37VYl1B7yZTpVpPDBbDM1xOcEfQZAJPPPPFY2p+J7VnKu5Vhwobt749atUu5k6827RRqC9W1s5GhIjiXkvu+Z/f6flXNkIjS3zYALfuj3Y+u09frVG5vmuldL1xcxv91yPnB7HPaoo2it5gtwBLtGNoY+ncj+VZTilojrw6lrJli5lvZ9skNxK0p+aR1UAj2B6Af54p1kZJbeaW8d2ZeS8jZ/AdzUOoyRLBHKiCFZjhVBBPHtT7SRZ1+zum8tg/P0X/AGvc1CR0t6aGxayBrdWWQlekYOF2++P8agsr1JNTkeK381kXClsMAfxByaa8e9Zg8u9UGGJfaPpk1NpOpw2zj7HGLmcDlsEJH+Pf6nFaxSRktm0rmxBBe3lr5V/xCGHLuR1PIGMqvGeSCf5U25jtdEtYZLx44kVsRSMvzyEkYOzOSPckfSqFz4mulZ4LjUoYkJBxboXZc/7Sgj8Mketc1qOrQ3V1EYrW5eKAlllaPczvggBRgAdc5wOnFa9NDKMJSl72x102tfabcJo1mHjGcXFwRkjvtRflX8TWPFrc66hJb6jeOomXy3EBXkHseCMfSsc3ms3rqLkNDbleUZ1Rse+TnPFZBAtr6BYZESUvwQhuH/Jev45pOTRtClFJpmvqtncWLPdWZEljE4MrojQsyjbn73f5u2f5VjXkl7dzTTJeS2sat+7juD+86Z67f1rt3huLqG3sktL24BcPO8sSxljwflDEYBPGBj+tYV7BHb/2lNqEVy7+ZgQzoCVXqNxBxnjp+VaWT2JjUd9dzjr6T7QvmsS8hOC2Thj3PPeociRVMcrLIAAQ5xxTXeOMb0VkPO3bzz9agtH/AH/3ogX4AcYA/E1g0drbsW7K2K3S4ZyHznYx5rYsLaKS+2eckbcFmbnj8KoP/ovlxTMreZ823HUdMj1H6cVbNjGYVlZ5I954wQePXAJoMnrqb58lY5IkWCQM2CWXJA9RzU0UEllGrw3KOrHDKvG30rHhltoVIhM0rqv8MbMfzANb2nva3McUKWjxuxyVcMoPvg0jN+6jaV1dIFjlErkYO3+E+n8quvDKsRSdyZWyfLfPGO9YiR2yXiLD/o10pI+ZiG7Y/kOma2V82CctdlpmYEZY5yfU+/8AjTMdh9rbNcQebJId2NpQZX8OK39OtlhjJjP3hyCSw/8ArVj2UiTs2wgCIjOen4/rWxZkqcKuEPXFVExqttEqBSjMwzIp7/pUscYmTplQeaewWJc54IxRFGyyMN2PYd6vyOe/UcU8tB8w3E4FWIUdgDnGOtLHbn5mI57ZGDUsSnA/u+1WkZyloGxk5Azn2op6YGck0VpoZ3M2Y7ozh+eAB6VDIxSRRLukAGcA5H0OaZdNJLEywgIynJcrnj0oiUNAdgeRuuQAFGPY1xm6MvVpGt7gyeX5LPnavAJ/Co4ILeQLNcMAVAzhsgn0qOS5i+0qsoMxB6be354H+etMfyobk3NwphgJymeOPrQbp6W6jY4vtDSu8q+USNqk4x/PP5VDqVzFaDym2oAAQchRj171bUs7tdW0bttHylyPzrE1O6EsqG4YSSdQEAJX354p2KV2yCcf2pIoeeaJHBASM5Oe3QZOaqXdrb2YjikSa5vl+Uh8jYe30NWriCeWDfBiNIujlzux/SmWknkSebOyTTsmFfI+Ue3H8qbkzRQS1Rk3r3ip5Hk4iYhj3YexPHNVbiVEtljjUxyKeWZM4rdJM9yFTHmFtoZ8de/PQVLPaQWsXm3SrcyuCwZeTu/rj8KzcTaNVRsmjAsFjH+kTTyKEGAGbkZ/u+59quuLddqw3UnlyYZ/NAU7uw4yxH8617TShcK9xeRJCGAw5JZlA9hVjT7Kze+S1tyskhb7wU59z04qS3OO7NTQPC0U1mkt7I5SRchMYB+oP9axvFHhqOzvYFtnuNkp2xw5UIMdgcfpXpukW6W8QVxvPqayviCALOIRSpCwffk8HHcDHPetFG0eZnBHESdW19GcRo+kW0Mix3kSs46AvlifpSa3bRJNDEE89c58iHkgf7WOB+dYl7renWwmFzq0VrbrhZdxLTSnH3VVcn8yB6msU/Ee0sL2IaLCwhA5eZcMx9dvIH604KUtzqle91qz0iPTEe3D22kWsM23aC3mykjv8iEY/EgfWslbqDQ7+RftsKzsG3W6p5bLwf4YnJPX+N81yU3i7WvFVuF1i9aG1zkW8Xy5HvjHFWfDVrYvqdtbLFE6M4G0nAb6n0q5yitI6mVOlUacp6I1NHvpATHZQXUkkjEjJI3k9fulmPHvj2qpq93Ax8iefE5x+6to0HyjggL83cH/AOtXZax4euredXtZYJoQAXs4ZRGQv+z25z7ZFebeKLx9Mvrm2swbe2kYFIIs5U5bO4AAZyRxk9Cc/NxLc4qzRvQhTrO8WGpaFd/aCIbGSSTP+qXBOcZxtPJ+grnVs3nV3I8qRWGFA9fQGup0vUpJbg3oW3jAAby5Jn3zEYxkKCSeOMlR69ayLy7s2lkNqkgUuQpYYO3qM+46dOlXy+7dlxnLm5RulmSO1NrO9uibjljD+9P1Of0q4YoYl2wOZlONzcr+VQmSGTHzRkjuq4H5VprIvy7YcxDvt4NZNmiRJaxQqIzbT3Qb03sP5n/OK3NGlijRluFkebordec96zrT7Pc3H71I4YwvGDxwK07QWrNF9njKhPvZY4PPbPSkZT7Mv2sdtcuykSNMvcNwo/8A196vWqxxSb5NzoRjao744/KqdsYmunFnuTP8JPIGK1YIZ1mLRAbwpySMjtTOebLUCCTc6q4T+6ABx9CR/jWnZgwRDaAIuwHUVTt3csVkDKVAZW3Z3GrkC9c7skdPxq0c89SebbMqlQBnnB61bVAGJAIP86qIm1yXBPHGBV225Xkfe6DpVLUwloh0e4kktirMXaoUBQgEj14qzzjjGK1iZSYGMN1HFFLkgYIorSyIuznpZCkGA+1j0BPX6mqFyJwir5hAfqB3+tWI4omYyGMbzzkjn61TuJVe7MSthsY256fjXEdMd7Fe6lFpEnyld7bRxgsfTFVZ7Z9RnVbsqoiPyl0yUP8ASpLp9kiLFcDAHOByvsKq3c0LGFlgYRg4JAPzfU5/SnY6FoR3YEUzRJK04BxiI4B9qqTzsZ0jMUVrheWYckY7+1X3RJpJJYGFtAqjEe4nP1/wrEkuCZP3ZSclurJnP4ntzQzSGo9oFcIiZkn6BMElvcAVk3sjA4OMA8cdD6Ut1dXEN0+QsZP3ghxgenFYeoXry7gIoFi+7kgFj+uam1zpjpuTw38pYo91iMHecoCTjpg9a2NI12Nro3JEU8afIUll2OMDjCAlj+HFcZqHmXkTS20UivHj5I0yij1Jz1NVLC21u3vWktRI9xKudmcE/X0rSMG9CanLa57doTi9KzXhVvMO4RkYCjoP0x1rcitLZb1WtEiEhyu5Bjj3I615b4QvZgs63Ujo6ghwOoavSdHSRnW3VT5kQBODnORnt7GsnTaZzT66nTabunTeWG+NtrA8YxXAfEW4uPEHiC30rTZWiSMbJ5lTfsZsYGMjJxzj6V03inXo/D3h6S/gAMswEccRYDfIeByeg7k9hXlmmalfQugttgv5MySshWQlj1JYjjr26etdFlGOpzUoylLmicN4y+HU2i6h/r5ftkmW3l928eprhtLVrfUZlvWZp42KgZ4H4V7j40lEmlW8zBjPyiksWyq8DryO/tXjEmg3dybvU4JGaUSf6tR9715pxu04o9CDdlKR1Wny73jRJBz97PyhfxrprC6a0JaBc3K8h0cEjv8AlXA6fdiGBPt0bW5I2B3XqRjjFdCmo26Ik1rvIxjcGA5PQ5HIxWag07nTVndWLGo69e3N6smqS/aokbiInCHnn5VwKoXd29xcG5sra3t4mUxSbQo5JBzjHGPbHWs+V3leRjEdmc/MarTXTMp2R7EXuBhfbNaJN7mSjFfAa6zJG0e1xLKT8xds7j6HoPyq5BvmlZyyCZjuyAODn+70/SsOOZfJCbR55PJxgkVZgupY0/0qJGjHXOAW7detEthxXY6K2+Rt8kkYk/uFBuJ9u1W0mvpiscNsEhz94nGT+H+NY+nMLyBUt7aOJ0PMoY7jz3zx+QFb9vDmDbLN+87kyAfyrBlp9wjicALMqBxySDn+tdXZ2s0FvBKrRxqUHyDqf97PX61yWn+VvkjDu8g6bOfz/WuisZopgAHuQ6AZ8w9T3/DNSRNG3JbrIUMFwN7DkoSCv6VoWUbJGUklHmg8FTyw+tUorhXdXVfKGfmOM1qRgId24YDfMCOf/rUI5Zt9S1aR7U+c72B4Pp7VoQsRgDkn9PpVSLYRkHGe3rUs1wbSITsskg6MqjLD3rSOhhLUvhjg5wPwxmpU3EZDHPTGaqQSpMmTuAPSrUeAPerRjJD8lee5HHOatRt8o456VWKHgg8VJFkYA/EVcdzN7FgFj1opikgc0VpoZnN3JeI8I0insvGKzLgiP53gJY8kbvl//XWkqMSCN0h6gAkA1Qubh7afy9jtI38IHyge5xiuM6YlICFXZ/LAkbAGBx9KaWY532n3htBkOAPeraKSDJdH5SuAVGPwzVadUjgMv2pYpR9xT83NFzZMoaoJbS0VCIW83gFcExj344/Oubd28wETYJO0KMZ+uK3RCbycLJBLdzZ3Fyckj39BWNrEAt7iXePK54UncQfQAE8e9Fzoproynd2qg+c8gmkHH3t2PrgAVlSWUNw2Gd1c9wVwPc8V1elWnm2byXGUQL8vnAnP0Ufzqg+m2zybidgYncXIRfelc2jbqc9FE63ITRY7i7mKhWXyd316E/59K2T4R1BGj+2zMjyf8u6t83v8wPFdfY6hY6R4ek8/bFcP/qli3FQOeScfyzXIXHioW7yTQq8kp6M5OPT14FaK6s0Yylz3XRDtKvp9B1dESwlbRxnzg7NNtPY9MD6DPbmu2vPHWj6cPtNna6jczMowkVo6D2yzAKB75ryTVte1TUWCSTRLAP8AlnEDj2ySKzZ7lfski3MFvBsUBpTJLuPuPnI7eneumEW9ZHFVsnZHU+ItY1DxBqsNxqfk26IALe1jkV0hBPLO3c4HTH/1yPW7OxRtOtCszyNzKAQnbnPevPrPVoZBNFBDHIsg+UyIWIxzuBIJH6Zra0Oxso5o7u/lkCqMYiJXGe2eePrmonBN6m9GTSskanii5u5LYAtsix8jH7z+wwx/w711Phvw5JbaVZSTIZIGAJBHQ9Tk/jXI66I9XvbCGxugZZHCImOcdSf0r3W28w6FEbPAkVcMjD5Tx3FQ1rZG6m40031POfibo+i3dvb/AGZoGkMG2REUgofTnrXluj+E1XyncO0DylHbP+rGRz/nNdX4lupLfUbqCX5bhW5wcgg9MVF4T1KPDx3EoERJymf1rVVGTKm4Rte5zHinwrdeF9XgUmN4Zx8rxnOOMgH0OKynWSQsiAlf4iQTivSPiJfWQ8N2/kptuHlG3587iASSPqMCuJtMCKFpQCmOI3z9ckelXH3o3Zgqkoz5SO1QpACxBbnDHqfrWxbp5sDgOw3DlcZLH/CnWVuZLeSMS+X5n3lzjj2q5oO61kCTEuUJXg4P5/SuaZ6MGrFXSLS8fc6easKHDY7VsrbRovls0hl7sRjNQxRMl1utXKBiTs61p2ciwSpMVDzDqkq4H61kym+pc0aSawkV4YoxO44dxzj0ziuoijlVUmdFHm8/IR+orLtn/tCMtIACTyW4rS0yCCGJwLhpX3ZA9vSpuc029zRtQBCI2DNISWGcDitW2T5nJyxYdznFUVl8zYwQbk7qf0rVikVuW4Zv88UIwk7k9uq4YMp+vpVkKTJlOwqtGCoLK/HT61NGCy/Ifwq0ZMsIAHyT9fSpIy4c5Xg0kSAxcde5NKVA2gYJAxWhm2WFkVOSTjuQKlUhWBxyaqpIrOU7rjIFSEgOcdPSrTMmi0Dljzj60VUL4A3HJoq7i5SgVaSPcd6A9A2BWTqETkqImWRs4ZnbIX6Dr/KtMqBERNJxjseTVELIEaRY49qdAMn8zXIbR0KU7Exqt7Ozxj+FOPy9K5zVGlvdRRLFBDCMYBY9upJP/wCqunnS4ukMjxxqqD1249q5eRv37SyRhXBwmMME/XBNFzopbkd6zR28v2m5uED/AHJI0JEmOw6cViid0lEtvGCMYzKct9a3msBcuBfSyOXAOM42jr9B+tZOoW0dtO5gbzAo4LHOBnFS2dMFrYZql/f3UUK3F5hTx+7AGB9SKqzy2NqkaxiS4nXlnlYnn0+nsMVYtrtArGRcyEbd7gHH0FQzacA7yCKbcRn95gcfQUI2UbaEGq325VlhnKyjKlgdowR0A/rXH6iJZQJI/vBsEgk5roYLf7VeLCiY3/gOmeak1KKCJ40lc3EUQJ8pQAufw7ZraLJcUtGcHI8/nlpXcYGCq9SPSo0KPeozLh2YMC+TgdjzWxcmQNNLbhYY5QU2rySvoCaxryWVykshyihVOfYcfhxXVGSscdWmk9jZsPD8ElzE1tJIqvnzCeMDOCc+nNO8R6nHpepjT7eIyQW4zmRwwZ8ewwf/AK9augXVyHis4dsquw+brgZ+9W34h8LQW2my/aFSSR5s75ByST1yKSindyJdRxaiit8OtMubq4tNXuLZWuWbZEq/dVMgn9B/SvdIYre1ikuVJjbGHTdw3HcVg+G7CPT9Btn27THGFUKPujHpWH4n8VywwLAYy0QJxxzWF7u5o056I4nxz9nm8RzSDYu+PAXGdxHTP6153f3jwWzMihMnAHUkVpazfSajrU/lOPMwVA9DWS8LaXO8t78y7doYg4II7D15FbwjZXZhOq5ScY9DMsra7mmNzNG8jhfMOTxs46fhXSQw3D6SzQsXtkPmEbjn8aZ4Vt4Lq3MclxJFIDwzHA29h16/41q2cTWkctvwCrdB0ZD047UpvTyNKVr67jdO8k26Tx7g0TbSC24eoPNWLfm7l2sChIPyjHNUdMAstalkeJJLdl5Vuep6j8qvlUhvS0GDDMBt5/z6iueR2RbWhpYmtYBNbNknkk9RUlxK91b75ZAZ16Bs88VHpsRuroW5P7vBJY9uKtC3WwuwsrK7nlWX5lb/AArJlqVjfsi8gjjlTt/DxmtiyI3F0hKBPlPFZ0F2ZY8SxHfjjtj9K0Yo5Io0d94RxuCkkEVJjJ3NO1nJIiCLknjA61qQrsyWy5PHzdqzoHRFWWIZBXA56e9aFu4OzB3MfT1NUjCXkTbShVW+ZeuKsxFkiyMLwBk81GVCA5HzdOtOJAAwcZ7VWxm9S15nyKV69DQ8m8K4IAqFZEVV5PTmlfEg29FNWQlqSQyR+YWQHJ5Jx196sGUKTkj86qwxiIYDk44GadztIYjnn6VSuTJJsdJM2R5RB45yKKhaNYzkjrRTGooJwhbDR8jnocfiarXL7RsjO498qcD6c1aPAGNuR3Peqt4JNo3TRbm469KxZEfMzLuEgBpJC4bqjMP5Dis64e2kXdf3SW8ajKoibmP+eKuXCW8fzFXZj1bd96qlzEb1QvkwxRK2d0nU1BvFmBcXBkcR26mVnP334wP6VFqsNnaRqGuIpLtsbo4VLbT+NTzWaM8hkkVYs43r1qpDYiS5KWhDSMPlc/1JPFSdkbbk6aLLbWS3F1NBCSm9FkkVpHyf7vQVlRTTTTeZMhlhDYyehpt/p4S8Hn3QcoMkB93Pp6VIqxxR+ZcLuVfuRc8/hTNYu++oy5eK5PkwBEl8xWEYBJCjqSfzFV7m1aEPuwxZsKpPJPXkelbMDS2nm3V5ZGEEjy4mGwnjrg8npWHc6oz38pMG6RxuHbGOP6itEyVdvQ57V7KXypHkKo7HAXOf/wBVZllZm8klt0RnKZJwe3f9K3tTnaOMYTM0j5wOcAcn6DOPzrFsLhy7lMlpHOSO2DitIuwpe8mjofAt0NI1i2iVWjl3Hy5Vbt0xXS+P9WNxq9pbyS73leNTk8/eGWPp6VwzlpZVKM8cqnCHPT3FWHja2lE4Z55sB2djluDkc1sveTOKUeWcWz6HsysGkqzY5ULg9K8d+KGoLAq/Z4wZmbAUfxf/AFq7C41xrjQYJYWUoUDE/hXkV411rWsmdYwwQhYSWwDk84/T8qiKehVrJu+piNZtZeXLPF5jL88jr94HGckZ6fSoL66j1EXJlheXemQwOdrKvH9CfpXdy6YstjulBMy/fPrXLaw0MIEcESwE/IxUcMO5rolNWscsaUr3QWvlS26mPZItwnKZ74ypz7Yqe2u7uw1S3W8CyK0RUoRwduMZ/DNc/Z3jyxGJUAER3IpHOMmtDXr1blLGS1V95OGUnPbtWDdzrUXobGntFcajI4cRopAVumPb6ZNT3EIifYZMtnajLxkk1TtIYntEktywbHzoxyQe9as2mrPp8FwbhN28Dy+c8c/0rGR0Rdi9HDNa6h5azmN8ZLHr/nmpbMeXdStdq4LECNzyCP8A9ZxVQQRO/nJKQY4yCJOcdeB+Qrdt2SZoI5D5UcChcjJ3knvn/PFQyr6GtaRsQiyhFUD5SoGcfhW5ZRGXcjzggfcycf57Vi2zCKcLsaQdRj0rXhhDoGyF6celIxmXUjdCEUKVPJA71eEYR1MTAgDOQe9ZsTqoDo244wRVxQyoH6Z447fWhGbRZtpWxg/MexJqUs3X1qqq/IRuANOjkK9ce9V6it1RY3lyAQAo61NGQc4JJ7Y71WaRARyCepoEiq+5yRjvmqWhLWmhaadjncOnGfWnB965b75qoJQFPHB5z60pJyM8etUibEkhJIwcY9qKCVYDpRVjQ5gVXeVP51VkztLhTgckd6fMfmG48e1QOFLYckKOo7msmc0V3Ksj3EyfcSKIHIGMnPrVC7jm+5LExdhxuO0f/rrQnkZWxb53dAfSs3UY5FlAllLkjLYJP4Vm0dEHqV9StLFbSNPtLPNjcyxoMD2zXPvY3FxatLbQTMoPAUErj3NdBc2b3FuZJJYoEA2ooHJqtvupoks7UsYV6Io4x6mkdEHpa5zllYx26fMqhs5z15qyLprdWeKNGlHQuM4HsKsGDZIVZdz+nTFU7rKZfBP93sBSN12Gi4+1ndcM8lwx/ibgCpL1bOG2LuuZlHBxis2JsSbjja5wT71Uvp2mm8tDmEHBz3+lCZUovZGbctM0DlcMzZKqx5/wrNtmS3eNTlJsKh44PrzW9JburkY5xjpjFZl3os0Vt5su5Y3IMTdRnOa0TBRXUmkjA3LkbQOT7mqj3ctrGxtw8gbjOen0qCW7kikeKdThMHevp7ioZLwM+5eUUc5PFaRdjOS5tC19slNiltHI6xSn5/mwAa09Hh3RLsI83JfBX7o7fTNY2nQvPMBOh8oHcARtBJ966W22RnyVkJYrnO3qf8B0rRSuYOCjqacEvmW7RMeh2sx7n0rktftFVGEeCQe/aum+0eTH5KFQGUEsOdx9P/rVh3e2eWd4ozIqDBI4Iz3xTkmrEU6kZNpHJiBoJ8vwckcHgjPWtJNFaDULdHnRlkUSJInQZwQPwqyLSZrNzs3IDgHHTPPP4VcEG6C2ljB2jnAP51k2dCZc0ezR7l/3qxuByrdGq6LcvcAxKBtySnrxVmxsoftLSB9i/eR2Gc8cA/lWpbmN5A42s6dGRuB+VQyVLW5Xe0t4LfzIZlldsFkI4IFW/OWeZBHEqAjnC8CpBZo8BEanzCOp9a0tOtm8slhtkI5ApCcupY0u1OQEG4cnJP8AOtF4JoVYqqsF6bWypptomyM/Lz1J9qQM8Uv3iqr8yr+lHQhTbZYgGyRWlTaWxj3q+N54yVI6jpWRBcTyABsMqjA7GrlvK0cQAG4nrzSQSRO8rb8MS1MOQSQBgVIpIfOwEegPSoHO+YLgg5zgHjFMSFTDHI4x/OrG4lv3vbsaYNq5wo4piTLKG4G71pjbJ4xmQdl/nUocnjGcnrUC/MNuSWqSM5cAdu1WjNjyTnCDiipEVc9KK0UTNyKjNuPOeO9IMBgxJ3DtSggj5hzTCwTovA61kzFPsRybXQtkqxPbiq5jRQWbBf1PNPc75QB8secnillG4gAgqPSpNY6GfchWKARdT9454qu+6EBbVz5jDBI4xWjcplDs37R1x3+lVTAybSHcJ3BGalo2jJGNchllCM5cg/Nn+lRa7PJdWsdqqCNEO5cDmtRoB9qjZkZl3ZPYkVBeQ/v2ZVYE9AT0FK3U3jPVGJa75rN4LZIywXh2HPrxWNNEY5R8pbac+nNb8tpJbxglzEeSSTjiqcjiMq8luXAXG4jjH50rWNlUMdEmlndpWIHTk9as6hdrcWK28i7lj+6oOMt61P5CuEyD5Y5GOM1C1ofOYohb+6o600hSkmcxEssl3K0ow6gKQ3cetZl3ZLHcFbdiM/PIuOD/APXrqoLCdr+VplwqjBUd/wDOKha0kE7T+WsYwVBPbPetUzLm1M2xeZleSaRQpAClRg4+lXrTznkuZIcSfIoLNxjrkD9KYtofnLRZONqAHHHqRTIS8F1LH8rKoBIHQGqi7Cn7yL8aTpKyuojJVSo7jr+RqO5hDxosEjAAkkDrmnI7NcFnZvNkXJ29h6DFMtPLhuW/1YYfxMevf86qcm0YwjGDdi9ZRxuqiXETDqezVft7NYwyJENrNkOCeKfYsso3bQQf0raSGMbdpG0jlQO9Yl8yKi2+4Rh8DBxkCrsViu3J5HWp1iCOrIvH90npVyGNpB85Vh7DBoJ5rFSBCHEeTg88itW1iKfNjC56ZpkVqrTLuJ2qcg4xV5EGcEge9FiZS6CfM/OcY7YpjxmRVbjjjJqQvmVQMMp7j0oDjzQqgYPrQxJ2I02o7MwwB/OpiQSjAZY/hTA0YZ0YAgehzQpywHzAYpWLuSpLhS2Mk8ewpfNUYyPmbp7VAxbzAuRtHr1psqxuQ27GOcetOwbGgFDR8kc8mjZwVXgd/eq8Eg2qex9e9SCdQMAYNUkZtseqsCSOMVJCUbAUgnrkCkRw5UDBA9KJBhflwmOST6VokS5FmWVwoCcjNFMWePYDnI7Ed6K0TM7sphgjHzMDuDUcjd0AP41HKMxrn2oj+5XMShXfKcg7fSmxSA5A+6PXpSuPkpicIAPWkWTEeYxxjHseKlyuCir070oAEfTtToejfWmK5XkQMSSmDjGR1qOa3BUbUCheC/UtVyMAsc9s1G3zRNnnFIfM+hhXUG6QEKzpnA3cZqo1kx3NJHkHjaDwPzrpFALtkdDxUbquSMDGDSNVUaOXNoXbPlttB+6R6VT8rdLIPLwzHonaunwMdKoXEEUk210BGRQVzsx5dOYZK5TPXI5pp0tWG4h/LXGFY9/WtxhtcIvCgYxUjACJuB1pk81jAezjWM5AzjIHb86564iEPnSwKROCCu32NdPegFRnuRmsW6RQZwB0OKa3HzOxx9zfsJ3Yh1lIwD/jSWupKJUGVPY855qvcDKuT1LN/Wuc3FZMqSDurpjHmVjCpLlldHr2l3KybCBx6ZrpLJlfOV6HmuC8MyM6qWOTiu10tj07FcmsGi1I2I4oyS6rls/MR3q7CgU42cetZ9uxCgDpkVr7QqIAMAipBvQMlSTgAYx9aY7DKgnGf0ocfMBzj60rkhuKQ0PyC67QR70woSGLdfY02FizNk5xShiEbBoGhvlNn5M5xUkYwoJYn8OKI2LRqSecmmqcPtHT0pjuyU4aT5upHPFQLCEYnOT6VZnJ8tj3AOKpb2JBzyTg07EqTLZCnBB5FNcIWDumSORTo+Y8nrUZY/MfQmqQKTJ7eViWO3A9O9TuytEwYbgeoPehOUUUg64q0jNu7ITlz8ox9TRUqKrE5GeTRTsFz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30600=[""].join("\n");
var outline_f29_56_30600=null;
var title_f29_56_30601="Pathophysiology of the short bowel syndrome";
var content_f29_56_30601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of the short bowel syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30601/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/56/30601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short bowel syndrome (SBS) is a malabsorptive state that may follow massive resection of the small intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/1\">",
"     1",
"    </a>",
"    ]. It is a functional definition, implying a significant amount of malabsorption of both macronutrients and micronutrients. SBS is the most common cause of intestinal failure, a term that describes the state when an individual&rsquo;s gastrointestinal function is inadequate to maintain his or her nutrient and hydration status without intravenous or enteral supplementation. In addition to SBS, diseases or congenital defects that cause severe malabsorption, bowel obstruction, and dysmotility (eg, pseudo-obstruction) are causes of intestinal failure.",
"   </p>",
"   <p>",
"    SBS in adults usually results from surgical resection for Crohn's disease, malignancy, radiation, or vascular insufficiency. In infants and small children, necrotizing enterocolitis and congenital intestinal anomalies such as atresias or gastroschisis are the most common causes of SBS.",
"   </p>",
"   <p>",
"    The pathogenesis of SBS will be reviewed here. The management of this disorder is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management and complications of SBS in children (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link\">",
"       \"Management of the short bowel syndrome in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of SBS in adults (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link\">",
"       \"Management of the short bowel syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American Gastroenterological Association (AGA) guideline for SBS and intestinal transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/2\">",
"       2",
"      </a>",
"      ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"      <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"       www.gastro.org/practice/medical-position-statements",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2285795\">",
"    <span class=\"h1\">",
"     SMALL INTESTINE LENGTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of the small intestine is an important determinant of intestinal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants, the normal length of the small intestine is approximately 125 cm at the start of the third trimester of gestation and 250 cm at term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/3\">",
"       3",
"      </a>",
"      ]. Infants with residual small intestine length of less than 75 cm are at risk for developing SBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/4\">",
"       4",
"      </a>",
"      ]. In one series of infants with SBS due to surgical resection during the neonatal period, the likelihood of achieving independence from parenteral nutrition was more than 60 percent for infants with residual small intestine length &gt;38 cm, as compared with 7 percent in those with residual small intestine length &lt;15 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, the normal length of the small intestine is approximately 480 cm. Adults with residual small intestine of less than 180 cm are at risk for developing SBS; those with less than 60 cm of small intestine (but with a colon) are unlikely to achieve independence from parenteral nutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors other than small intestine length contribute to determining intestinal function, including the site of intestinal resection, the presence or absence of the ileocecal valve, whether the colon is present, the gradual process of intestinal adaptation after surgical resection, and intestinal motility. Indeed, patients with severely impaired intestinal motility (eg, some individuals with gastroschisis) may have SBS despite normal length of the small intestine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPLICATIONS OF THE SITE OF INTESTINAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with bowel resection are highly dependent upon the physiology of the remaining small bowel, because each bowel segment has unique characteristics for absorption (",
"    <a class=\"graphic graphic_figure graphicRef83401 \" href=\"mobipreview.htm?33/61/34775\">",
"     figure 1",
"    </a>",
"    ), and different abilities to adapt after intestinal resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intestinal adaptation refers to changes that occur after intestinal resection that tend to increase absorptive capacity. The mechanisms include lengthening of the intestinal villi, and small bowel dilation. Most intestinal adaptation occurs in the ileum, as described below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Ileal adaptation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Jejunal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jejunum, with its long villi, large absorptive surface, highly concentrated digestive enzymes, and many transport carrier proteins, is the primary digestive and absorptive site for most nutrients. Thus, when the jejunum is resected, a temporary reduction in absorption of most nutrients occurs.",
"   </p>",
"   <p>",
"    The jejunum exhibits modest adaptive changes in response to intestinal resection, and most of these changes are functional (changes in transport and enzyme activity) rather than structural (changes in absorptive area) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/9\">",
"     9",
"    </a>",
"    ]. Increases in mucosal weight, DNA, and protein have been demonstrated in jejunal and ileal tissue of rat models of short bowel syndrome (SBS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/10\">",
"     10",
"    </a>",
"    ]. Studies in experimental models of SBS suggest that adaptive changes can be induced in the jejunum by several maneuvers:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral feedings &ndash; this effect is modest, and may require the presence of residual ileum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with IGF-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/11\">",
"       11",
"      </a>",
"      ] (which mediates many of the effects of growth hormone).",
"     </li>",
"     <li>",
"      Topical application of benzalkonium chloride [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of exogenous thyroid hormone during a hypothyroid phase of SBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/13\">",
"       13",
"      </a>",
"      ]. Thyroid hormone is known to be an important regulator of intestinal epithelial differentiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among these interventions, only oral feedings have established benefit in humans. Human experience with growth hormone and other growth factors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H1887170#H1887170\">",
"     \"Management of the short bowel syndrome in children\", section on 'Growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ileal resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having residual ileum is advantageous because of its specialized functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin B12 absorption &ndash; The ileum is the selective site for absorption of vitamin B12, bound to intrinsic factor (",
"      <a class=\"graphic graphic_figure graphicRef83401 \" href=\"mobipreview.htm?33/61/34775\">",
"       figure 1",
"      </a>",
"      ). Resection of the terminal ileum is associated with malabsorption of vitamin B12 and can lead to clinical deficiency unless supplemented. In adults, vitamin B12 malabsorption tends to occur if more than 60 cm of ileum is resected, while resection of &gt;100 cm leads to disruption of the enterohepatic circulation, resulting in bile salt deficiency and fat malabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/14\">",
"       14",
"      </a>",
"      ]. The length of ileal resection that causes such consequences in infants is not well defined. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bile acid absorption &ndash; The ileum also is the selective site for absorption bile acids. After ileal resection, malabsorption of bile acids leads to a compensatory increase in their production by the liver, but losses can exceed production. The diminished bile acid pool can further exacerbate malabsorption of fat and fat-soluble vitamins. In addition, the increased passage of bile acids into the colon may induce a colonic secretory diarrhea (choleretic enteropathy). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=see_link&amp;anchor=H2#H2\">",
"       \"Chronic complications of the short bowel syndrome in children\", section on 'Watery diarrhea'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Malabsorption of bile acids also causes excessive absorption of oxalate, leading to hyperoxaluria and possible kidney stone formation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ileal brake &ndash; Unabsorbed lipids reaching the ileum cause delay in gastric emptying (the &ldquo;ileal brake&rdquo;), which is beneficial because it facilitates absorption of nutrients within the small intestine, and is mediated by hormones secreted by the ileum including peptide YY [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Ileal resection may be associated with loss of this compensatory mechanism, which may contribute to the diarrhea observed in SBS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gut hormones'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Fluid absorption &ndash; The ileum normally reabsorbs a large portion of the fluid secreted by the jejunum during the digestive process, particularly in response to hypertonic feedings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. If a substantial part of the ileum is resected, fluid and electrolyte loss will occur. Such patients often cannot tolerate large bolus feedings or to feedings containing high concentrations of rapidly digested foods (ie, simple carbohydrates).",
"     </li>",
"     <li>",
"      Intestinal adaptation &ndash; The ileum has a greater capacity for intestinal adaptation as compared to the jejunum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ileal adaptation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Loss of the ileocecal valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ileocecal valve is an important barrier to reflux of colonic material from the colon into the small intestine. It also helps to regulate the passage of fluid and nutrients from the ileum into the colon (",
"    <a class=\"graphic graphic_figure graphicRef83401 \" href=\"mobipreview.htm?33/61/34775\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Loss of the ileocecal valve is generally considered to be an important negative predictor of the ability to wean a patient from parenteral nutrition (PN). Absence of the ileocecal valve typically is associated with a longer duration of parenteral nutrition when resection occurs in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/20\">",
"     20",
"    </a>",
"    ], and infants with less than 30 cm of small bowel and lacking the ileocecal valve are less likely to be weaned from parenteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/21\">",
"     21",
"    </a>",
"    ]. These effects are thought to be explained by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction of small intestinal transit time, which impairs nutrient absorption",
"     </li>",
"     <li>",
"      Promotion of small bacterial overgrowth, which may cause malabsorption of vitamin B12, fats, and bile salts, causing diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/22\">",
"       22",
"      </a>",
"      ]. Bacterial overgrowth is associated with progressive dilation and decreased motility in the small intestine, changes that can exacerbate the degree of overgrowth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/23\">",
"       23",
"      </a>",
"      ]. More severe complications of bacterial overgrowth, including bacterial translocation, liver injury, D-lactic acidosis, arthritis and colitis, can also occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/22,24\">",
"       22,24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2286058\">",
"       'The microbiome of SBS and pathophysiology of bacterial overgrowth'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, another study suggests that the ileocecal valve does not independently affect small bowel transit, the risk of bacterial overgrowth, or the likelihood of weaning from PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/23\">",
"     23",
"    </a>",
"    ]. Instead, small bacterial overgrowth was related to small intestinal length and the presence of ileal peristalsis, and these factors were the primary predictors of the likelihood of weaning from PN, rather than the ileocecal valve itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Loss of the colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colon has an important role in absorption of water, electrolytes and short chain fatty acids (",
"    <a class=\"graphic graphic_figure graphicRef83401 \" href=\"mobipreview.htm?33/61/34775\">",
"     figure 1",
"    </a>",
"    ). Loss of the colon in combination with extensive small bowel resection is poorly tolerated and is likely to lead to dehydration and electrolyte depletion. Such patients usually require long-term parenteral nutrition. The colon also helps to slow intestinal transit and stimulate intestinal adaptation. Moreover, the colon can absorb up to 15 percent of energy requirements, primarily in the form of fermented carbohydrates; in patients with SBS on a high-carbohydrate diet the colon can absorb as much as 50 percent of energy requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Thus, in a patient with SBS and a colon, a high carbohydrate feeding has the advantage of being absorbed in the colon. However, concentrated carbohydrates also have the disadvantage of high osmolarity, which can lead to diarrhea, especially in infants, children, and patients without a colon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of the short bowel syndrome in children\", section on 'Enteral feeding'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Diet composition and diarrhea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The retained colon undergoes adaptation after small bowel resection, with gradual increases in enterocytes and other cells, and in gut hormones including peptide YY [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/28\">",
"     28",
"    </a>",
"    ]. There is some evidence that feeding with an elemental diet slows the rate of colonic adaptation as compared with feeding with a more complex diet. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gut hormones'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27027264\">",
"     'Nutrient effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For the above reasons, patients who retain their colon are more likely to tolerate small intestinal resection. As an example, adult patients with SBS but at least half of the colon are likely to have similar intestinal function to those with about 50 cm longer small intestine but no colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/29\">",
"     29",
"    </a>",
"    ]. In general, adults with little or no colon and less than 50 to 100 cm of jejunum are likely to require permanent parenteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/7,30\">",
"     7,30",
"    </a>",
"    ]. By contrast, studies in infants and children have reached inconsistent conclusions about whether or not the presence of the colon is an important predictor of weaning from PN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/23,31,32\">",
"     23,31,32",
"    </a>",
"    ]. Thus, the retained colon may be a less important predictor of survival off of PN in infants with SBS as compared with adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ILEAL ADAPTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ileum has shorter villi and reduced surface area as compared to the jejunum. However, it is capable of undergoing marked adaptation after small bowel resection, with significant growth in villus surface area, as well as increases in intestinal length, diameter, and motor function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These structural changes are primarily responsible for enhancement of nutrient uptake in a given segment of bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/35\">",
"     35",
"    </a>",
"    ].&nbsp;However, there is also some evidence for functional improvement of absorption through upregulation of transporters and of brush border enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/6\">",
"     6",
"    </a>",
"    ]. These adaptations lead to a gradual improvement in macronutrient absorption during the first one to three years after jejunal resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/5,36\">",
"     5,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models of SBS provide insight into the adaptive process. After bowel resection, epithelial hyperplasia is seen within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. The length of villi and intestinal absorptive area increases, and digestive and absorptive function gradually improve. These morphologic changes are associated with changes in expression of a variety of genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], some of which are known mediators of intestinal growth. Some of these effects may be mediated by microRNAs, which are short non-coding RNAs that are able to silence numerous genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/46\">",
"     46",
"    </a>",
"    ]. Other changes, such as upregulation of genes associated with intestinal angiogenesis and new blood vessel growth, appear to be a result rather than a cause of the adaptive process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/47\">",
"     47",
"    </a>",
"    ]. For other genes, the mechanism through which they may participate in intestinal adaptation is not yet clear.",
"   </p>",
"   <p>",
"    The mechanisms underlying intestinal adaptation are not fully understood, but it is clear that adaptation is strongly enhanced by the presence of nutrients in the gut lumen. The nutritional and hormonal mediators of this effect are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27027264\">",
"    <span class=\"h2\">",
"     Nutrient effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best established stimulant of intestinal adaptation is the presence of nutrients in the intestinal lumen; as a result, enteral feeding is the cornerstone of management in patients with SBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/48\">",
"     48",
"    </a>",
"    ]. This effect is mediated by growth factors produced by the intestine as well as by functional and hormonal biliary and pancreatic secretions. Studies of parenterally-fed animal models of SBS have demonstrated that adaptation requires enteral feeding, and will not occur if there is total reliance on parenteral nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/49\">",
"     49",
"    </a>",
"    ]. Accordingly, adaptation appears to be enhanced when intestinal continuity is preserved through a primary anastomosis (rather than using an ostomy): in a retrospective review of 78 children with SBS, patients without an ostomy had better water and electrolyte absorption, perhaps because the nutrients in the lumen stimulated the colon to assume more absorptive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of various nutrients on intestinal adaptation have been studied in animals and humans, as described below. These include the amino acids, arginine and glutamine, and medium- and long-chain triglycerides.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Arginine or citrulline",
"      </strong>",
"      &ndash; Animal studies have demonstrated that parenteral arginine supplementation reduces intestinal permeability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/50\">",
"       50",
"      </a>",
"      ]. Similar effects are seen with enteral or parenteral supplementation of citrulline, which is metabolized to arginine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. Studies in animal models suggest that supplementing citrulline in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      can enhance intestinal adaptation.",
"      <br/>",
"      <br/>",
"      Consistent with a possible role as a growth factor, plasma citrulline levels correlate with enterocyte mass in children with SBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/53\">",
"       53",
"      </a>",
"      ], and low levels of plasma citrulline correlate with catheter-related bloodstream infections in children with intestinal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/54\">",
"       54",
"      </a>",
"      ]. Measurement of serum citrulline concentrations (a nonprotein amino acid produced by intestinal mucosa) has been proposed to predict permanent versus transient intestinal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/55\">",
"       55",
"      </a>",
"      ]. The level of serum citrulline associated with permanent dependence on parenteral nutrition varies among several studies, but typically is less than 15",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Glutamine",
"      </strong>",
"      &ndash; Parenteral supplementation of glutamine reversed intestinal hypoplasia in an animal model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Enteral glutamine supplementation in animals yields little or no improvement in intestinal adaptation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/59\">",
"       59",
"      </a>",
"      ]. Studies in humans have shown that enteral glutamine provides modest benefit in body weight and fluid and electrolyte balance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/60\">",
"       60",
"      </a>",
"      ]. However, most patients in these studies were also supplemented with growth hormone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H1887170#H1887170\">",
"       \"Management of the short bowel syndrome in children\", section on 'Growth factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Triglycerides",
"      </strong>",
"      &ndash; In animal models, enteral supplementation with long-chain triglycerides appears to be more beneficial than medium-chain triglycerides in promoting overall intestinal adaptation, although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/51/19250?source=see_link\">",
"       medium chain triglycerides",
"      </a>",
"      may be more easily absorbed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Human data is limited. One series demonstrated that feedings high in long chain triglycerides (as in breast milk or some amino acid formulas) are associated with improved intestinal adaptation in neonates with short bowel syndrome, as compared with feedings with lower concentrations of long chain triglycerides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Omega-3 fatty acids",
"      </strong>",
"      &ndash; Dietary fish oil, which is rich in omega-3 fatty acids, appears to be beneficial in inducing adaptation in the small intestine and colon. This was shown in an animal model of SBS in which fish oil reduced diarrhea and fecal fat excretion as compared with corn oil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a separate study,",
"      <strong>",
"       parenteral",
"      </strong>",
"      administration of omega-3 fatty acids also induced intestinal adaptation in rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/65\">",
"       65",
"      </a>",
"      ]. In this model, parenteral administration was more effective than enteral administration of the nutrient. Much of the published data in human trials are observational and limited to the pediatric population. However, increasing evidence suggests that parenteral administration of lipids derived from fish oil (rich in omega-3 fatty acids) may reduce serum bilirubin levels, and reverse parenteral-nutrition associated liver disease, as compared to conventional soy-based lipids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18730?source=see_link&amp;anchor=H22#H22\">",
"       \"Parenteral nutrition-associated liver disease in infants\", section on 'Fish oil-based fat emulsions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these observations, diets higher in fat and protein are often recommended for patients with SBS to promote intestinal adaptation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of the short bowel syndrome in children\", section on 'Composition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Composition'",
"    </a>",
"    .). However, for adult patients with retained colon, a higher concentration of carbohydrates may be advantageous, as discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Loss of the colon'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gut hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutrients probably induce intestinal adaptation by inducing release of one or more trophic gastrointestinal hormones, a stimulus that is mediated primarily by fat. Several enterocyte-derived mediators of the adaptation process have been described.",
"   </p>",
"   <p>",
"    An example is glucagon-like peptide 2 (GLP-2), a growth factor produced by the enteroendocrine L cells of the ileum and colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/66\">",
"     66",
"    </a>",
"    ]. In animal models undergoing mid small bowel resection, plasma concentrations of GLP-2 increase rapidly, and this induces adaptation in the remaining intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/67\">",
"     67",
"    </a>",
"    ]. However, this response does not occur if the GLP-2 producing cells in the ileum and proximal colon are resected. Exogenous administration of GLP-2 induces marked villus hyperplasia of the ileum and jejunum within four days of administration to mice with SBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/68\">",
"     68",
"    </a>",
"    ], accompanied by an increase in glucose absorption and a decrease in intestinal permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/69\">",
"     69",
"    </a>",
"    ]. Studies in humans with SBS suggest that GLP-2 and its analog,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/33/10772?source=see_link\">",
"     teduglutide",
"    </a>",
"    , promote adaptation and increase nutrient absorption, but the clinical value of this approach has not been established. Similarly, human studies have explored the use of growth hormone, with or without glutamine or other growth factors, but results have been inconclusive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of the short bowel syndrome in children\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other trophic gastrointestinal hormones, such as enteroglucagon (or fragments or precursors of this molecule), epidermal growth factor, hepatocyte growth factor, trefoil peptides, and insulin-like growth factor 1 (IGF-1), are produced by the ileal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. As a result, ileal resection may decrease the potential for adaptation induced by these hormones. In animal models of SBS, epidermal growth factor induces changes in the intestinal smooth muscle, and also enhances mucosal integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/72\">",
"     72",
"    </a>",
"    ]. Similarly, IGF 1 delivered via colostrum supplementation positively affects the muscularis mucosa in the intestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/73\">",
"     73",
"    </a>",
"    ]. Thus, these substances appear to play a primary role in tissue proliferation, but clinical trials of these hormones in humans with SBS are lacking.",
"   </p>",
"   <p>",
"    Some hormones have antitrophic effects. Transforming growth factor beta-1 inhibits stem cells, enterocyte proliferation and adaptation in rat intestinal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    , the synthetic somatostatin analogue, impairs gut structural adaptation by decreasing cell proliferation following massive resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/76\">",
"     76",
"    </a>",
"    ]. This adverse effect limits the utility of octreotide as a treatment for diarrhea in SBS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gut hormones also can affect the pathophysiology of SBS in ways other than ileal adaptation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motility &ndash; Gastrointestinal motility is regulated by gut hormones, and massive resection of the small bowel may alter various aspects of gut motility, such as gastroduodenal emptying and intestinal transit. Resection of the ileum has particularly important effects on motility.",
"     </li>",
"     <li>",
"      Ileal brake &ndash; Unabsorbed lipids reaching the ileum cause delay in gastric emptying (the &ldquo;ileal brake&rdquo;), which is beneficial because it facilitates absorption of nutrients within the small intestine. This effect is mediated by hormones secreted by the ileum including peptide YY and perhaps other local hormones, such as neurotensin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with SBS lacking ileum lose the beneficial effects of the ileal brake; the presence of malabsorbed fat in the distal small intestine will not have its usual ability to reduce gastrointestinal motility. The resulting rapid transit will further reduce the time of contact of nutrients with the mucosal surface, impairing both their absorption and their trophic effect on the small intestine. However, if some ileum is present, the feeding of lipids engages the ileal brake, which might enhance intestinal adaptation by delaying transit through the small bowel, resulting in increased nutrient contact with the epithelium. This mechanism has been supported by animal experiments in which administration of menhaden oil enhanced intestinal adaptation, with an associated increase in peptide YY and delayed gastrointestinal motility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrin &ndash; Hypergastrinemia is present in many patients with SBS, probably because the negative feedback mechanism for inhibiting gastrin secretion and reducing gastric acid production has been removed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/80\">",
"       80",
"      </a>",
"      ]. Acid hypersecretion is common and may be transient, or may lead to peptic ulcer disease and esophagitis (which can be exacerbated by delayed gastric emptying). Acid hypersecretion may impair absorption by inactivating pancreatic lipase and deconjugating bile salts. As a result, many patients benefit from acid suppression using a histamine 2 receptor antagonist (H2 blocker) or a proton pump inhibitor, particularly during the early phase of SBS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H8#H8\">",
"       \"Management of the short bowel syndrome in children\", section on 'Early management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of the short bowel syndrome in adults\", section on 'Pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins stimulate intestinal proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Inhibition of prostaglandin synthesis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal anti-inflammatory drugs, or corticosteroids may inhibit the adaptation process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2286058\">",
"    <span class=\"h1\">",
"     THE MICROBIOME OF SBS AND PATHOPHYSIOLOGY OF BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial population of the intestine is altered in patients with SBS. As an example, in one study, adults with SBS and partial colon resection had reduced bacterial diversity and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    was over-represented, while normal colonic bacteria were markedly reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/84\">",
"     84",
"    </a>",
"    ]. Humans without SBS typically have only a small population of bacteria in the proximal small intestine (mostly aerobic), and most of the bacterial population and anaerobic species are found in the colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial flora can have beneficial effects in patients with SBS. In patients with residual colon, colonic bacteria participate in metabolism and recovery of malabsorbed macronutrients, and thereby improve overall nutrient absorption. The over-representation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    noted above probably enhances absorption of sugars in the colon, since this is a facultative anaerobe, capable of fermenting carbohydrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Loss of the colon'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bacterial flora also can have pathologic effects in patients with SBS. Invasion of the small intestine with excessive or imbalanced population of bacteria can lead to bacterial overgrowth, which tends to exacerbate malabsorption. Bacterial overgrowth is defined as increased numbers and species of bacteria in the small intestine creating inflammation. Bacterial growth in the normal bowel is controlled by gastric acid, pancreatic enzyme activity, enterocyte turnover, normal antegrade peristaltic activity in the small intestine, and the ileocecal valve. Compromise of one or both of the last two mechanisms is common in the short bowel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/85\">",
"     85",
"    </a>",
"    ]. The excess bacteria may exacerbate malabsorption by several mechanisms. Bacterial deconjugation of bile acids diminishes the intestinal absorption of monoglycerides and fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the inflammatory response caused by bacterial overgrowth damages the absorptive surface, resulting in malabsorption and protein loss.",
"   </p>",
"   <p>",
"    Diagnosis and management of bacterial overgrowth in patients with SBS is discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=see_link&amp;anchor=H10#H10\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Bacterial overgrowth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic complications of the short bowel syndrome in adults\", section on 'Bacterial overgrowth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIET COMPOSITION AND DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrates in the diet are a major cause of diarrhea in SBS because of their high osmotic load. This is especially true with simple carbohydrates that are osmotically active. Even complex carbohydrates may be a problem because they can create a significant osmotic load in the small bowel after digestion by pancreatic enzymes. In the colon, further breakdown of these compounds by gut bacteria creates additional osmotic loads and fluid losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with retained colon tolerate carbohydrates better than those without because the colon can absorb fluids, electrolytes, and even the short-chain fatty acids that are the product of carbohydrate fermentation. The use of continuous or small bolus feedings enhances absorption in patients with SBS and may reduce diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Frequency of feeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the short bowel syndrome in children\", section on 'Frequency of feeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protein in the diet is usually well-tolerated as a calorie source, and contributes relatively little to the osmotic load, probably because it is not present in large quantities. Fats are large molecules and do not create an osmotic load in the small intestine. Because they also are a dense source of calories relative to carbohydrates and proteins, they are a valuable source of calories in patients with SBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/86\">",
"     86",
"    </a>",
"    ]. Considerations about the protein source (eg, breast milk or formula type) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H18643821#H18643821\">",
"     \"Management of the short bowel syndrome in children\", section on 'Protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fats are another important stimulant of gut adaptation, releasing a number of trophic hormones more effectively than do carbohydrates or proteins. Specific benefits have been shown for enterally administered triglycerides and fish oil (omega-3 fatty acids), as well as for parenterally administered omega-3 fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30601/abstract/65\">",
"     65",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H27027264\">",
"     'Nutrient effects'",
"    </a>",
"    above).&nbsp;Thus, parenteral use of omega-3 fatty acids may have benefits outside of those involved in the prevention and treatment of cholestasis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18730?source=see_link&amp;anchor=H22#H22\">",
"     \"Parenteral nutrition-associated liver disease in infants\", section on 'Fish oil-based fat emulsions'",
"    </a>",
"    ). Clinical decisions about dietary fat, including selection of long-chain versus medium-chain triglycerides (MCT) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H18643835#H18643835\">",
"     \"Management of the short bowel syndrome in children\", section on 'Fats'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Composition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical considerations relevant to diet composition in SBS are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Composition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of the short bowel syndrome in children\", section on 'Composition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration of the pathophysiology of the short bowel syndrome (SBS) is important in making many decisions regarding patient management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of the ileum has important implications for patients with SBS, because of the ileum&rsquo;s special roles in absorbing vitamin B12 and bile acids (",
"      <a class=\"graphic graphic_figure graphicRef83401 \" href=\"mobipreview.htm?33/61/34775\">",
"       figure 1",
"      </a>",
"      ) and reducing intestinal motility when stimulated by fat (the &ldquo;ileal brake&rdquo;), and its ability to undergo adaptive changes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ileal resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loss of the ileocecal valve reduces the likelihood that a patient will be able to be weaned a patient from parenteral nutrition (PN). This is because of reduced intestinal transit time, and promotion of small bacterial overgrowth, which may cause malabsorption of vitamin B12, fats, and bile salts, causing diarrhea. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Loss of the ileocecal valve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The colon has an important role in absorption of water, electrolytes and short chain fatty acids. The latter can provide a significant portion of energy requirements in patients with SBS. The colon also helps to slow intestinal transit and stimulate intestinal adaptation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Loss of the colon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal adaptation refers to changes that occur after intestinal resection that tend to increase absorptive capacity. The mechanisms include lengthening of the intestinal villi, and small bowel dilation. Most intestinal adaptation occurs in the ileum. This process leads to a gradual improvement in macronutrient absorption during the first one to three years after jejunal resection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ileal adaptation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best established stimulant of intestinal adaptation is the presence of nutrients in the intestinal lumen; as a result enteral feeding is the cornerstone of treatment for patients with SBS. This effect is mediated by growth factors produced by the intestine, and by functional and hormonal biliary and pancreatic secretions. (See",
"      <a class=\"local\" href=\"#H27027264\">",
"       'Nutrient effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucagon-like peptide 2 (GLP-2) is an important mediator of intestinal adaptation. Exogenous administration of GLP-2 promotes adaptation and nutrient absorption in animal models of SBS. Preliminary studies in humans with SBS suggest that GLP-2 and its analog,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/33/10772?source=see_link\">",
"       teduglutide",
"      </a>",
"      , promote adaptation and increase nutrient absorption, but the clinical value of this approach has not been established. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gut hormones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major cause of diarrhea in SBS is the osmotic load generated by malabsorbed carbohydrates, particularly in patients who lack a colon. The use of continuous or small bolus feedings reduces the osmotic load, which may enhance absorption and reduce diarrhea. Diets higher in fat decrease the osmotic load to the small bowel and help stimulate gut adaptation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diet composition and diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=see_link\">",
"     \"Management of the short bowel syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link\">",
"     \"Management of the short bowel syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/1\">",
"      O'Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006; 4:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/2\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/3\">",
"      Touloukian RJ, Smith GJ. Normal intestinal length in preterm infants. J Pediatr Surg 1983; 18:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/4\">",
"      Thompson JS, Rochling FA, Weseman RA, Mercer DF. Current management of short bowel syndrome. Curr Probl Surg 2012; 49:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/5\">",
"      Quir&oacute;s-Tejeira RE, Ament ME, Reyen L, et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr 2004; 145:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/6\">",
"      Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/7\">",
"      Jeong SH, Lee HJ, Bae HJ, et al. Factors affecting postoperative dietary adaptation in short bowel syndrome. Hepatogastroenterology 2009; 56:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/8\">",
"      Longshore SW, Wakeman D, McMellen M, Warner BW. Bowel resection induced intestinal adaptation: progress from bench to bedside. Minerva Pediatr 2009; 61:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/9\">",
"      De Francesco A, Malfi G, Delsedime L, et al. Histological findings regarding jejunal mucosa in short bowel syndrome. Transplant Proc 1994; 26:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/10\">",
"      Vanderhoof JA, Kollman KA, Griffin S, Adrian TE. Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat. J Pediatr Gastroenterol Nutr 1997; 25:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/11\">",
"      Gillingham MB, Dahly EM, Carey HV, et al. Differential jejunal and colonic adaptation due to resection and IGF-I in parenterally fed rats. Am J Physiol Gastrointest Liver Physiol 2000; 278:G700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/12\">",
"      Michopoulou A, Triggas B, Hra E, et al. Early intestinal morphological changes following benzalkonium chloride treatment in a rat model of short bowel syndrome. Ann Ital Chir 2009; 80:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/13\">",
"      Yuksel O, Tatlicioglu E, Poyraz A, et al. Effects of thyroid hormone on the adaptation in short bowel syndrome. J Surg Res 2009; 155:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/14\">",
"      Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972; 62:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/15\">",
"      Welch IM, Cunningham KM, Read NW. Regulation of gastric emptying by ileal nutrients in humans. Gastroenterology 1988; 94:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/16\">",
"      Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep 2006; 8:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/17\">",
"      Fordtran JS, Rector FC Jr, Carter NW. The mechanisms of sodium absorption in the human small intestine. J Clin Invest 1968; 47:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/18\">",
"      Fordtran JS, Rector FC Jr, Ewton MF, et al. Permeability characteristics of the human small intestine. J Clin Invest 1965; 44:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/19\">",
"      Thompson JS, Quigley EM, Adrian TE. Factors affecting outcome following proximal and distal intestinal resection in the dog: an examination of the relative roles of mucosal adaptation, motility, luminal factors, and enteric peptides. Dig Dis Sci 1999; 44:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/20\">",
"      Goulet O, Baglin-Gobet S, Talbotec C, et al. Outcome and long-term growth after extensive small bowel resection in the neonatal period: a survey of 87 children. Eur J Pediatr Surg 2005; 15:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/21\">",
"      Goulet OJ, Revillon Y, Jan D, et al. Neonatal short bowel syndrome. J Pediatr 1991; 119:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/22\">",
"      Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol 2006; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/23\">",
"      Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997; 131:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/24\">",
"      Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/25\">",
"      Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. Lancet 1994; 343:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/26\">",
"      Jeppesen PB, Mortensen PB. Significance of a preserved colon for parenteral energy requirements in patients receiving home parenteral nutrition. Scand J Gastroenterol 1998; 33:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/27\">",
"      DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel syndrome: part 2. Am J Gastroenterol 2004; 99:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/28\">",
"      Healey KL, Bines JE, Thomas SL, et al. Morphological and functional changes in the colon after massive small bowel resection. J Pediatr Surg 2010; 45:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/29\">",
"      Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992; 33:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/30\">",
"      Gouttebel MC, Saint-Aubert B, Astre C, Joyeux H. Total parenteral nutrition needs in different types of short bowel syndrome. Dig Dis Sci 1986; 31:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/31\">",
"      Diamond IR, Struijs MC, de Silva NT, Wales PW. Does the colon play a role in intestinal adaptation in infants with short bowel syndrome? A multiple variable analysis. J Pediatr Surg 2010; 45:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/32\">",
"      Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 2005; 242:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/33\">",
"      McDuffie LA, Bucher BT, Erwin CR, et al. Intestinal adaptation after small bowel resection in human infants. J Pediatr Surg 2011; 46:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/34\">",
"      Schmidt T, Pfeiffer A, Hackelsberger N, et al. Effect of intestinal resection on human small bowel motility. Gut 1996; 38:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/35\">",
"      Qandeel HG, Alonso F, Hernandez DJ, et al. Peptide absorption after massive proximal small bowel resection: mechanisms of ileal adaptation. J Gastrointest Surg 2011; 15:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/36\">",
"      Kurkchubasche AG, Rowe MI, Smith SD. Adaptation in short-bowel syndrome: reassessing old limits. J Pediatr Surg 1993; 28:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/37\">",
"      Dowling RH, Booth CC. Functional compensation after small-bowel resection in man. Demonstration by direct measurement. Lancet 1966; 2:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/38\">",
"      Dowling RH, Booth CC. Structural and functional changes following small intestinal resection in the rat. Clin Sci 1967; 32:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/39\">",
"      Hanson WR, Osborne JW. Epithelial cell kinetics in the small intestine of the rat 60 days after resection of 70 per cent of the ileum and jejunum. Gastroenterology 1971; 60:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/40\">",
"      Hanson WR, Osborne JW, Sharp JG. Compensation by the residual intestine after intestinal resection in the rat. I. Influence of amount of tissue removed. Gastroenterology 1977; 72:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/41\">",
"      Hanson WR, Osborne JW, Sharp JG. Compensation by the residual intestine after intestinal resection in the rat. II. Influence of postoperative time interval. Gastroenterology 1977; 72:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/42\">",
"      Nygaard K. Resection of the small intestine in rats. 3. Morphological changes in the intestinal tract. Acta Chir Scand 1967; 133:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/43\">",
"      Juno RJ, Knott AW, Profitt SA, et al. Preventing enterocyte apoptosis after massive small bowel resection does not enhance adaptation of the intestinal mucosa. J Pediatr Surg 2004; 39:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/44\">",
"      Stern LE, Erwin CR, Falcone RA, et al. cDNA microarray analysis of adapting bowel after intestinal resection. J Pediatr Surg 2001; 36:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/45\">",
"      Erwin CR, Jarboe MD, Sartor MA, et al. Developmental characteristics of adapting mouse small intestine crypt cells. Gastroenterology 2006; 130:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/46\">",
"      Balakrishnan A, Stearns AT, Park PJ, et al. Upregulation of proapoptotic microRNA mir-125a after massive small bowel resection in rats. Ann Surg 2012; 255:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/47\">",
"      Martin CA, Perrone EE, Longshore SW, et al. Intestinal resection induces angiogenesis within adapting intestinal villi. J Pediatr Surg 2009; 44:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/48\">",
"      DiBaise JK, Young RJ, Vanderhoof JA. Intestinal rehabilitation and the short bowel syndrome: part 1. Am J Gastroenterol 2004; 99:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/49\">",
"      Feldman EJ, Dowling RH, McNaughton J, Peters TJ. Effects of oral versus intravenous nutrition on intestinal adaptation after small bowel resection in the dog. Gastroenterology 1976; 70:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/50\">",
"      Wakabayashi Y, Yamada E, Yoshida T, Takahashi N. Effect of intestinal resection and arginine-free diet on rat physiology. Am J Physiol 1995; 269:G313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/51\">",
"      Osowska S, Neveux N, Nakib S, et al. Impairment of arginine metabolism in rats after massive intestinal resection: effect of parenteral nutrition supplemented with citrulline compared with arginine. Clin Sci (Lond) 2008; 115:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/52\">",
"      Osowska S, Moinard C, Neveux N, et al. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut 2004; 53:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/53\">",
"      Bailly-Botuha C, Colomb V, Thioulouse E, et al. Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome. Pediatr Res 2009; 65:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/54\">",
"      Hull MA, Jones BA, Zurakowski D, et al. Low serum citrulline concentration correlates with catheter-related bloodstream infections in children with intestinal failure. JPEN J Parenter Enteral Nutr 2011; 35:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/55\">",
"      Rhoads JM, Plunkett E, Galanko J, et al. Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr 2005; 146:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/56\">",
"      Fitzgibbons S, Ching YA, Valim C, et al. Relationship between serum citrulline levels and progression to parenteral nutrition independence in children with short bowel syndrome. J Pediatr Surg 2009; 44:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/57\">",
"      Tamada H, Nezu R, Matsuo Y, et al. Alanyl glutamine-enriched total parenteral nutrition restores intestinal adaptation after either proximal or distal massive resection in rats. JPEN J Parenter Enteral Nutr 1993; 17:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/58\">",
"      Chen K, Nezu R, Sando K, et al. Influence of glutamine-supplemented parenteral nutrition on intestinal amino acid metabolism in rats after small bowel resection. Surg Today 1996; 26:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/59\">",
"      Michail S, Mohammadpour H, Park JH, Vanderhoof JA. Effect of glutamine-supplemented elemental diet on mucosal adaptation following bowel resection in rats. J Pediatr Gastroenterol Nutr 1995; 21:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/60\">",
"      Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr 1995; 19:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/61\">",
"      Vanderhoof JA, Grandjean CJ, Kaufman SS, et al. Effect of high percentage medium-chain triglyceride diet on mucosal adaptation following massive bowel resection in rats. JPEN J Parenter Enteral Nutr 1984; 8:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/62\">",
"      Sukhotnik I, Hayari L, Bashenko Y, et al. Dietary palmitic acid modulates intestinal re-growth after massive small bowel resection in a rat. Pediatr Surg Int 2008; 24:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/63\">",
"      Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr 2001; 139:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/64\">",
"      Yang Q, Kock ND. Effects of dietary fish oil on intestinal adaptation in 20-day-old weanling rats after massive ileocecal resection. Pediatr Res 2010; 68:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/65\">",
"      Sukhotnik I, Shany A, Bashenko Y, et al. Parenteral but not enteral omega-3 fatty acids (Omegaven) modulate intestinal regrowth after massive small bowel resection in rats. JPEN J Parenter Enteral Nutr 2010; 34:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/66\">",
"      Koopmann MC, Liu X, Boehler CJ, et al. Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. JPEN J Parenter Enteral Nutr 2009; 33:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/67\">",
"      Koopmann MC, Nelson DW, Murali SG, et al. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. JPEN J Parenter Enteral Nutr 2008; 32:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/68\">",
"      Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93:7911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/69\">",
"      Sigalet DL, Bawazir O, Martin GR, et al. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci 2006; 51:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/70\">",
"      Vanderhoof JA, McCusker RH, Clark R, et al. Truncated and native insulinlike growth factor I enhance mucosal adaptation after jejunoileal resection. Gastroenterology 1992; 102:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/71\">",
"      Liu CD, Rongione AJ, Shin MS, et al. Epidermal growth factor improves intestinal adaptation during somatostatin administration in vivo. J Surg Res 1996; 63:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/72\">",
"      Martin CA, Bernabe KQ, Taylor JA, et al. Resection-induced intestinal adaptation and the role of enteric smooth muscle. J Pediatr Surg 2008; 43:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/73\">",
"      Pereira-Fantini PM, Thomas SL, Taylor RG, et al. Colostrum supplementation restores insulin-like growth factor -1 levels and alters muscle morphology following massive small bowel resection. JPEN J Parenter Enteral Nutr 2008; 32:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/74\">",
"      Sukhotnik I, Mogilner JG, Ben Lulu S, et al. Nutritional supplementation with transforming growth factor-beta inhibits intestinal adaptation after massive small bowel resection in a rat. Pediatr Surg Int 2011; 27:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/75\">",
"      Puolakkainen PA, Ranchalis JE, Gombotz WR, et al. Novel delivery system for inducing quiescence in intestinal stem cells in rats by transforming growth factor beta 1. Gastroenterology 1994; 107:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/76\">",
"      Sukhotnik I, Khateeb K, Krausz MM, et al. Sandostatin impairs postresection intestinal adaptation in a rat model of short bowel syndrome. Dig Dis Sci 2002; 47:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/77\">",
"      de Miguel E, G&oacute;mez de Segura IA, Bonet H, et al. Trophic effects of neurotensin in massive bowel resection in the rat. Dig Dis Sci 1994; 39:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/78\">",
"      Nightingale JM, Kamm MA, van der Sijp JR, et al. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying. Gut 1996; 39:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/79\">",
"      Vanderhoof JA, Park JH, Herrington MK, Adrian TE. Effects of dietary menhaden oil on mucosal adaptation after small bowel resection in rats. Gastroenterology 1994; 106:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/80\">",
"      Williams NS, Evans P, King RF. Gastric acid secretion and gastrin production in the short bowel syndrome. Gut 1985; 26:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/81\">",
"      Pawlikowski M. Are prostaglandins involved in the mitogenic actions of hormones? Exp Clin Endocrinol 1983; 81:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/82\">",
"      Vanderhoof JA, Grandjean CJ, Baylor JM, et al. Morphological and functional effects of 16,16-dimethyl-prostaglandin-E2 on mucosal adaptation after massive distal small bowel resection in the rat. Gut 1988; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/83\">",
"      Vanderhoof JA, Park JH, Grandjean CJ. Reduced mucosal prostaglandin synthesis after massive small bowel resection. Am J Physiol 1988; 254:G373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/84\">",
"      Joly F, Mayeur C, Bruneau A, et al. Drastic changes in fecal and mucosa-associated microbiota in adult patients with short bowel syndrome. Biochimie 2010; 92:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/85\">",
"      Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007; 9:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30601/abstract/86\">",
"      Bongaerts GP, Severijnen RS. Arguments for a lower carbohydrate-higher fat diet in patients with a short small bowel. Med Hypotheses 2006; 67:280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4770 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-0D05C0E861-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30601=[""].join("\n");
var outline_f29_56_30601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2285795\">",
"      SMALL INTESTINE LENGTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPLICATIONS OF THE SITE OF INTESTINAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Jejunal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ileal resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Loss of the ileocecal valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Loss of the colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ILEAL ADAPTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27027264\">",
"      Nutrient effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gut hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2286058\">",
"      THE MICROBIOME OF SBS AND PATHOPHYSIOLOGY OF BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIET COMPOSITION AND DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4770|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/61/34775\" title=\"figure 1\">",
"      Intestinal sites of nutrient absorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=related_link\">",
"      Chronic complications of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=related_link\">",
"      Management of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_56_30602="Bacterial vaginosis";
var content_f29_56_30602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial vaginosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Jack D Sobel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/56/30602/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/56/30602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women of childbearing age, accounting for 40 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In the United States, the National Health and Nutrition Examination Survey (NHANES), which included results from self-collected vaginal swabs from over 3700 women, estimated the prevalence of BV was 29 percent in the general population of women aged 14 to 49 years and 50 percent in African-American women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/4\">",
"     4",
"    </a>",
"    ]. This included both symptomatic and asymptomatic infection. Worldwide, BV is common among women of reproductive age, with variations according to the population studied.",
"   </p>",
"   <p>",
"    The absence of inflammation is the basis for the term \"vaginosis\" rather than \"vaginitis.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial vaginosis (BV) represents a complex change in the vaginal flora characterized by a reduction in concentration of the normally dominant hydrogen-peroxide producing lactobacilli and an increase in concentration of other organisms, especially anaerobic gram negative rods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The major bacteria detected are Gardnerella vaginalis, Prevotella species, Porphyromonas species, Bacteroides species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and Mobiluncus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/5\">",
"     5",
"    </a>",
"    ]. Fusobacterium species and Atopobium vaginae are also common. The mechanism by which the floral imbalance occurs and the role of sexual activity in the pathogenesis of BV are not clear, but formation of an epithelial biofilm may play a role.",
"   </p>",
"   <p>",
"    Hydrogen-peroxide producing lactobacilli appear to be important in preventing overgrowth of the anaerobes normally present in the vaginal flora. With the loss of lactobacilli, pH rises and massive overgrowth of vaginal anaerobes occurs. These anaerobes produce large amounts of proteolytic carboxylase enzymes, which break down vaginal peptides into a variety of amines that are volatile, malodorous, and associated with increased vaginal transudation and squamous epithelial cell exfoliation, resulting in the typical clinical features observed in patients with BV. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    below.) The rise in pH also facilitates adherence of G. vaginalis to the exfoliating epithelial cells.",
"   </p>",
"   <p>",
"    The difference in vaginal flora between women with and without BV was illustrated in a study that used broad range DNA probes to determine the vaginal flora of 27 women with BV and 46 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall, 35 bacterial phylotypes were identified in women with BV, including 16 which were newly recognized. Women with BV had a mean of 12.6 phylotypes (range 9 to 17) per sample compared to 3.3 phylotypes (range 1 to 6) per sample in women without BV. The organisms newly identified by polymerase chain reaction (PCR) include fastidious bacteria termed &ldquo;BV associated bacterium (BVAB) 1, 2 and 3&rdquo; in the Clostridiales order, which appear to be specific indicators of BV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, increasing evidence suggests that G. vaginalis is the key player in the pathogenesis of BV and the development of a biofilm may be an essential component of this process, in addition to the gradual overgrowth of resident anaerobic vaginal flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/11\">",
"     11",
"    </a>",
"    ]. In this model, a cohesive form of G. vaginalis adheres to the vaginal epithelium and then becomes the scaffolding to which other species adhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/12\">",
"     12",
"    </a>",
"    ]. This hypothesis is supported by a study of microbiota on the epithelial surfaces of vaginal biopsy specimens from women with BV that showed a biofilm adhered to part or all of the epithelium, and Gardnerella vaginalis comprised 90 percent of bacteria in the biofilm, while Atopobium vaginae accounted for most of the remainder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/13\">",
"     13",
"    </a>",
"    ]. Subsequent desquamation of these epithelial cells would result in the classic clue cells diagnostic of the disorder. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnosis'",
"    </a>",
"    below.) In contrast, most healthy controls had unstructured accumulations of bacteria within secretions loosely attached to epithelial surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity is a risk factor for bacterial vaginosis (BV), and most experts believe that BV does not occur in women who have never had vaginal intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Epidemiologic studies are strongly supportive of sexual transmission of BV pathogens. There is a high occurrence of BV and concordance of flora in women who have sex with women, further suggesting sexual transmission is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. It is not clear, however, whether one type of sexual activity may be more important in the pathogenesis of infection than another. As an example, oral-genital sex may be a more important risk factor than penile intromission into the vagina.",
"   </p>",
"   <p>",
"    Among sexually active women, additional risk factors for acquisition of BV include multiple or new sexual partners, douching, and cigarette smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/1,2,19-23\">",
"     1,2,19-23",
"    </a>",
"    ]. Douching, but not other personal hygienic behaviors, appears to be causally associated with BV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some degree of genetic susceptibility to BV is likely, no association between a gene polymorphism and BV has been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of condoms and estrogen-containing contraceptives may be protective factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty to 75 percent of women with bacterial vaginosis (BV) are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/14,27,28\">",
"     14,27,28",
"    </a>",
"    ]. Symptomatic women typically present with vaginal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal odor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/14,27,28\">",
"     14,27,28",
"    </a>",
"    ]. The discharge is off-white, thin, and homogeneous; the odor is an unpleasant \"fishy smell\" that may be more noticeable after sexual intercourse and during menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BV alone does not cause dysuria, dyspareunia, pruritus, burning, or vaginal inflammation (erythema, edema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The presence of these symptoms suggests mixed vaginitis (symptoms due to two pathogens) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although BV does not involve the cervix, the disorder may be associated with acute cervicitis (endocervical mucopurulent discharge or easily induced cervical bleeding) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general diagnostic approach to women with vaginal discharge is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical practice, the diagnosis of bacterial vaginosis (BV) in premenopausal women is usually based on the presence of at least three Amsel criteria (characteristic vaginal discharge, elevated pH, clue cells, fishy odor) if microscopy is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Use of Nugent or",
"    <span class=\"nowrap\">",
"     Hay/Ison",
"    </span>",
"    criteria to evaluate a Gram-stained smear of vaginal discharge is the diagnostic standard in research studies, but requires more time, resources, and expertise. If microscopy is not available, the diagnosis should be based on findings on clinical examination (characteristic vaginal discharge, elevated vaginal pH, fishy odor) and results of commercial diagnostic tests. The best performing commercial diagnostic test is a DNA probe-based test for high concentrations of G. vaginalis (Affirm VP III). Acceptable alternatives include a proline-aminopeptidase test card (Pip Activity TestCard) or a test for elevated sialidase activity (OSOM BVBlue test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110845310\">",
"    <span class=\"h2\">",
"     Amsel crtieria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of BV is usually based on Amsel criteria, which are simple and useful in an office practice where microscopy is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/27\">",
"     27",
"    </a>",
"    ]. The first three findings are sometimes also present in patients with trichomoniasis (",
"    <a class=\"graphic graphic_table graphicRef68759 \" href=\"mobipreview.htm?38/29/39388\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Amsel criteria for diagnosis of BV (at least three criteria must be present):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls",
"     </li>",
"     <li>",
"      Vaginal pH &gt;4.5",
"     </li>",
"     <li>",
"      Positive whiff-amine test, defined as the presence of a fishy odor when a drop of 10 percent potassium hydroxide (KOH) is added to a sample of vaginal discharge",
"     </li>",
"     <li>",
"      Clue cells on saline wet mount (",
"      <a class=\"graphic graphic_picture graphicRef52425 graphicRef73248 \" href=\"mobipreview.htm?22/6/22634\">",
"       picture 1A-B",
"      </a>",
"      ). Clue cells are vaginal epithelial cells studded with adherent coccobacilli that are best appreciated at the edge of the cell. For a positive result, at least 20 percent of the epithelial cells on wet mount should be clue cells. The presence of clue cells diagnosed by an experienced microscopist is the single most reliable predictor of BV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using Gram&rsquo;s stain as the standard for diagnosing BV, the sensitivity of Amsel criteria for diagnosis of BV is over 90 percent and specificity is 77 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9465755\">",
"    <span class=\"h2\">",
"     Gram's stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram&rsquo;s stain of vaginal discharge is the gold standard for diagnosis of BV (",
"    <a class=\"graphic graphic_picture graphicRef78328 graphicRef54837 \" href=\"mobipreview.htm?4/21/4435\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/36\">",
"     36",
"    </a>",
"    ], but is mostly performed in research studies because it requires more time, resources, and expertise than Amsel criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The Gram-stained smear is evaluated using Nugent criteria (",
"    <a class=\"graphic graphic_table graphicRef70348 \" href=\"mobipreview.htm?38/32/39435\">",
"     table 2",
"    </a>",
"    ) or",
"    <span class=\"nowrap\">",
"     Hay/Ison",
"    </span>",
"    criteria (",
"    <a class=\"graphic graphic_table graphicRef86620 \" href=\"mobipreview.htm?5/2/5163\">",
"     table 3",
"    </a>",
"    ). If clinical criteria are used to define infection, then reported sensitivity ranges from 62 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9465762\">",
"    <span class=\"h2\">",
"     Cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Papanicolaou smear is",
"    <strong>",
"     not",
"    </strong>",
"    reliable for diagnosis of BV (sensitivity 49 percent, specificity 93 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/41\">",
"     41",
"    </a>",
"    ]. No information is available on the sensitivity and specificity of liquid-based cervical cytology screening methods. If a cytology smear suggests BV (ie, shift in flora from predominantly lactobacilli to predominantly coccobacilli with or without clue cells), the patient should be asked about symptoms, and if symptomatic, she should undergo standard diagnostic testing for BV and treatment, if appropriate. Treatment of asymptomatic women is not routinely indicated. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Asymptomatic infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110845295\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because BV represents complex changes in the vaginal flora, vaginal culture has",
"    <strong>",
"     no",
"    </strong>",
"    role in diagnosis. Although cultures for G. vaginalis are positive in almost all women with symptomatic infection, the organism is detected in up to 50 to 60 percent of healthy asymptomatic women; thus, its presence alone is not diagnostic of BV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9465777\">",
"    <span class=\"h2\">",
"     Commercial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial tests for diagnosis of BV are not widely used, given the excellent performance of Amsel criteria, but can be useful when microscopy is not available.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     Affirm VP III",
"    </strong>",
"    test is an automated DNA probe assay for detecting G. vaginalis when present at a high concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/42\">",
"     42",
"    </a>",
"    ]. It takes less than one hour to perform and is the best option when findings on physical examination suggest BV (characteristic vaginal discharge and results of pH and whiff test, if available), but microscopy cannot be performed to look for clue cells. In one study, for example, the combination of a positive DNA probe (concentration of G. vaginalis &ge;2 times 10",
"    <sup>",
"     7",
"    </sup>",
"    <span class=\"nowrap\">",
"     CFU/mL)",
"    </span>",
"    and vaginal pH &gt;4.5 had a sensitivity and specificity of 95 and 99 percent, respectively, for diagnosis of BV when clinical criteria were used as the diagnostic standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/43\">",
"     43",
"    </a>",
"    ]. Not all studies have reproduced these excellent results, and over-diagnosis is possible.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     OSOM BVBlue",
"    </strong>",
"    system is a chromogenic diagnostic test based on the presence of elevated sialidase enzyme activity in vaginal fluid samples. This enzyme is produced by bacterial pathogens associated with bacterial vaginosis including Gardnerella, Bacteroides, Prevotella, and Mobiluncus. The test can be performed at the point of care and results are available in 10 minutes (Clinical Laboratory Improvement Amendments [CLIA]-waived). Sensitivity ranging from 88 to 94 percent and specificity ranging from 91 to 98 percent have been reported when compared with Amsel and Nugent criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     FemExam G. vaginalis Pip Activity",
"    </strong>",
"    Test card detects proline aminopeptidase activity of anaerobes, especially G. vaginalis, in vaginal discharge. Sensitivities of 89 and 92 percent and specificities of 94 and 96 percent have been reported, when clinical criteria were used as the diagnostic standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. It can be performed at the point of care in less than two minutes and is pending CLIA-waiver.",
"   </p>",
"   <p>",
"    <strong>",
"     FemExam",
"    </strong>",
"    pH and amines test card is a point of care test (CLIA-waived) that can detect an elevated vaginal fluid pH (pH &ge; 4.7) and the presence of trimethylamine in a sample of vaginal discharge. Results are available within two minutes. However, this test performs less well than other tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9466208\">",
"    <span class=\"h2\">",
"     Investigational tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative polymerase chain reaction (PCR)-based assays are based upon molecular quantification of G. vaginalis and Atopobium vaginae, and other bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Although these tests have good sensitivity and specificity compared with standard clinical tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/53\">",
"     53",
"    </a>",
"    ], they are not commercially available, are expensive, and are of questionable advantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A urine test that uses fluorescence in situ hybridization (FISH) to identify the BV biofilm on desquamated vaginal epithelial cells in urine sediment appears promising and is also under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86552574\">",
"    <span class=\"h2\">",
"     Diagnosis without speculum examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;BV has been diagnosed using a swab of vaginal discharge obtained by the patient or clinician without physical examination. However, omission of the speculum examination results in under-diagnosis and should be avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, young women with or without vaginitis symptoms self-tested for BV using a pH or sialidase test and results were compared with clinician-performed examination with clinical diagnosis of BV by modified Amsel criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/56\">",
"       56",
"      </a>",
"      ]. Compared with diagnosis by clinician examination, self-pH was 73 percent sensitive and 67 percent specific and self-sialidase was 40 percent sensitive and 90 percent specific.",
"     </li>",
"     <li>",
"      In another study of the diagnostic accuracy for BV among women presenting with vaginal discharge to a sexually transmitted diseases (STD) clinic, all women provided self-obtained vaginal swabs for examination, completed a questionnaire, and then were examined by a clinician [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/57\">",
"       57",
"      </a>",
"      ]. A non-examining clinician reviewed the findings of the questionnaire and self-obtained vaginal swab and diagnosed BV if at least two of three Amsel criteria were positive (pH&gt;4.5, &gt;20 percent clue cells, positive Whiff test). Examining clinicians diagnosed BV if at least three of the four standard Amsel criteria were positive (characteristic discharge, pH&gt;4.5, &gt;20 percent clue cells, positive Whiff test). In all cases, Gram-stained slides for diagnosis of BV by Nugent criteria were made, but the results were not disclosed, and 125 were positive. The investigators found that clinical examination with a speculum exam was more likely to result in a correct diagnosis of BV than just examination of a self-obtained vaginal swab",
"      <span class=\"nowrap\">",
"       (90/125",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       68/125),",
"      </span>",
"      but also resulted in over",
"      <span class=\"nowrap\">",
"       diagnosis/over",
"      </span>",
"      treatment in 15 patients (105 positive diagnoses versus 61 positive diagnoses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of microscopy, a lack of fishy odor (negative whiff test) makes the diagnosis of bacterial vaginosis (BV) unlikely. BV is usually suspected because of high vaginal pH (&gt;4.5). Other causes of increased pH include trichomoniasis, atrophic vaginitis, and desquamative inflammatory vaginitis. These four entities are easily distinguishable by clinical and microscopic features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with BV do not have dyspareunia or signs of vaginal inflammation; in contrast, women with atrophic vaginitis, desquamative inflammatory vaginitis, and trichomoniasis usually have these signs and symptoms.",
"     </li>",
"     <li>",
"      Both atrophic vaginitis and desquamative inflammatory vaginitis are associated with an increased number of parabasal cells on microscopy, which is not observed in women with BV.",
"     </li>",
"     <li>",
"      A large number of polymorphonuclear leukocytes on microscopy are characteristic of desquamative inflammatory vaginitis, trichomoniasis, and atrophic vaginitis with infection, but not BV.",
"     </li>",
"     <li>",
"      Visualization of trichomonads readily makes the diagnosis of trichomoniasis in the setting of an elevated pH, however, in other cases, we suggest using more sensitive and specific diagnostic tests to diagnose or exclude trichomoniasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONSEQUENCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with bacterial vaginosis (BV) are at higher risk of preterm delivery (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Pregnant women'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/58-61\">",
"       58-61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BV is a cause of [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endometrial bacterial colonization",
"     </li>",
"     <li>",
"      Plasma-cell endometritis",
"     </li>",
"     <li>",
"      Postpartum fever",
"     </li>",
"     <li>",
"      Post-hysterectomy vaginal cuff cellulitis",
"     </li>",
"     <li>",
"      Postabortal infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BV is a risk factor for human immunodeficiency virus (HIV) acquisition and transmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/65-67\">",
"       65-67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BV is a risk factor for acquisition of herpes simplex virus type 2 (HSV-2), gonorrhea, and chlamydial infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Although BV is more common among women with pelvic inflammatory disease (PID), it is not clear whether it is a causal factor or an independent risk factor for this disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It has been hypothesized that the increased risk of acquisition of sexually transmitted infections in women with BV may be due to lack of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      -producing lactobacilli in the vaginal flora of affected women; other factors associated with BV infection, such as local cytokine production, may also play a role.",
"     </li>",
"     <li>",
"      BV may be a factor in development of precancerous cervical lesions. In a systematic review and meta-analysis of primarily cross-sectional studies, the risk of cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL) was increased in women with BV (OR 1.15, 95% CI 1.24-1.83); however, there was considerable heterogeneity among these studies and both CIN 1 and low-grade SIL, which do not usually progress to cancer, were included as outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/72\">",
"       72",
"      </a>",
"      ]. BV appears conducive to the persistence of human papillomavirus (HPV) infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/73,74\">",
"       73,74",
"      </a>",
"      ], which is necessary but not sufficient for development of high grade cervical lesions and cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H3#H3\">",
"       \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Role of human papillomavirus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial vaginosis (BV) resolves spontaneously in up to one-third of nonpregnant and one-half of pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. Treatment is indicated for relief of symptoms in women with symptomatic infection and to prevent postoperative infection in those with asymptomatic infection prior to abortion or hysterectomy (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Gynecologic procedures'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Treatment of BV may also reduce the risk of acquiring sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/66,79\">",
"     66,79",
"    </a>",
"    ]. For this reason, some experts support the concept of treating all women with BV regardless of presence or absence of symptoms; however, we agree with the United States Centers for Disease Control and Prevention (CDC) recommendations to not treat asymptomatic women.",
"   </p>",
"   <p>",
"    Asymptomatic pregnant women with previous preterm births may also benefit, but screening and treatment of these women is controversial (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Pregnant women'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The following treatment recommendations are consistent with those of the CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ]. Guidelines from other organizations are available elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110845488\">",
"    <span class=\"h2\">",
"     Nonpregnant women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    administered either orally or intravaginally results in a high rate of clinical cure (70 to 80 percent at four weeks of follow-up) (",
"    <a class=\"graphic graphic_table graphicRef77648 \" href=\"mobipreview.htm?39/29/40411\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Oral medication is more convenient, but associated with a higher rate of systemic side effects than vaginal administration.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    is a reasonable oral alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has been established in randomized trials using either placebo or active drug controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. The oral regimen we recommend is 500 mg twice daily for seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ]. Treatment with a single oral dose of 2 grams of metronidazole has lower efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/87\">",
"     87",
"    </a>",
"    ] and is no longer recommended for treatment of BV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ]. Alcohol should not be consumed during therapy and for one day after completion of therapy.",
"   </p>",
"   <p>",
"    There is little evidence of benefit from prolonging therapy longer than seven days. Most comparative studies using divided-dose oral regimens for one week achieved early cure rates in excess of 90 percent, and cure rates (by Amsel criteria) at four weeks of approximately 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/83,85,88-92\">",
"     83,85,88-92",
"    </a>",
"    ]. Although early cure rates are significantly higher when the initial course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy is 14 days rather than 7 days, long-term cure rates (21 days after completion of therapy) are similar for both treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/22\">",
"     22",
"    </a>",
"    ]. Published cure rates vary widely according to the investigators&rsquo; diagnostic criteria, definition of cure and treatment failure, and length of time post-therapy before the follow-up visit.",
"   </p>",
"   <p>",
"    Vaginal therapy with 0.75 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel (5 grams once daily for five days) is as effective as oral metronidazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/89,90,93,94\">",
"     89,90,93,94",
"    </a>",
"    ]. The choice of oral versus vaginal therapy should depend upon patient preference.",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    include a metallic taste, nausea (in 10 percent of patients), transient neutropenia (7.5 percent), a disulfiram-like effect with alcohol, prolongation of International Normalized Ratio (INR) in patients taking vitamin K antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ), and peripheral neuropathy. Gastrointestinal side effects are less common with vaginal administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/90\">",
"     90",
"    </a>",
"    ]. Allergy to metronidazole is uncommon; it manifests as rash, urticaria, pruritus, and rarely, anaphylaxis, which can be successfully treated by oral desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    has been demonstrated in a meta-analysis of randomized trials, both comparative and placebo controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/85\">",
"     85",
"    </a>",
"    ]. The preferred regimen is a seven-day course of 2 percent clindamycin cream vaginally (5 grams of cream containing 100 mg of clindamycin phosphate), but may be less effective than the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    regimens; nevertheless, vaginal clindamycin cream is a reasonable therapeutic choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative regimens include oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg twice daily for seven days) or clindamycin ovules (100 mg intravaginally once daily for three days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32,96\">",
"     32,96",
"    </a>",
"    ]. A one-day or single application of clindamycin as a bioadhesive is another option (Clindesse). These regimens have not been studied extensively and may have lower efficacy for eradicating BV.",
"   </p>",
"   <p>",
"    Intravaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    therapy has been associated with an increased prevalence of clindamycin resistant anaerobic bacteria in the vagina posttreatment (17 percent of bacterial isolates before versus 53 percent of isolates after therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/97\">",
"     97",
"    </a>",
"    ]. This effect persisted in most women for at least 90 days after clindamycin treatment. In contrast, increased resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    was not observed in women treated with that drug. Further investigation is required to determine the clinical implications of these findings.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    cream should not be used concurrently with latex condoms, which may be weakened.",
"   </p>",
"   <p>",
"    Pseudomembranous colitis has been reported with both oral and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Tinidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    is a second generation nitroimidazole. It has a longer half-life than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (12 to 14 hours versus 6 to 7 hours) and fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/98\">",
"     98",
"    </a>",
"    ], but is more costly since no generic formulation is available. If used, we suggest 1 gram orally once daily for five days, as efficacy is slightly higher and side effects are slightly less frequent than with shorter course therapy (tinidazole 2 grams orally daily for two days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/99\">",
"     99",
"    </a>",
"    ]. Randomized trials have shown that it is at least as effective as metronidazole, but not superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/99-103\">",
"     99-103",
"    </a>",
"    ], and a single dose regimen appears to be as effective as vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    cream [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86556287\">",
"    <span class=\"h4\">",
"     Secnidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secnidazole is a nitroimidazole antibiotic not available in the United States, but available internationally. In a randomized double-blind non-inferiority trial, a single 2 gram oral dose of secnidazole was at least as effective as a seven-day course of 500 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    administered orally twice daily, and was well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/105\">",
"     105",
"    </a>",
"    ]. A single 1 gram oral dose of secnidazole appears to be as effective as the 2 gram dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194270516\">",
"    <span class=\"h4\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics (live microorganisms which confer a health benefit on the host when administered in adequate amounts) have been used alone and as adjunctive therapy to antibiotics for treatment of BV and prevention of relapse. Systemic reviews of trials of probiotics for treatment of BV have not found sufficient evidence for or against efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Although some trials have reported very promising results, we feel the results should be reproduced in more well-designed and larger trials before use of this therapy is considered. In addition, further investigation is needed to determine the optimum route of administration (oral or vaginal), which strains or combination of strains are most effective (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    rhamnosus GR-1, Lactobacillus reuteri RC-14, Lactobacillus acidophilus), and the dose and duration of use. Lastly, the quality of commercially available probiotics varies worldwide. In the United States, the content of these products is not standardized and often of poor quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86556170\">",
"    <span class=\"h4\">",
"     Less effective and ineffective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple-sulfa creams,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , lactic acid gel,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    gel, ascorbic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , and povidone-iodine vaginal douches are significantly less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and should not be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/22,109-115\">",
"     22,109-115",
"    </a>",
"    ]. Cure rates with ampicillin and amoxicillin are mediocre.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1396145\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up is unnecessary if symptoms resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sexual partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not necessary to treat male sexual partners of affected women, as there is no strong evidence that the woman's response to therapy and risk of relapse are influenced by treatment of her male sex partner(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32,116\">",
"     32,116",
"    </a>",
"    ]. However, the available trials are flawed; well-designed and larger trials should be performed to assess the efficacy of male partner treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual intercourse appears to play a role in disease activity. Some studies have reported reduced rates of recurrence when male sexual partners used condoms routinely during coitus or when women remained abstinent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/22,26,118-121\">",
"     22,26,118-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with BV who have sex with women should be encouraged to inform their sexual partner(s) regarding the need for screening, diagnosis, and treatment, given the high risk of concordant infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25113?source=see_link\">",
"     \"Medical care of women who have sex with women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Relapse and recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of patients with initial responses to therapy have a recurrence of symptoms within three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/88\">",
"     88",
"    </a>",
"    ] and more than 50 percent experience a recurrence within 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/118\">",
"     118",
"    </a>",
"    ]. The explanation for this high rate of recurrence is unclear. Reinfection is possible, but recurrence more likely reflects a failure to eradicate the offending organisms or to reestablish the normal protective vaginal flora dominated by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    . Infections involving biofilms can be more difficult to eradicate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest symptomatic relapse be treated initially with a seven-day course of oral or vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . The treatment regimen may be the same or different from the initial or previous treatment regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After initial induction therapy, most women with a history of recurrent infection benefit from suppressive therapy to maintain an asymptomatic state. We feel any patient with more than three documented episodes of BV in the previous 12 months should be offered a long-term maintenance regimen consisting of maintenance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel. Long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    regimens, oral or topical, are not advised because of toxicity and lack of documented efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/26\">",
"     26",
"    </a>",
"    ]. Accordingly, if any of the aforementioned antimicrobials fail, we prescribe metronidazole gel 0.75 percent or an oral nitroimidazole for 7 to 10 days followed by twice weekly dosing of gel for four to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ]. In one multicenter prospective trial of this metronidazole gel regimen, recurrent BV occurred in 25.5 percent of patients on suppressive therapy versus 59.1 percent of those receiving placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/123\">",
"     123",
"    </a>",
"    ]. Secondary vaginal candidiasis was a common side effect.",
"   </p>",
"   <p>",
"    Results can be improved by adding vaginal boric acid to the oral nitroimidazole induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/124\">",
"     124",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    is taken orally for seven days; vaginal boric acid 600 mg is begun at the same time and continued for 21 days. Patients are seen for follow-up a day or two after their last boric acid dose; if they are in remission, we immediately begin metronidazole gel twice weekly for four to six months as suppressive therapy. Therapy is then discontinued.",
"    <strong>",
"     Boric acid can cause",
"    </strong>",
"    <strong>",
"     death if consumed orally",
"    </strong>",
"    ; patients should be told to store boric acid in a secure place that is inaccessible to children.",
"   </p>",
"   <p>",
"    As discussed above, no study has demonstrated reduced rates of recurrence in women whose partners were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . However, some studies have reported reduced rates of recurrence when sexual partners used condoms routinely with coitus or the patient remained abstinent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/22,26,118-121\">",
"     22,26,118-121",
"    </a>",
"    ]. For this reason, some experts suggest these behavioral interventions for women with recurrent infection.",
"   </p>",
"   <p>",
"    A single trial has reported that use of condoms and combination",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"      metronidazole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/53/32592?source=see_link\">",
"      nystatin",
"     </a>",
"    </span>",
"    ovule therapy may reduce the frequency of recurrent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/119\">",
"     119",
"    </a>",
"    ]. The higher efficacy of the ovule may be due to the higher content of metronidazole (500 mg) compared with the gel (37.5 mg).",
"   </p>",
"   <p>",
"    Exogenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    recolonization with 30 days of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in addition to seven days of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy has been suggested, but there is minimal evidence of the efficacy of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/85,125\">",
"     85,125",
"    </a>",
"    ]. These results should be reproduced in other trials before use of this therapy is considered.",
"   </p>",
"   <p>",
"    Vaginal acidifying agents, although popular and widely used, have no role in the treatment of acute or chronic BV, as they have never been shown to enhance cure rates. Douching should be avoided. Likewise, in a randomized trial, probiotics were not more effective than placebo for prevention of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Asymptomatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of asymptomatic BV is typically avoided since patients often spontaneously improve over a period of several months and any antibacterial therapy is often followed by symptomatic vaginal yeast infection. This practice is supported by a double-blind, placebo controlled trial of 54 women with asymptomatic BV who were randomly assigned to receive intravaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or placebo gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/77\">",
"     77",
"    </a>",
"    ]. There was no difference in the proportion of women in either group who noticed improvement in vaginal odor or discharge. In addition, 6 of 28 women receiving metronidazole developed symptomatic vaginal candidiasis compared with no women taking placebo.",
"   </p>",
"   <p>",
"    Although some experts recommend treatment of asymptomatic BV because affected women are more susceptible to acquiring other STDs (including HIV and herpes simplex virus), available evidence is insufficient to clearly support or exclude a benefit of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/79,126-128\">",
"     79,126-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is indicated for asymptomatic women who are scheduled for certain gynecologic procedures (see below). Treatment of asymptomatic infection in pregnant women is more complex and is discussed in detail below (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Pregnant women'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gynecologic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence linking asymptomatic BV with gynecologic complications has caused this issue to be reassessed, especially with the availability of topical therapy. It is reasonable to treat asymptomatic BV prior to hysterectomy and before pregnancy termination to prevent postprocedure infection (cuff infection after hysterectomy, endometritis after abortion). Reported reductions in postoperative infectious complications range from 10 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/129-135\">",
"     129-135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Symptomatic BV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women with symptomatic BV should be treated to relieve bothersome symptoms. Oral treatment is effective and has not been associated with adverse fetal or obstetrical effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/136-141\">",
"     136-141",
"    </a>",
"    ]. The therapeutic options include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      500 mg orally twice daily for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      250 mg orally 3 times daily for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      300 mg orally twice daily for 7 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians avoid use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in the first trimester because it crosses the placenta, and thus has a potential for teratogenicity. However, meta-analysis has not found any relationship between metronidazole exposure during the first trimester of pregnancy and birth defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/142\">",
"     142",
"    </a>",
"    ], and the CDC no longer discourage the use of metronidazole in the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/143\">",
"     143",
"    </a>",
"    ]. An additional concern is that the drug is mutagenic in bacteria and carcinogenic in mice, but there is no evidence of harm in humans.",
"   </p>",
"   <p>",
"    As mentioned above, topical therapy is as effective as oral therapy in the treatment of nonpregnant women with BV. In contrast, some experts avoid topical therapy in pregnant women because they believe oral treatment is more effective against potential subclinical upper genital tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/144-146\">",
"     144-146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Asymptomatic infection and screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as one-third of pregnant women in the United States have BV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/58\">",
"     58",
"    </a>",
"    ]. Of concern, a 2007 meta-analysis reported a statistically significant increased risk of preterm birth in these women; the pooled odds ratio for prematurity was 2.16 (95% CI 1.56-3.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/147\">",
"     147",
"    </a>",
"    ]. The increased risk of preterm birth attributable to BV appears to be linked to preterm labor due to chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/59,148\">",
"     59,148",
"    </a>",
"    ]. Other complications of BV include postpartum endometritis (OR 2.53, 95% CI 1.25-5.08), and an increased risk of late miscarriage (OR 6.32, 95% CI 3.65-10.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the association between BV and adverse outcome, screening and treatment of asymptomatic BV during pregnancy is controversial. Meta-analyses of randomized trials performed in general obstetric populations have generally found that treatment of asymptomatic infection does not reduce the incidence of preterm labor or delivery in the overall obstetrical population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/136,149,150\">",
"     136,149,150",
"    </a>",
"    ], but some subgroups of women, such as those at high risk for preterm birth, may benefit. The available evidence is discordant due to differences in selection of trials and differences between the included trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2013 Cochrane meta-analysis including 21 trials involving 7847 pregnant women with BV (symptomatic or asymptomatic) detected through screening, antibiotic therapy was highly effective in eradicating infection, but did not significantly reduce the odds of preterm birth at less than 37 weeks (OR 0.88, 95% CI 0.71-1.09) or the risk of preterm premature rupture of membranes (OR 0.74, 95% CI 0.30-1.84) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/136\">",
"       136",
"      </a>",
"      ]. Treatment initiated before 20 weeks of gestation also did not reduce the risk of preterm birth before 37 weeks (OR 0.85, 95% CI 0.62-1.17).",
"      <br/>",
"      <br/>",
"      When the Cochrane reviewers separately analyzed the subgroup of women with a history of one or more prior preterm births (ie, women at high risk for preterm birth), the detection and treatment of BV still did not significantly reduce the risk of preterm birth (OR 0.78, 95% CI 0.42-1.48; 3 trials, 421 women).",
"     </li>",
"     <li>",
"      In 2008, the United States Preventive Services Task Force (USPSTF) evaluated the effect of treatment of asymptomatic BV in women at high risk for preterm birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/149\">",
"       149",
"      </a>",
"      ]. Due to heterogeneity, results could not be pooled. Three trials showed fewer deliveries before 37 weeks of gestation with treatment, one showed no benefit, and one trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/151\">",
"       151",
"      </a>",
"      ] reported an increase in preterm deliveries after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      . For delivery before 34 weeks of gestation, meta-analysis was possible and showed no significant treatment benefit.",
"     </li>",
"     <li>",
"      In a 2011 meta-analysis of five randomized trials of asymptomatic women with BV at &lt;22 weeks of gestation treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      or",
"      <span class=\"nowrap\">",
"       placebo/no",
"      </span>",
"      treatment, clindamycin therapy was associated with a reduction in preterm birth &lt;37 weeks (3.7 percent",
"      <span class=\"nowrap\">",
"       [44/1183]",
"      </span>",
"      versus 6.2 percent",
"      <span class=\"nowrap\">",
"       [72/1163];",
"      </span>",
"      fixed effects RR 0.60, 95% CI 0.42-0.86, random effects 0.64, 95% CI 0.39-1.05) and late miscarriage (0.3 percent",
"      <span class=\"nowrap\">",
"       [2/639]",
"      </span>",
"      versus 1.9 percent",
"      <span class=\"nowrap\">",
"       [12/631];",
"      </span>",
"      RR 0.20, 95% CI 0.05-0.76) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/150\">",
"       150",
"      </a>",
"      ]. Subgroup analysis revealed that oral, not vaginal, clindamycin therapy was associated with a significant reduction in preterm birth (oral therapy RR 0.39, 95% CI 0.20-0.76; vaginal RR 0.73, 95% CI 0.47-1.14). The analysis included a mixed population of women at both low and high risk of preterm birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, we agree with the American College of Obstetricians and Gynecologists (ACOG), USPSTF, and CDC recommendations to not routinely screen and treat all pregnant women with asymptomatic BV to prevent preterm birth and its consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32,149,152\">",
"     32,149,152",
"    </a>",
"    ]. It is not possible to define specific features characterizing a subgroup of women who might respond favorably to a screening and treatment protocol. Defining these features is an active area of investigation.",
"   </p>",
"   <p>",
"    As illustrated above, there may be benefits to early screening and treatment of asymptomatic pregnant women who have a history of a previous preterm delivery, but there are insufficient data to recommend this as a routine practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/138,153-156\">",
"     138,153-156",
"    </a>",
"    ]. Further definition of high risk subgroups is under investigation. As an example, women with polymorphisms of genes regulating cytokine production (eg, tumor necrosis factor variants) have a greater proinflammatory immune response to infectious stimuli, such as BV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/157\">",
"     157",
"    </a>",
"    ]. Enhanced induction of cytokines in these women could then lead to preterm labor or rupture of membranes. Other aspects of host response (eg, low levels of IgA to Gardnerella vaginalis) or the specific types of BV associated bacteria involved (eg, bacteria that produce high levels of sialidase or protease) may also play a role in placing some women with BV at high risk of preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When treatment of BV is initiated, the optimal choice of antibiotic, timing of therapy, duration of use, and harms of therapy are also controversial. The first trials demonstrated a reduction in preterm birth in high risk women treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or oral metronidazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60950 \" href=\"mobipreview.htm?34/49/35611\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. However, in two studies, metronidazole use in pregnancy appeared to increase the risk of preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/151,158\">",
"     151,158",
"    </a>",
"    ]. This association requires further investigation and confirmation before avoiding metronidazole for treatment of BV in pregnancy. Other trials suggest that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    given early in pregnancy is an effective therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/150\">",
"     150",
"    </a>",
"    ] and that topical clindamycin given in the second half of pregnancy is less effective and even associated with an increase in low birth weight and neonatal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/159\">",
"     159",
"    </a>",
"    ]. Therefore, we use oral therapy when treatment is indicated, and consider both metronidazole and clindamycin acceptable choices. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) considers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    use compatible with breastfeeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/160\">",
"     160",
"    </a>",
"    ]. However, clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora so the infant should be monitored for diarrhea, candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/161\">",
"     161",
"    </a>",
"    ]. Infant side effects are less likely with vaginal than oral use since only about 30 percent of a vaginal dose is absorbed.",
"   </p>",
"   <p>",
"    When indicated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is used for treatment of infection in neonates. There are no human data supporting an association between metronidazole use and cancer; however, an association with carcinogenesis in rodents has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/162\">",
"     162",
"    </a>",
"    ]. Outcomes data of maternal metronidazole use did not show a significant increase in adverse events compared to use of other antimicrobials, although a cohort study found a nonsignificant trend toward more loose stools and more candidal colonization in metronidazole-exposed infants. Since the relative infant dose of metronidazole is high (29 percent) with maternal administration of the 2 gram one-time dose, a cautious approach for mothers receiving this dose is to express and discard their milk for 12 to 24 hours. This recommendation has not been extended to other metronidazole regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    has not been studied during breastfeeding. After vaginal administration, plasma levels are less than 2 percent of those after a 500 mg oral dose, so vaginal use of metronidazole during breastfeeding is unlikely to be of concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/56/30602/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/56/22402?source=see_link\">",
"       \"Patient information: Bacterial vaginosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=see_link\">",
"       \"Patient information: Bacterial vaginosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BV represents a complex change in the vaginal flora characterized by a reduction in concentration of the normally dominant hydrogen-peroxide producing lactobacilli and an increase in concentration of other organisms, particularly anaerobes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis and microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 50 to 75 percent of women with BV are asymptomatic. Those with symptoms often present with an off-white, thin, and homogeneous \"fishy smelling\" discharge that is more noticeable after coitus and during menses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sequelae of BV can include an increased risk of preterm birth, plasma-cell endometritis, postpartum fever, post-hysterectomy vaginal cuff cellulitis, postabortal infection, pelvic inflammatory disease, and acquisition of other sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Consequences'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When microscopy is available, the diagnosis of BV is based on the presence of at least three of the following four Amsel criteria (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls",
"     </li>",
"     <li>",
"      Vaginal pH greater than 4.5",
"     </li>",
"     <li>",
"      Positive whiff-amine test, defined as the presence of a fishy odor when 10 percent potassium hydroxide (KOH) is added to a sample of vaginal discharge",
"     </li>",
"     <li>",
"      Clue cells on saline wet mount, comprising at least 20 percent of epithelial cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If microscopy is not available, we suggest using physical examination, pH testing, whiff-amine test, and a commercial test using a DNA probe (eg, Affirm VP III) to make the diagnosis of BV. (See",
"      <a class=\"local\" href=\"#H9465777\">",
"       'Commercial tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal culture is",
"      <strong>",
"       not",
"      </strong>",
"      useful. (See",
"      <a class=\"local\" href=\"#H110845295\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment of nonpregnant women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of symptomatic women with bacterial vaginosis is indicated to reduce vaginal discharge and odor. We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.) Options include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      500 mg twice daily orally for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      gel 0.75 percent (5 grams) once daily vaginally for 5 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      2% vaginal cream once daily at bedtime for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      300 mg twice per day orally for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      100 mg vaginal suppositories at bedtime for 3 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      bioadhesive cream (Clindesse) 2% as a single vaginal dose of 5 grams of cream containing 100 mg of clindamycin phosphate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , alcohol should not be consumed. During therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      cream, latex condoms should not be used. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Metronidazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Clindamycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not treating sexual partners of women with BV (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sexual partners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of patients with an initial response to therapy have a recurrence of symptoms within three months and more than 50 percent experience a recurrence within 12 months. We treat symptomatic relapse with a longer course of therapy, using a different antibiotic than that used for the initial episode. For women who prefer preventive therapy instead of treatment of frequent episodes of BV, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      orally for 7 days; vaginal boric acid 600 mg is begun at the same time and continued for 21 days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients are seen for follow-up a day or two after their last boric acid dose; if they are in remission, we immediately begin metronidazole gel twice weekly for four to six months as suppressive therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Relapse and recurrent infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of asymptomatic women who are to undergo hysterectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Preoperative treatment decreases the frequency of postoperative infectious complications. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Gynecologic procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment of pregnant women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with BV are at increased risk of preterm birth. We recommend not screening all pregnant women for BV, given there is no evidence that screening and treatment of asymptomatic infection reduces the risk of preterm birth (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Asymptomatic infection and screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We treat pregnant women with symptomatic BV infection to relieve symptoms. We prescribe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      300 mg orally twice daily for 7 days or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      500 mg orally twice daily for 7 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Symptomatic BV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of asymptomatic women who are to undergo pregnancy termination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Preoperative treatment decreases the frequency of postoperative infectious complications. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Gynecologic procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Joesoef, M, Schmid, G. Bacterial vaginosis. In: Clinical evidence, BMJ Publishing Group, London 2001. p.887.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/2\">",
"      Morris M, Nicoll A, Simms I, et al. Bacterial vaginosis: a public health review. BJOG 2001; 108:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/3\">",
"      Tolosa JE, Chaithongwongwatthana S, Daly S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol 2006; 195:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/4\">",
"      Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007; 109:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/5\">",
"      Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/6\">",
"      Ling Z, Kong J, Liu F, et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 2010; 11:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/7\">",
"      Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/8\">",
"      Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011; 118:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/9\">",
"      Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/10\">",
"      Fredricks DN, Fiedler TL, Thomas KK, et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007; 45:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/11\">",
"      Patterson JL, Stull-Lane A, Girerd PH, Jefferson KK. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiology 2010; 156:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/12\">",
"      Verstraelen H, Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2013; 26:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/13\">",
"      Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/14\">",
"      Yen S, Shafer MA, Moncada J, et al. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol 2003; 102:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/15\">",
"      Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009; 200:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/16\">",
"      Skinner CJ, Stokes J, Kirlew Y, et al. A case-controlled study of the sexual health needs of lesbians. Genitourin Med 1996; 72:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/17\">",
"      Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000; 76:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/18\">",
"      Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis 2009; 199:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/19\">",
"      Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol 2002; 100:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/20\">",
"      Schwebke JR, Desmond RA, Oh MK. Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis 2004; 31:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/21\">",
"      Ness RB, Kip KE, Soper DE, et al. Variability of bacterial vaginosis over 6- to 12-month intervals. Sex Transm Dis 2006; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/22\">",
"      Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/23\">",
"      Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am J Epidemiol 2008; 168:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/24\">",
"      Klebanoff MA, Nansel TR, Brotman RM, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis 2010; 37:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/25\">",
"      Verstraelen H, Verhelst R, Nuytinck L, et al. Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae. J Reprod Immunol 2009; 79:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/26\">",
"      Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/27\">",
"      Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/28\">",
"      Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol 2004; 104:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/29\">",
"      Livengood CH 3rd, Thomason JL, Hill GB. Bacterial vaginosis: diagnostic and pathogenetic findings during topical clindamycin therapy. Am J Obstet Gynecol 1990; 163:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/30\">",
"      Sobel JD, Subramanian C, Foxman B, et al. Mixed Vaginitis-More Than Coinfection and With Therapeutic Implications. Curr Infect Dis Rep 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/31\">",
"      Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/32\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/33\">",
"      Sherrard J, Donders G, White D, et al. European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011. Int J STD AIDS 2011; 22:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/34\">",
"      Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/35\">",
"      Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 2004; 190:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/36\">",
"      Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/37\">",
"      Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996; 88:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/38\">",
"      Tam MT, Yungbluth M, Myles T. Gram stain method shows better sensitivity than clinical criteria for detection of bacterial vaginosis in surveillance of pregnant, low-income women in a clinical setting. Infect Dis Obstet Gynecol 1998; 6:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/39\">",
"      Gratac&oacute;s E, Figueras F, Barranco M, et al. Prevalence of bacterial vaginosis and correlation of clinical to Gram stain diagnostic criteria in low risk pregnant women. Eur J Epidemiol 1999; 15:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/40\">",
"      Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev 1991; 4:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/41\">",
"      Greene JF 3rd, Kuehl TJ, Allen SR. The papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy. Am J Obstet Gynecol 2000; 182:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/42\">",
"      Briselden AM, Hillier SL. Evaluation of affirm VP Microbial Identification Test for Gardnerella vaginalis and Trichomonas vaginalis. J Clin Microbiol 1994; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/43\">",
"      Sheiness D, Dix K, Watanabe S, Hillier SL. High levels of Gardnerella vaginalis detected with an oligonucleotide probe combined with elevated pH as a diagnostic indicator of bacterial vaginosis. J Clin Microbiol 1992; 30:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/44\">",
"      Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol 2003; 41:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/45\">",
"      Sumeksri P, Koprasert C, Panichkul S. BVBLUE test for diagnosis of bacterial vaginosis in pregnant women attending antenatal care at Phramongkutklao Hospital. J Med Assoc Thai 2005; 88 Suppl 3:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/46\">",
"      Bradshaw CS, Morton AN, Garland SM, et al. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol 2005; 43:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/47\">",
"      Nelson GH, Bacon JL. Correlation between the clinical diagnosis of bacterial vaginosis and the results of a proline aminopeptidase assay. Infect Dis Obstet Gynecol 1994; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/48\">",
"      Calder&oacute;n E, Rivera R, Gordillo S, Conde-Glez C. Evaluation of a fast test to identify the presence of proline aminopeptidase in women with bacterial vaginosis. Infect Dis Obstet Gynecol 1997; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/49\">",
"      Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol 2005; 105:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/50\">",
"      West B, Morison L, Schim van der Loeff M, et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex Transm Dis 2003; 30:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/51\">",
"      Menard JP, Fenollar F, Henry M, et al. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/52\">",
"      Cartwright CP, Lembke BD, Ramachandran K, et al. Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis. J Clin Microbiol 2012; 50:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/53\">",
"      Menard JP, Mazouni C, Fenollar F, et al. Diagnostic accuracy of quantitative real-time PCR assay versus clinical and Gram stain identification of bacterial vaginosis. Eur J Clin Microbiol Infect Dis 2010; 29:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/54\">",
"      Dumonceaux TJ, Schellenberg J, Goleski V, et al. Multiplex detection of bacteria associated with normal microbiota and with bacterial vaginosis in vaginal swabs by use of oligonucleotide-coupled fluorescent microspheres. J Clin Microbiol 2009; 47:4067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/55\">",
"      Swidsinski A, Doerffel Y, Loening-Baucke V, et al. Gardnerella biofilm involves females and males and is transmitted sexually. Gynecol Obstet Invest 2010; 70:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/56\">",
"      Huppert JS, Hesse EA, Bernard MC, et al. Accuracy and trust of self-testing for bacterial vaginosis. J Adolesc Health 2012; 51:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/57\">",
"      Singh RH, Zenilman JM, Brown KM, et al. The role of physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm Infect 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/58\">",
"      Klebanoff MA, Hillier SL, Nugent RP, et al. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol 2005; 192:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/59\">",
"      Eschenbach DA. Bacterial vaginosis: emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989; 16:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/60\">",
"      Flynn CA, Helwig AL, Meurer LN. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. J Fam Pract 1999; 48:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/61\">",
"      Hauth JC, Macpherson C, Carey JC, et al. Early pregnancy threshold vaginal pH and Gram stain scores predictive of subsequent preterm birth in asymptomatic women. Am J Obstet Gynecol 2003; 188:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/62\">",
"      Andrews WW, Hauth JC, Cliver SP, et al. Association of asymptomatic bacterial vaginosis with endometrial microbial colonization and plasma cell endometritis in nonpregnant women. Am J Obstet Gynecol 2006; 195:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/63\">",
"      Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. Infect Dis Obstet Gynecol 1995; 3:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/64\">",
"      MacDermott RI. Bacterial vaginosis. Br J Obstet Gynaecol 1995; 102:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/65\">",
"      Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/66\">",
"      Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/67\">",
"      Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012; 9:e1001251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/68\">",
"      Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/69\">",
"      Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/70\">",
"      Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease? Sex Transm Dis 2013; 40:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/71\">",
"      Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004; 104:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/72\">",
"      Gillet E, Meys JF, Verstraelen H, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 2012; 7:e45201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/73\">",
"      Guo YL, You K, Qiao J, et al. Bacterial vaginosis is conducive to the persistence of HPV infection. Int J STD AIDS 2012; 23:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/74\">",
"      King CC, Jamieson DJ, Wiener J, et al. Bacterial vaginosis and the natural history of human papillomavirus. Infect Dis Obstet Gynecol 2011; 2011:319460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/75\">",
"      Klebanoff MA, Hauth JC, MacPherson CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/76\">",
"      Hay PE, Morgan DJ, Ison CA, et al. A longitudinal study of bacterial vaginosis during pregnancy. Br J Obstet Gynaecol 1994; 101:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/77\">",
"      Schwebke JR. Asymptomatic bacterial vaginosis: response to therapy. Am J Obstet Gynecol 2000; 183:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/78\">",
"      Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993; 81:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/79\">",
"      Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007; 196:517.e1.",
"     </a>",
"    </li>",
"    <li>",
"     European (International Union against Sexually Transmitted Infections [IUSTI]/World Health Organization [WHO]) Guideline on the Management of Vaginal Discharge. 2011",
"    </li>",
"    <li>",
"     UK national guideline for the management of bacterial vaginosis 2012",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/82\">",
"      National guideline for the management of bacterial vaginosis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/83\">",
"      Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28 Suppl 1:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/84\">",
"      Greaves WL, Chungafung J, Morris B, et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988; 72:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/85\">",
"      Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009; :CD006055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/86\">",
"      Koumans EH, Markowitz LE, Hogan V, CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 2002; 35:S152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/87\">",
"      Swedberg J, Steiner JF, Deiss F, et al. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985; 254:1046.",
"     </a>",
"    </li>",
"    <li>",
"     Hillier, S, Holmes, KK. Bacterial vaginosis. In: Holmes, KK, Mardh, PA, Sparling, PF, Wiesner, PJ (Eds), Sexually Transmitted Diseases, 2nd ed, McGraw-Hill, New York: 1990, p. 547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/89\">",
"      Ferris DG, Litaker MS, Woodward L, et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/90\">",
"      Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med 2000; 45:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/91\">",
"      Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1995; 20 Suppl 1:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/92\">",
"      Bro F. Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis. Scand J Prim Health Care 1990; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/93\">",
"      Livengood CH 3rd, Soper DE, Sheehan KL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/94\">",
"      Ransom SB, McComish JF, Greenberg R, Tolford DA. Oral metronidazole vs. Metrogel Vaginal for treating bacterial vaginosis. Cost-effectiveness evaluation. J Reprod Med 1999; 44:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/95\">",
"      Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/96\">",
"      Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 2000; 96:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/97\">",
"      Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/98\">",
"      Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis. Med Lett Drugs Ther 2007; 49:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/99\">",
"      Ekgren J, Norling BK, Degre M, Midtvedt T. Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis. Gynecol Obstet Invest 1988; 26:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/100\">",
"      Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007; 110:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/101\">",
"      Schindler EM, Thamm H, Ansmann EB, et al. [Treatment of bacterial vaginitis. Multicenter, randomized, open study with tinidazole in comparison with metronidazole]. Fortschr Med 1991; 109:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/102\">",
"      Prakash AT, Sharma LK, Pandit PN. Primary carcinoma of the gallbladder. Br J Surg 1975; 62:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/103\">",
"      Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011; 204:211.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/104\">",
"      Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur J Obstet Gynecol Reprod Biol 2003; 109:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/105\">",
"      Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/106\">",
"      N&uacute;&ntilde;ez JT, G&oacute;mez G. Low-dose secnidazole in the treatment of bacterial vaginosis. Int J Gynaecol Obstet 2005; 88:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/107\">",
"      Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009; :CD006289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/108\">",
"      Falagas M, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007; 13:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/109\">",
"      McCormack WM, Covino JM, Thomason JL, et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transm Dis 2001; 28:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/110\">",
"      Wathne B, Holst E, Hovelius B, M&aring;rdh PA. Erythromycin versus metronidazole in the treatment of bacterial vaginosis. Acta Obstet Gynecol Scand 1993; 72:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/111\">",
"      Piot P. Bacterial vaginosis. An evaluation of treatment. Scand J Urol Nephrol Suppl 1984; 86:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/112\">",
"      Wewalka G, Stary A, Bosse B, et al. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology 2002; 204 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/113\">",
"      Duff P, Lee ML, Hillier SL, et al. Amoxicillin treatment of bacterial vaginosis during pregnancy. Obstet Gynecol 1991; 77:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/114\">",
"      Schoeman J, Steyn PS, Odendaal HJ, Grov&eacute; D. Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy. J Obstet Gynaecol 2005; 25:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/115\">",
"      Verstraelen H, Verhelst R, Roelens K, Temmerman M. Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect Dis 2012; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/116\">",
"      Potter J. Should sexual partners of women with bacterial vaginosis receive treatment? Br J Gen Pract 1999; 49:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/117\">",
"      Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis 2012; 39:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/118\">",
"      Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/119\">",
"      Sanchez S, Garcia PJ, Thomas KK, et al. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004; 191:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/120\">",
"      Schwebke JR, Desmond R. Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis 2005; 32:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/121\">",
"      Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004; 80:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/122\">",
"      Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198:97.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/123\">",
"      Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/124\">",
"      Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009; 36:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/125\">",
"      Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006; 8:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/126\">",
"      Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/127\">",
"      Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/128\">",
"      Moreira C, Venkatesh KK, DeLong A, et al. Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis 2009; 49:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/129\">",
"      Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol 1998; 105:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/130\">",
"      Larsson PG, Platz-Christensen JJ, Dalaker K, et al. Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. Acta Obstet Gynecol Scand 2000; 79:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/131\">",
"      Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. BJOG 2004; 111:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/132\">",
"      Crowley T, Low N, Turner A, et al. Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial. BJOG 2001; 108:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/133\">",
"      Larsson PG, Platz-Christensen JJ, Thejls H, et al. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol 1992; 166:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/134\">",
"      Larsson PG, Carlsson B. Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis? Infect Dis Obstet Gynecol 2002; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/135\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/136\">",
"      Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013; 1:CD000262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/137\">",
"      Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/138\">",
"      Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005; 105:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/139\">",
"      Guise JM, Mahon SM, Aickin M, et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/140\">",
"      Riggs MA, Klebanoff MA. Treatment of vaginal infections to prevent preterm birth: a meta-analysis. Clin Obstet Gynecol 2004; 47:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/141\">",
"      Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995; 173:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/142\">",
"      Caro-Pat&oacute;n T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/143\">",
"      Centers for Disease Control and Prevention, Workowsk,i KA, Berman, SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/144\">",
"      McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997; 104:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/145\">",
"      Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/146\">",
"      Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/147\">",
"      Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007; 21:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/148\">",
"      Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/149\">",
"      Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/150\">",
"      Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/151\">",
"      Odendaal HJ, Popov I, Schoeman J, et al. Preterm labour--is bacterial vaginosis involved? S Afr Med J 2002; 92:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/152\">",
"      Committee on Practice Bulletins&mdash;Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/153\">",
"      Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/154\">",
"      U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/155\">",
"      Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/156\">",
"      Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/157\">",
"      Macones GA, Parry S, Elkousy M, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol 2004; 190:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/158\">",
"      Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/159\">",
"      Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999; 106:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/56/30602/abstract/160\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     LactMed available at file://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~R2NQWq:1 (Accessed on January 19, 2010).",
"    </li>",
"    <li>",
"     Lactmed. Available at file://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~R2NQWq:2. (Accessed on January 19, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5451 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30602=[""].join("\n");
var outline_f29_56_30602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS AND MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110845310\">",
"      Amsel crtieria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9465755\">",
"      Gram's stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9465762\">",
"      Cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110845295\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9465777\">",
"      Commercial tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9466208\">",
"      Investigational tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86552574\">",
"      Diagnosis without speculum examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110845488\">",
"      Nonpregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clindamycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tinidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86556287\">",
"      Secnidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H194270516\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H86556170\">",
"      Less effective and ineffective therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1396145\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sexual partners",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Relapse and recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Asymptomatic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gynecologic procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Symptomatic BV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Asymptomatic infection and screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment of nonpregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment of pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5451|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/47/21240\" title=\"picture 1A\">",
"      Clue cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/29/37332\" title=\"picture 1B\">",
"      Clue cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/47/32496\" title=\"picture 2A\">",
"      Gram stain bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/13/19678\" title=\"picture 2B\">",
"      Gram stain of normal vaginal flora",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/29/39388\" title=\"table 1\">",
"      Clinical features of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/32/39435\" title=\"table 2\">",
"      Nugent score for diagnosis of bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/2/5163\" title=\"table 3\">",
"      Hay Ison criteria for diagnosis of bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/29/40411\" title=\"table 4\">",
"      Rx bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/49/35611\" title=\"table 5\">",
"      Treatment studies BV preg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25113?source=related_link\">",
"      Medical care of women who have sex with women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=related_link\">",
"      Patient information: Bacterial vaginosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/56/22402?source=related_link\">",
"      Patient information: Bacterial vaginosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_56_30603="Hemicrania continua diagnostic criteria";
var content_f29_56_30603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemicrania continua diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Description:",
"        </strong>",
"        Persistent strictly unilateral headache responsive to indomethacin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Diagnostic criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Headache for more than three months fulfilling criteria B through D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. All of the following characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Unilateral pain without side-shift",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Daily and continuous, without pain-free periods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Moderate intensity, but with exacerbations of severe pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. At least one of the following autonomic features occurs during exacerbations and ipsilateral to the side of pain:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Conjunctival injection and/or lacrimation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Nasal congestion and/or rhinorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Ptosis and/or miosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Complete response to therapeutic doses of indomethacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30603=[""].join("\n");
var outline_f29_56_30603=null;
var title_f29_56_30604="Comparison between WHO criteria and the irRC";
var content_f29_56_30604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison between WHO criteria and the Immune-related response criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        WHO",
"       </td>",
"       <td class=\"subtitle1\">",
"        irRC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         New, measurable lesions",
"         <br/>",
"         (ie, &ge;5 x 5 mm)",
"        </strong>",
"       </td>",
"       <td>",
"        Always represent PD",
"       </td>",
"       <td>",
"        Incorporated into tumor burden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         New, nonmeasurable lesions",
"         <br/>",
"         (ie, &lt;5 x 5 mm)",
"        </strong>",
"       </td>",
"       <td>",
"        Always represent PD",
"       </td>",
"       <td>",
"        Do not define progression (but preclude irCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Non-index lesions",
"        </strong>",
"       </td>",
"       <td>",
"        Changes contribute to defining best objective response of CR, PR, SD, and PD",
"       </td>",
"       <td>",
"        Contribute to defining irCR (complete disappearance required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CR",
"        </strong>",
"       </td>",
"       <td>",
"        Disappearance of all lesions in two consecutive observations not less than 4 wk apart",
"       </td>",
"       <td>",
"        Disappearance of all lesions in two consecutive observations not less than 4 wk apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         PR",
"        </strong>",
"       </td>",
"       <td>",
"        &ge;50 percent decrease in SPD of all index lesions compared with baseline in two observations at least 4 wk apart, in absence of new lesions or unequivocal progression of non-index lesions",
"       </td>",
"       <td>",
"        &ge;50 percent decrease in tumor burden compared with baseline in two observations at least 4 wk apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SD",
"        </strong>",
"       </td>",
"       <td>",
"        50 percent decrease in SPD compared with baseline cannot be established nor 25 percent increase compared with nadir, in absence of new lesions or unequivocal progression of non-index lesions",
"       </td>",
"       <td>",
"        50 percent decrease in tumor burden compared with baseline cannot be established nor 25 percent increase compared with nadir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         PD",
"        </strong>",
"       </td>",
"       <td>",
"        At least 25 percent increase in SPD compared with nadir and/or unequivocal progression of non-index lesions and/or appearance of new lesions (at any single time point)",
"       </td>",
"       <td>",
"        At least 25 percent increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 wk apart",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     irRC: immune-related response criteria; PD: progressive disease; CR: complete response; PR: partial response; SD: stable disease; SPD: sum of the product of the two largest perpendicular diameters; irCR: immune-related complete response.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: the American Association for Cancer Research: Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 Dec 1; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30604=[""].join("\n");
var outline_f29_56_30604=null;
var title_f29_56_30605="Developmental-behavioral pediatrics professional development";
var content_f29_56_30605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Internet resources for professional development of clinicians caring for children with confirmed or suspected developmental and behavioral disabilities*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Web site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         American Academy of Pediatrics",
"        </p>",
"        <p>",
"         www.aap.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides policy statements, parenting information, and continuing medical education. The online book store offers brochures for families, tool kits for caring for children with autism spectrum disorders and ADHD, and a variety of other informational resources.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         American Academy of Pediatrics",
"        </p>",
"        <p>",
"         National Center for Medical Home Implementation",
"        </p>",
"        <p>",
"         www.medicalhomeinfo.org",
"        </p>",
"       </td>",
"       <td>",
"        Designed to help establish for children with special health care needs health care that is \"accessible, family-centered, continuous, comprehensive, coordinated, compassionate, and culturally-competent.\" Provides training materials, rating scales, an e-mail announcement list for providers, etc, and sponsors several conferences each year.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         American Academy of Pediatrics",
"        </p>",
"        <p>",
"         Section on Developmental and Behavioral Pediatrics",
"        </p>",
"        <p>",
"         www.aap.org/sections/dbpeds/",
"        </p>",
"       </td>",
"       <td>",
"        Provides information on routine and challenging aspects of developmental-behavioral pediatrics (eg, obesity, autism, medication management, etc); includes a library of relevant articles; hosts an e-mail discussion for challenging cases, management strategies, etc (participants include general and developmental-behavioral pediatricians, speech-language pathologists, and other allied health professionals); provides a newsletter with a coding column and helpful how-to articles, etc.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Bright Futures",
"        </p>",
"        <p>",
"         www.brightfutures.org",
"        </p>",
"        <p>",
"         brightfutures.aap.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides activity books in English and Spanish that can be shared with families; health supervision guides, training and technical assistance in social-emotional development, mental health, nutrition, physical activity, oral health, etc; CME and distance learning activities; and links to Bright Futures Activities in every state.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Centers for Disease Control and Prevention. Learn the Signs. Act Early.",
"        </p>",
"        <p>",
"         www.cdc.gov/ncbddd/actearly/",
"        </p>",
"       </td>",
"       <td>",
"        Provides wall charts about developmental milestones and developmental indicators/red flags that can be ordered (for free).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Developmental Screening Tool Kit for Primary Care Providers",
"        </p>",
"        <p>",
"         www.developmentalscreening.org",
"        </p>",
"       </td>",
"       <td>",
"        Focuses on the challenges of implementing early detection in primary care, including a video about the process&mdash;challenges and solutions, strategies for encouraging colleagues and clinic staff, selecting tools, etc.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         First Signs",
"        </p>",
"        <p>",
"         www.firstsigns.org",
"        </p>",
"       </td>",
"       <td>",
"        Provides wall charts for waiting/examination rooms and brochures for parents (for a small fee).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Maternal and Child Health Library (Georgetown University)",
"        </p>",
"        <p>",
"         www.mchlibrary.info",
"        </p>",
"       </td>",
"       <td>",
"        Provides a guide to help providers find local services for children and families to address mental health, parenting, child abuse, substance abuse, early intervention, etc.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         National Initiative for Children's Healthcare Quality",
"        </p>",
"        <p>",
"         www.nichq.org",
"        </p>",
"       </td>",
"       <td>",
"        Devoted to quality improvement in health care and has focused on several conditions, including ADHD, asthma, and obesity. Provides algorithms, parent information handouts, etc, for download (free with registration).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         PEDStest.com",
"        </p>",
"        <p>",
"         www.pedstest.com",
"        </p>",
"       </td>",
"       <td>",
"        Offers the \"Early Detection Discussion List,\" where you can post questions about training, implementation, translation, etc; provides training materials, including videos, slide shows, a post-test, background information on child development and psychosocial risk, parenting handouts, and additional screens helpful for developmental-behavioral surveillance, etc; offers trials of online screening and surveillance tools.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Reach Out and Read",
"        </p>",
"        <p>",
"         www.reachoutandread.org",
"        </p>",
"       </td>",
"       <td>",
"        Helps providers promote school success by encouraging book reading. The site explains the process and training requirements, sells appropriate books for children of different ages, and provides articles describing the positive effects of book sharing, etc.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Pediatric NeuroLogic Exam (the University of Utah)",
"        </p>",
"        <p>",
"         library.med.utah.edu/pedineurologicexam/html/home_exam.html",
"        </p>",
"       </td>",
"       <td>",
"        Provides a detailed video on how to perform a neurodevelopmental examination in young children.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADHD: attention deficit hyperactivity disorder; CME: continuing medical education.",
"     <br>",
"      * Many of the sites listed in the table \"Educational resources for developmental-behavioral concerns\" are also useful for professionals wishing to gather a range of information handouts on developmental promotion.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30605=[""].join("\n");
var outline_f29_56_30605=null;
var title_f29_56_30606="Classification tree dx FMF1";
var content_f29_56_30606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classification tree using the detailed criteria for the diagnosis of familial mediterranean fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Livneh A, Langevitz P, Zemer D, et al. Arthritis Rheum 1997; 40:1879.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30606=[""].join("\n");
var outline_f29_56_30606=null;
var title_f29_56_30607="Mirizzi syndrome MRCP";
var content_f29_56_30607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mirizzi syndrome seen on magentic resonance cholangiopancreatography (MRCP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRCP study in an 81-year-old woman with jaundice and right upper quadrant pain shows dilation of the common hepatic duct (CHD) and gallbladder (GB) with a filling defect in the common bile duct (arrow) caused by an impacted stone. The patient required surgical resection and stone removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_56_30607=[""].join("\n");
var outline_f29_56_30607=null;
